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Abstract 
The correct development and functioning of the immune system is critical for the 
defence of the host organism against pathogens and cancers. V(D)J recombination 
generates diversity of immunoglobulin (Ig) and T cell receptor (TCR) genes by the 
regulated joining of variable (V), diversity (D) and joining (J) gene segments. Tissue-
specific enhancers in the DNA genome activate these genes to undergo recombina-
tion by triggering non-coding transcription through the recombining gene segments, 
following interaction with the respective promoters. How this is achieved is un-
known.  
The specificity of enhancer/promoter interactions was examined using the murine 
Igλ chain locus. The transcription factors that bind to the three main promoters 
were identified by DNase I footprinting. Of these, a factor termed E47 was shown to 
interact with IRF4 by co-immunoprecipitation experiments. The importance of these 
interactions was confirmed by mutagenesis where it was shown that mutations of 
any of the binding sites in DNA for the transcription factors or mutations in the 
amino acids involved in protein-protein interactions decreased the rate of transcrip-
tion. Together, these studies suggest that IRF4/E47 interactions may play a key role 
in triggering locus activation. 
RNA-Seq data from HPV-positive samples and cell lines were analysed to identify 
putative biomarkers for cervical cancer. Infection with HPVs is the main cause for 
cervical cancer accounting for 10-15% of cancer-related deaths in women world-
wide. It is established that HPVs escape the immune response over decades to es-
tablish tumorigenesis but the specific mechanism is unknown. Virus integration into 
the host genome and deregulation of several genes may play a key role in promot-
ing cancer; of particular interest are those transcripts that form the “surfacesome”. 
Among these, particular interest was given to connexin 26 (Cx26), which is classified 
as cancer-predisposition gene and was found to be commonly down regulated in all sam-
ples analysed. 
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Recombinant adenoviruses expressing the two HPV16 oncogenes were generated 
and employed to transduce HaCaT cells to analyse Cx26 mRNA and protein levels 
coupled with dye transfer assays to study the structural behaviour of connexins. The 
data presented showed that E6 and E7 alter Cx26 protein expression by relocating 
Cx26 within the cytoplasm from the membrane-bound form. This was confirmed in 
the dye transfer assay where cell-cell communications were lost.  
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Chapter 1. INTRODUCTION 
1.1 Overview of the immune system: innate and adaptive immunity 
Mammals are constantly exposed to a variety of harmful pathogens and microbes, 
which can invade the host through the skin, via food ingestion, inhalation, or 
through the genitourinary tract. The immune system protects the body from patho-
gens in two ways: first by posing physical barriers such as the skin and the mucosa 
or secreting specific molecules (lysozyme produced in the eyes, stomach acids or 
skin oils); secondly by producing antigen-specific antibodies and T cell receptors. 
The first line of defence represents the innate immune system, while the second 
falls within the adaptive system (Figure 1-1). When a pathogen overcomes these 
physical or chemical barriers, then more specialised molecules and cell types inter-
vene, from both the innate and adaptive immune system. 
 
 
Figure 1-1 Differences between innate and adaptive immunity. 
The first line of defence involves epithelial barriers such as skin as well as a cellular component 
represented by phagocytes, dendritic cells and NK cells. In adaptive immunity, which is more spe-
cific, the immune response is mainly mediated by B and T cells through generation of antibodies 
by B cells and T cell recognition of infected and transformed cells (Abbas, 2010). 
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1.1.1 Cells of the immune system 
Both innate and adaptive immune responses have a wide range of cells that inter-
vene in the case of an infection. All cells originate from haemapoietic stem cells 
(HSCs) that give rise to the myeloid and lymphoid lineage. The myeloid lineage gives 
rise to granulocytes (which includes neutrophils, basophils, eosinophils and mast 
cells) as well as the monocyte/dendritic cell progenitor from which macrophages 
and dendritic cells originate (Liu & Nussenzweig, 2010). The lymphoid lineage in-
cludes T cells (helper, cytotoxic and suppressor), B cells (plasma cells and memory 
cells) and natural killer (NK) cells (Figure 1-2).  B lymphocytes originate and mature 
in the bone marrow and they are capable of developing into antibody-secreting 
plasma cells following stimulation by antigens; after a first infection, they are also 
able to differentiate into memory B cells, which retain an immunological memory of 
the antigen. In addition, B cells also contain the membrane-bound form of the anti-
body, namely the B cell receptor (BCR).  T cells originate in the bone marrow but 
mature in the thymus; they are divided into T helper (TH, CD4
+) or cytotoxic (TC, 
CD8+) and they both play a key role in coordinating the immune response. T helper 
cells “see” peptide antigen in the context of major histocompatibilty complex (MHC) 
class II molecules on antigen presenting cells  (APCs) and stimulate the secretion of 
certain lymphokines which in turn trigger responses from other cells of the immune 
system (such as B cells and TC), while TC are involved in killing infected or tumour 
cells following presentation of the antigen by MHC class I molecules. Both B and T 
cells undergo a stringent mechanism of selection that eliminates self-reacting cells.  
The same lymphoid progenitor from which B and T cells originate also gives rise to 
NK cells. These cells kill virus-infected cells as well as tumour cells, in a similar man-
ner to TC cells, however they do not require recognition of antigen in association 
with MHC molecules. 
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In the adaptive immune response, macrophages and dendritic cells play a key role. 
Both cells are APCs as they present on their surface epitopes of the ingested patho-
gen following phagocytosis. 
 
 
Figure 1-2 Cells of the innate and adaptive immune response. 
A lymphoid and a myeloid progenitor give rise to the vast number of cells involved in the immune 
system (Dranoff, 2004).  
1.1.2  Innate immunity 
The innate immune system represents the first line of defence against pathogens 
including bacteria, viruses, fungi and parasites. Physical barriers, such as the skin 
(epithelial cells) and the linings of the body’s tubular structures (mucosal epithelial 
containing glycoproteins such as mucins) help prevent and reduce infections. In ad-
dition, the human body produces tears and saliva, which contain lysozymes and 
phospholipase that act against the cell wall of many bacteria, to protect the mouth 
and eyes. The low pH environment that prevents growth of many bacteria protects 
the gastrointestinal tract. In case of a microtrauma however, pathogens will enter 
the body and, at that site where infection has occurred, the innate response will 
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intervene with the recruitment phagocytic cells, as well the innate humoral re-
sponse which activates proteins of the complement system. Activation of the com-
plement system triggers increased vascular permeability, recruitment of phagocytic 
cells, and lysis and opsonization of bacteria. In addition, the serum provides other 
factors such as lactoferrin and transferrin which limit bacteria growth by depriving 
them of iron, as well as interferons (INFs), which are specific for response against 
viruses (Abbas, 2010).  
1.1.2.1 Phagocytosis in the innate response 
Cells of the innate immune system are able to destroy and kill pathogens by phago-
cytosis. Mainly dendritic cells, neutrophils and macrophages perform this. Following 
the entry of the pathogen, these cells recognize pathogen-associated molecular pat-
terns (PAMPs) which are absent from the host cells and are found in both patho-
genic and non-pathogenic micro-organisms (Medzhitov, 2007). PAMPs include LPS 
(lipopolysaccharide) and other components of bacterial cell walls, unmethylated 
CpG islands or double strand RNA (dsRNA). Upon recognition via Pattern Recogni-
tion Receptors (PRRs), the pathogen is endocytosed and digested in a phagosome 
(Figure 1-3). This digestion releases peptides that can be presented at the plasma 
membrane by MHC class II molecules. PRRs also include the large family of Toll Like 
Receptors (TLRs); for example, TLR-4 recognise PAMPS (LPS) and activate NF-kB de-
pendent transcription of genes encoding inflammatory cytokines such as TNF-α 
(tumour necrosis factor-α); TNF is pro-inflammatory and, as well as activating innate 
immunity, it prepares the immune system to initiate adaptive responses by 
delivering maturation signals to dendritic cells.  Other factors such as, chemokines 
and Interleukin-1 (IL-1) serve to attract other cell types  to the site of the infection 
(Fauriat et al, 2010) . 
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Figure 1-3 Mechanism of phagocytosis. 
Phagocytes are attracted to microorganisms via chemotaxis; macrophages have cell-surface recep-
tors that recognize molecules on the surface of various pathogens. The phagocytes will engulf the 
microorganism and enclose it in a phagocytic vesicle to complete ingestion. Most of the ingested 
microorganisms are killed by lysosomal enzymes and oxidizing agents (Underhill & Goodridge, 
2012). 
1.1.2.2 Role of NK cells in the innate immune response 
NK cells develop in the foetal liver and, after birth in the bone marrow. NK cells play 
a key role in the innate immune response as they are responsible for killing in-
fected, as well as malignant cells by producing granzymes and perforin which are 
the major effector proteins responsible for killing infected cells and tumours 
(Chiang et al, 2013) by both NK and TC cells.  
NK cells can kill target cells by two main mechanisms; antibody dependent cellular 
cytotoxicity (ADCC) and via the detection of altered expression of host proteins on 
the target cell surface (Tyler et al, 1989). For ADCC, IgG coated target cells are rec-
ognized by the Fc receptor CD16. For altered self, NK cells express an array of cell 
surface receptors that detect infection and tumour-induced proteins (such as 
NKG2D ligands) and deliver activating signals to the NK cell and inhibitory receptors 
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for MHC class I that, when not engaged, fail to counteract these activating signals 
(the missing self-model; (Karre et al, 1986)).  A net balance of cellular activation 
leads to the release of granzymes and perforin onto the target cells and the release 
of cytokines such as TNF-α and IFNγ. NK cells also receive activating signals from 
DCs, coupling them to other pathways of innate immune activation (Amadei et al, 
2010; Narni-Mancinelli et al, 2013).  
1.1.2.3 Immune response to viral infection 
Viruses are intracellular parasites that use the host cell machinery for replication. 
Infections are first counteracted by the innate immunity that stops viral invasion 
and replication.  NK cells and the production of type I interferons (IFNα and IFNβ) 
therefore play a major role. More specifically, viral RNA or DNA is recognized by en-
dosomal TLRs such as TLR-7, -8, -9 which recognize ssRNA and dsDNA, while TLR-3 
recognizes dsRNA (Meylan et al, 2006). These are found on plasma and endosomal 
membrane of various cell types such as B cells, phagocytes and endothelial cells. 
When viral particles are encountered in the cytosol compartment, such as following 
replication, viral nucleic acid is recognized by receptors such as RIG-like receptors, 
RLRs (i.e. RIG-I and MDA-5). Ultimately, both pathways, TLR or RLR-mediated, lead 
to the activation of protein kinases, which in turn activate the IRF transcription fac-
tors in the nuclei to stimulate type I interferon gene transcription (Takaoka et al, 
2005). The latter includes IFN-α isoforms, a single IFN-β, and other IFN family mem-
bers (IFN-ε, -κ -ω and many others) (Stetson & Medzhitov, 2006). 
However, when the infection is persistent and the innate immune system fails to 
stop the infection, higher virus titre activate the adaptive immunity with the pro-
duction of antibodies and TC cells aimed to kill infected cells. Antibodies bind to viral 
envelope where present or capsid antigens to neutralize particles and prevent virus 
attachment and entry into host cells (ADCC system, classical pathway of comple-
ment activation, phagocytosis). However, CD8+ TC cells that recognize cytosolic viral 
peptides presented by MHC class I molecules mainly carry out elimination of an in-
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fected cell. Infected cells could be either APCs or a tissue cell. In the latter case, 
dendritic cells that process the viral antigens and present them to naive CD8+ TC 
cells phagocytise these cells.  Activated TC cells differentiate into effector CTLs, 
which can kill any infected nucleated cell, and in addition are also able to secrete 
IFN-γ, potent antiviral cytokine.  
However, viruses have evolved numerous mechanisms for evading host immunity. A 
good example, as described in Chapter 1.4, is exemplified by the human papilloma 
virus (HPV).  
1.1.3 Adaptive immunity 
Adaptive immunity, or the acquired immune response, represents the second line 
of defence, when the less specific, innate immunity fails. The adaptive immune re-
sponse is carried out by B and T lymphocytes: these are able to recognize a seem-
ingly limitless repertoire of antigens and humans can produce over 107 lympho-
cytes, each specific for a particular antigen. Once an antigen or more precisely an 
epitope from that antigen binds to its receptor on the surface of B and/or T cells, 
clonal expansion of lymphocytes will begin, producing a vast number of that type of 
cell with its associated antigen specificity. While these cells are highly specific 
against that antigen, the response to completely eliminate the pathogen will take 
few days. On the other hand, since lymphocytes are able to retain an immunological 
“memory”, upon a second infection with the same pathogen, the response will be 
much quicker (Figure 1-4) (Abbas, 2010). 
Adaptive immunity can be divided into branches: humoral immunity, which medi-
ated by B cells via production of antibodies, and cell-mediated immunity, which in-
volves T cells. When the innate immune system fails to prevent an infection, anti-
gens are transported to the lymphoid organs where they will be in contact with na-
ïve B and T cells. The contact will trigger activation of the lymphocytes which differ-
entiate into effector cells. Epitopes of the antigen are recognized by the B cell re-
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ceptor (BCR) and T cell receptor (TCR) on the surface of B and T cells, respectively. 
While B cells can bind directly to the epitopes, T cells require the antigen (mainly 
short peptides) to be presented on the surface of APCs such as macrophages, den-
dritic cells and B lymphocytes via MHC molecules.  
 
 
Figure 1-4 Primary and secondary immune response. 
The graph shows specificity and memory of adaptive immunity compared to the innate immune 
response (Abbas, 2010).  
MHC molecules regulate both the innate and adaptive immune responses where 
they bind to epitopes of the processed antigen and present it on the surface of the 
cells for recognition by T cells (as well as NK cells). MHC molecules are divided into 
two classes: class I and class II and they present antigens to CD8+ T and CD4+ T lym-
phocytes, respectively. MHC class I molecules are expressed on almost all nucleated 
cells of the body, while MHC class II molecules are mainly expressed on the surface 
of APCs (such as dendritic cells, macrophage and B cells) which have trapped ex-
ogenous antigens from the extracellular fluid and are able to interact with helper T 
cells.  
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Figure 1-5 Type of adaptive immune response.  
In the humoral response, B cells are activated by T helper cells into antibody-secreting plasma cells 
that will trigger opsonisation of the microorganisms. In the cellular immune response, interaction 
with the APCs can either trigger activation of T cells into TH cells or, in case of interaction with MHC 
class I molecules on the surface of the APCs, activation of TC cells which will kill the infected cells 
(Mortellaro & Ricciardi-Castagnoli, 2011). 
Since MHC molecules are highly polygenic and polymorphic, it is unlikely that a 
pathogen will easily evade the immune response, both innate and adaptive (Alberts 
et al, 2002). Indeed, being polygenic confers these molecules the ability to produce 
a vast array of peptides allowing them to recognize different epitopes. Secondly, 
being polymorphic, each copy of the genes can exists in different isoform, conse-
quently generating different forms of MHC molecules, increasing the ability to rec-
ognize and bind different antigens for presentation (Alberts et al, 2002). Dendritic 
cells express both classes of MHCs and following binding of the foreign antigen, 
they present it to naïve CD8+ or CD4+ T cells, triggering their activation into effector 
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cells. Macrophages express MHC II and they present antigens on their surface for 
recognition by CD4+ T cells: following this interaction, macrophages are activated by 
the release of cytokines by T cells to kill intracellular pathogens and chemokines to 
attract them to the site of infection. In addition, B cells express MHC class II mole-
cules and they present the antigen to CD4+ T cells that will in turn activate B cell into 
antibody- secreting plasma cells.  Thus B cells and T cells interact to orchestrate 
both humoral and cell mediated immunity. The key to their specificity is the pres-
ence of clonally expressed antigen receptor molecules, immunoglobulin and the T 
cell receptor. 
1.1.4 Lymphocyte development 
Lymphocytes are white blood cells that originate in the bone marrow (B lympho-
cytes) and in the thymus (T cells). While B cells generate and mature in the bone 
marrow, T cells migrate to the thymus from the bone marrow to complete the 
maturation process. Both B and T cells then migrate to the secondary lymphoid or-
gans such as spleen and lymph nodes to encounter the antigen and be eventually 
activated. Humans have an average of 2x1012 B and T lymphocytes. They are the 
only cells capable of undergoing V(D)J recombination, the process by which B and T 
cell receptors are generated (Chapter 1.2). Lymphocyte development occurs in a 
number of different stages. It is an ordered process that parallels the progressive 
assembly and expression of the antigen receptor genes on the surface o B and T 
cells.  
Lymphocytes originate from pluripotent HSCs. HSCs give rise to multipotent pro-
genitors (MPPs) that in turn develop into early lymphocyte progenitors (ELPs) 
(Traver et al, 2000). ELPs up-regulate the lymphoid-specific recombinase genes Rag1 
and Rag2, the only proteins required to initiate V(D)J recombination, and differenti-
ate into common lymphoid progenitors (CLPs) that are restricted to B, T and NK cell 
development (Kondo et al, 1997) (Figure 1-6). 
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Figure 1-6 Overview of lymphocyte development from human stem cells.  
Both B and T cells orginate in the bone marrow from human stem cells. B cells mature in the bone 
marrow, while T cells migrate to the thymus to complete their maturation (Matthias & Rolink, 
2005). 
 
Pluripotent haematopoietic stem cells (HSCs) give rise to all blood cells in foetal 
liver and bone marrow. The lymphoid lineage, B, T and NK cells, derive from multi-
potent progenitors (MPPs). MPPs differentiate into early lymphocyte progenitors 
(ELPs), which in turn differentiate into common lymphoid progenitors (CLPs) that 
are restricted to B, T, NK and DC cell development.  A fraction of CLPs enter the B 
cell differentiation pathway and those cells that successfully complete DH-JH rear-
rangements will constitute the early pro-B cell stage (Brass et al, 1996; Hardy & 
Hayakawa, 1991; Li et al, 1993).  Following productive VH-DJH rearrangement dur-
ing the late pro-B cell stage, the Igµ chain is expressed on the surface of the cell to-
gether with the surrogate light chains, lambda 5 and V pre-B (Melchers, 2005). This 
complex is known as the pre-B cell receptor (pre-BCR). The pre-BCR represents an 
important checkpoint in B-cell development. Signals through the pre-BCR are re-
quired for B cell proliferation and subsequent recombination of the κ or λ light chain 
gene. The latter triggers differentiation of pre-B cells to immature B cells. 
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1.1.4.1 B cell development 
B cells development initiates in the foetal liver and continues in the bone marrow 
throughout the life. During an on going infection, B cells migrate to the secondary 
lymphoid organs where they will be activated following interaction with a peptide-
derived antigen. B cell development parallels the generation of the antigen receptor 
loci: only when a mature BCR is produced, will naïve B cells migrate to the periphery 
where they will encounter the antigen and will be activated into effector B cells.  
Development begins when the lymphoid progenitors start expressing the recombi-
nase activating genes, RAG1 and RAG2, in CD34+ cells (for more details about V(D)J 
recombination refer to Chapter 1.2). These cells first undergo D-J joining on the 
heavy chain and also express CD45 (B220) and MHC class II molecules, which de-
fines early pro-B cells, with limited self-renewal capacity. V-to-DJ joining on the 
heavy chain completes the late pro-B cell stage defined by the expression of the μ 
heavy chain (Packard & Cambier, 2013); at this stage, heavy chain rearrangement is 
therefore stopped to promote light chain recombination: these cells express the 
surrogate light chains lambda 5 and V pre-B (pre-BCR) and  are characterised by the 
expression of signal transduction molecules IgαIgβ from the earlier stage; since the 
heavy chain is not capable of transmitting signals to the cytoplasm due to its short 
tail, this is carried by the signal transduction molecules which have ITAM motifs 
(Immunoreceptor Tyrosine Activation Motifs) (Niiro & Clark, 2002). This triggers a 
series of cascade reactions which promotes large pre-B cell proliferation and devel-
opment to the next stage, into small pre-B cell (Miosge & Goodnow, 2005). When 
these cells have successfully rearranged the light chain, lambda or kappa, a com-
plete immunoglobulin, IgM, is produced and expressed on the cell surface. These 
cells are defined as immature B cells and they are still found in the bone marrow. 
Their complete maturation occurs in the peripheral lymphoid organs once they en-
counter a peptide-derived antigen (Figure 1-7). 
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Figure 1-7 B cell development in the bone marrow.  
B cells originate and mature in the bone marrow where parallel generation of the antibody recep-
tors occur. In the bone marrow B cells proliferate from pro-B cells to immature B cells which ex-
press a complete B cell receptor; however, only migration to secondary lymphoid organs and in-
teraction with an antigen will complete the maturation process into plasma or memory cells 
(Cambier et al, 2007). 
1.1.4.1.1 Transcriptional regulation of B lymphocytes development 
B cell development is regulated by the combination of different transcription factors 
including Ikaros, PU.1, early B-cell factor (EBF), E2A (E12 and E47), Pax5, nuclear fac-
tor (NF)-κB, interferon regulatory factor 4 (IRF4) and Oct2 (Schebesta et al, 2002).  
Mice deficient for E2A, PU.1, EBF or Pax5 have B cell development arrested prior to 
rearrangement and expression of the Ig heavy chain genes (at the pro-B cell stage 
(Bain et al, 1994; Georgopoulos et al, 1994; Scott et al, 1994; Zhuang et al, 2004; 
Zhuang et al, 1994)). 
Ikaros and PU.1 are important for the generation of lymphoid progenitors: Ikaros-/- 
mice fail to generate any B, T or NK cells (Georgopoulos et al, 1994; Kirstetter et al, 
2002; Wu et al, 1997), while PU.1-/- mice die around birth and lack  B, T and mye-
loid cells, suggesting that PU.1 is involved in lymphoid and macrophage lineage de-
termination (McKercher et al, 1996; Scott et al, 1994). E2A, EBF, and Pax5 control 
the development of CLPs into committed pro-B cells (Schebesta et al, 2002). Mice 
deficient for the E2A gene arrest B cell development at the very first stages of B cell 
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development before rearrangement of the immunoglobulin heavy chain (IgH) (Bain 
et al, 1994; Bain et al, 1997; Zhuang et al, 1994). These mice fail to undergo DH-JH 
rearrangement because Rag1 is not expressed and thus V(D)J recombination fails to 
initiate.  
E proteins, to which E2A belongs to, were first discovered due to their ability to bind 
sequences within the IgH and Igκ loci, specifically the IgH intronic enhancer (µE5) 
and the κE3' and κEi sites of the Igκ enhancers. Cells lacking these sites, and thus 
inability of E proteins to bind and exert their effect, developed severe recombina-
tion defects (Afshar et al, 2006; Inlay & Xu, 2003; Schlissel, 2004). Studies on the Igκ 
locus have shown that E47 can bind the κEi enhancer and moreover can also bind 
the Igκ 3' enhancer upon interaction with interferon regulatory factor 4 (IRF4) 
(Lazorchak et al, 2006; Nagulapalli & Atchison, 1998). These studies within the Igκ 
locus show that in E2A-deficient pre-B cells, the B cell stage at which Igκ rearrange-
ment occurs, Igκ germ line transcription is severely impaired and recombination is 
blocked in the absence of E47/E12. Ectopic expression of E47/E12 and therefore 
recruitment to κEi and κE3′ correlates with activation of Igκ. Since at the κE3′ en-
hancer E47 recruitment is dependent on IRF4, inhibition of IRF-4 expression leads to 
a reduction of Igκ germ line transcription (Nagulapalli & Atchison, 1998) and 
E12/E47 alone, or IRF4 expression alone is not sufficient to promote Igκ sterile tran-
scription (transcription in the absence of protein synthesis) and subsequent recom-
bination.  While E2A proteins play a crucial role in Igκ locus rearrangement, recom-
bination of the IgH locus does not necessarily depend on their expression. In fact, 
forced expression of the EBF1 transcription factors in E2A-deficient mice is sufficient 
to induce DH to JH and DJH to VH recombination (Seet et al, 2004), more likely be-
cause the other two E proteins (HEB and E2-2) can compensate for loss of E2A. 
E47 is involved in lymphocyte differentiation, lineage commitment, proliferation, 
and survival as well as immunoglobulin rearrangement (Bain et al, 1994). E2A 
knock-out mouse strains display a complete block in B-cell development and altered 
T-cell development (Bain et al, 1994; Zhuang et al, 1996; Zhuang et al, 1994). These 
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mice do not express CD19 and other B-cell-lineage-associated genes, such as com-
ponents of the pre-B-cell receptor (pre-BCR composed of Vpre-B, Vλ5 and an Igμ) 
and its signalling complex (Igα and Igβ), the paired box protein 5 (Pax5) and RAG1/2 
genes (Massari & Murre, 2000; Murre, 2005).  As a consequence, no D to J or V to 
DJ rearrangements at the heavy chain locus are found in the foetal liver or bone 
marrow (Bain et al, 1994; Zhuang et al, 2004; Zhuang et al, 1994), confirming that in 
B cells, E2A products regulate both activation of early B cells genes and commit-
ment to the B lineage by expression of the Igs. Ectopic/transgenic expression of ei-
ther E12 or E47 rescues B cell development, suggesting that E2A proteins are func-
tionally redundant in this process (Bain et al, 1997).  
However, other studies have shown that E2A-deficient progenitor cells (obtained by 
E12 knock-out,) can be isolated (Ikawa et al, 2004): analysis of these cells revealed 
that they are indeed able to carry low levels of IgH DJ rearrangement and they also 
possess some pro-B characteristics such as expression of RAG-1, EBF, Pax5 and sev-
eral BCR-associated proteins. Since E47 production was affected by E12 knock-out, 
it is thought that the low level of E47 allows the observed rearrangement. 
Similarly to E2A, EBF null mice fail to undergo to VH-DJH rearrangement (Lin & 
Grosschedl, 1995). EBF is also expressed from the HSC stage and works in concert 
with E2A to regulate expression of Rag1 and Rag2 genes (O'Riordan & Grosschedl, 
1999). Commitment to the B-lymphoid lineage depends on the transcription factor 
Pax5 (Enver, 1999; Nutt et al, 1999). Pax5 can be either an activator or repressor 
depending on its interacting proteins. It can repress lineage-inappropriate genes 
and simultaneously activate B-cell-specific genes (Busslinger & Urbanek, 1995). It is 
expressed from the pro-B to the mature B cell stage and Pax5-/- mice have B cell de-
velopment arrested at the early pro-B cell stage (Adams et al, 1992; Urbanek et al, 
1994). 
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Figure 1-8 Role of transcription factors in B cell development. 
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Table 1-1 B cell development and sequential expression of the antigen receptor loci.  
Stages  in  B   Cell  Development 
  stem cell 
early pro-B  
cell 
late pro-B  
cell 
large pre-B  
cell 
small pre-B  
cell 
immature B  
cell 
mature B  
cell 
H chain genes Germline 
D-J 
joining 
V-DJ 
joining 
VDJ  
rearranged 
VDJ  
rearranged 
VDJ  
rearranged 
VDJ 
rearranged 
L chain genes Germline germline germline germline V-J joining VJ rearranged VJ rearranged 
Surface Ig None None None 
μ chain in pre-B 
receptor 
μchain in cyto-
plasm and on sur-
face 
Membrane IgM Membrane IgM and IgD 
RAG, TdT expression No Yes Yes  No  Yes  Yes  No  
Surrogate L chain 
expression 
No Yes Yes  Yes  No  No  No  
Ig αβ expression No Yes  Yes  Yes  Yes  Yes  Yes  
Btk (Bruton’s Tyrosin 
kinsase) 
No Little  Yes  Yes  Yes  Yes  Yes  
Membrane markers CD34 
CD34  
CD45 (B220)  
Class II 
CD45R  
Class II  
CD19  
CD40 
CD45R  
Class II  
pre-B-R  
CD19  
CD40 
CD45R  
Class II  
pre-B-R  
CD19  
CD40 
CD45R  
Class II  
IgM  
CD19  
CD40 
CD45R  
Class II  
IgM  
IgD 
CD19  
CD21 
CD40 
Table adapted from http://microvet.arizona.edu 
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1.1.4.2 T cell development 
T cells originate in the bone marrow from the common lymphoid progenitor but mi-
grate to the thymus where they undergo a strict selection before maturation known 
as positive and negative selection. This selection leaves only about 2-4% of the total 
T cells that enter the thymus from the bone marrow. Since the size of the thymus 
decreases over the years and rapidly from puberty, the whole T cell repertoire will 
be decreasing with aging. Positive selection promotes the survival of only T cells 
whose TCRs recognize self-MHC molecules, while negative selection eliminates 
those T cells that have a strong affinity for self-MHC or self-MHC in presence of self-
peptides. Both classes of MHC molecules are indeed highly expressed on the surface 
of thymic cells, making the selection process effective. 
During the first stages of proliferation, which takes place in the cortex region of the 
thymus, T cells are identified as double negative (DN), since developing thymocytes 
lack the expression of the co-receptors CD4 and CD8, identifiers of helper and cyto-
toxic cells, respectively. Change in cell-surface protein expression is crucial within 
the DN state. This is divided into four stages, DN1 to DN4, each characterised by the 
expression of specific cell-surface molecules: DN1 are c-Kit+CD44+CD25-, this stage 
also defines the germline configuration of the antigen receptor loci for T cells; in 
DN2, cells are CD44+CD25+ and levels of c-Kit are reduced.  Expression of the re-
combination activating genes, RAG1 and RAG2, essential for V(D)J recombination, 
occurs in stage 2; DN3 are CD44-CD25+ and at this stage a rearrangement of the β 
chain of the TCR occurs which pairs up with a surrogate α chain to form a pre-TCR 
(pTα);  DN4 T cells are CD44-CD25. T cells which fail the rearrangement of the β 
chain do not progress to the later stages of development; on the other hand, suc-
cessful rearrangement leads to cell proliferation and expression of CD4 and CD8 on 
the cell surface. These cells are identified as double positive T cells (CD4+ CD8+) and 
will proliferate and express high levels of the TCR only if they recognize self MHC 
(positive selection), otherwise they will die. Double positive T cells will then start 
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expressing only one of the two co-receptors, becoming either CD4+ or CD8+ (single 
positive thymocytes).  Negative selection also occurs in double positive thymocytes 
and selects for those cells that recognize MHC bound to self-antigen. These cells will 
be ultimately eliminated and, of those that survive, only 2% will migrate to the pe-
ripheral lymphoid organs (Figure 1-9). 
               
Figure 1-9 T cell development stages in the thymus.  
Committed lymphoid progenitors arise in the bone marrow and migrate to the thymus. T cells at 
this stage are identified as double negative since they lack expression of CD4 and CD8 co-
receptors. In the last stage of the DN status, T cells express a pre-TCR composed of the non-
rearranging pre-Tα chain and a rearranged TCRβ-chain. Successful rearrangement of the TCR trig-
gers transition to double positive T cells (DP) which also express a complete αβTCR (Germain, 
2002).  
1.1.4.3 Signalling through the BCR and TCR triggers induction of new gene ex-
pression 
Both the BCRs and TCRc are associated with co-receptors that transmits information 
following binding of the antigens-derived peptides, in case of TCRs presented on the 
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surface of APCs by MHC molecules. BCRs are associated with Igα and Igβ, while TCRs 
with the CD3 complex and CD3ξ. These co-receptors contain ITAMs motifs whose 
phosphorylation by the Src protein kinase family triggers a cascade of events, 
which, through phophorylation of downstream proteins, triggers ultimately to the 
activation of transcription factors in the nucleus, which in turn will regulate gene 
expression.   
During BCR signalling, Src phosphorylate SyK protein kinase, while in TCR signalling, 
Src phophorylate Lck (which is associated with CD4 and CD8 molecules) and Fin (as-
sociated with CD3ξ and CDε), with the aim to phophorylate ZAP-70, the main target 
in TCR activation. The signals are then propagated onwards, with ultimately activa-
tion of MAP kinase family. The different activation pathways of this family will de-
termine specific gene expression.  
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1.2 Mechanism of V(D)J recombination  
A key characteristic of the adaptive immune system is its ability to recognise and 
destroy a large variety of pathogens by generating a vast array of immunoglobulin 
(Ig) and T cell receptor genes. V(D)J recombination generates Ig and TCR gene diver-
sity by assembling germline variable (V), diversity (D) and joining (J) gene segments.  
The TCR consists of either α and β chains or γ and δ chains, whilst immunoglobulins 
are composed of a heavy chain and light chain, where the latter can be of two iso-
types, kappa (κ) or lambda (λ) (Figure 1-10). 
 
Figure 1-10 Schematic representation of V(D)J recombination in B cells. 
In germline, V, D and J gene segments are separated. Following V(D)J recombination, specific gene 
fragments are selected to form the heavy and light chains of the immunoglobulins. 
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V(D)J recombination occurs in B and T cells at early stages of development: in pro-B 
and pre-B cells in the bone marrow and pro-T and pre-T cells in the thymus. Only 
two lymphoid specific proteins, RAG1 and RAG2, that are encoded by the recombi-
nation activating genes Rag1 and Rag2 initiate the process. These proteins intro-
duce double strand DNA breaks (DSBs) within the highly conserved recombination 
signal sequences (RSSs), which flank each V, D and J gene segment.  The RSSs con-
sist of a conserved heptamer and nonamer separated by 12 or 23 bp of non-
conserved DNA spacer. Efficient recombination occurs only between functional 
gene segments abutted by spacers of different length, the 12-RSS and the 23-RSS 
(Gillies et al, 1983).This restriction is known as the 12/23 rule (Eastman et al, 1996; 
Gillies et al, 1983). Following the cleavage reaction, two structures are generated 
(McBlane et al, 1995): a coding end with a hairpin structure and a blunt signal end 
(Figure 1-11).  The coding end and signal end are joined by the non-homologous 
end-joining (NHEJ) machinery that includes the Ku70/80 protein complex, XRCC4 (X-
ray cross complementing group 4), Artemis and DNA ligase IV. The Ku70/80 protein 
complex initiates the NHEJ pathway. First, this heterodimer binds to each of the 
broken ends of the double strand DNA and recruits the DNA-dependent protein 
kinase catalytic subunit (DNA-PKCS) to the DSB forming a protein complex where 
both DNA ends have been brought in close proximity. Nucleases and polymerases 
then process the non-compatible DNA. The hairpin structure of the coding ends is 
opened by the endonuclease Artemis (Bassing et al, 2002) and next the DNA ligase 
IV/XRCC4 complex catalyses ligation of the processed DNA ends. During the repair 
process, antibody diversity is greatly increased by a process called junctional diver-
sity: whilst the signal ends are precisely joined, repair of the coding ends involves 
the addition or deletion of nucleotides. The cleavage of the hairpin by Artemis is 
random and this generates a short single strand of nucleotides. Therefore, comple-
mentary nucleotides are added to generate a palindromic sequence at the end of 
the coding end (Lewis, 1994). These are called P nucleotides. After this reaction, the 
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terminal deoxynucleotidyl transferase, (TdT) fills the gap with non-templated nu-
cleotides (N nucleotides) (Desiderio et al, 1984). 
 
Figure 1-11 Generation of coding and signal end following RAG cutting. 
A. Rag proteins recognize and bind a DNA sequence flanking the V, D and J gene segments charac-
terised by the presence of a heptamer sequence separated from a nonamer sequence by a spacer 
of 12 or 23 nucleotides. B/C. Following binding, the two fragments are brought in close proximity 
and double strand DNA breaks are introduced. E/D. The non-homologous end-joining machinery 
joins the coding and signal ends. H, heptamer; N, nonamer; 12/23, spacer.  
1.2.1 Structure of the B cell receptor   
B cell receptors, the membrane-bound and secreted form of the immunoglobulins 
(Igs) are “Y” shaped proteins composed of two heavy chains of 50-55 KDa bound by 
a disulphide bond to two light chains of 25 KDa. There are five classes of Ig: IgG (γ), 
IgA (α), IgD (δ), IgM (μ) and IgE (ε) (Figure 1-12 B). Both heavy and light chains are 
composed of a variable region (product of the V(D)J recombination process) which 
contains the three complementary determining regions, CDRs, where antigens bind 
and a constant region (C). Structurally, Igs can be divided into two different portions 
when digested with papain: the Fc (fragment crystallizable) and Fab (fragment anti-
gen binding) (Figure 1-12 A). These are connected by a hinge region that is present 
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in all class of immunoglobulin with the exception of IgM and IgE. Treatment of im-
munoglobulins with pepsin instead results in cleavage of the heavy chain after inter-
chain disulfide bonds generating a fragment that contains the variable region to 
which antigens bind. This fragment is called F(ab')2 because it is divalent. The F(ab')2 
binds antigen but without mediating the effector functions (Figure 1-12 A). 
 
Figure 1-12 Structure of the B cell receptor and classes of Igs. 
A. Immunoglobulin molecules can be divided into two portions: the Fab portion is generated by 
digestion with papain. This digestion generates a fragment that contains both heavy and light 
chains as well as the region to which the antigen will bind.  The other fragment, Fc, contains the 
rest of the two heavy chains and the constant region. Treatment of immunoglobulins with pepsin 
results in cleavage of the heavy chain resulting in a fragment that contains both antigen binding 
sites. This fragment is known as F(ab')2 (Hewitt, 2006). B. Structural classification of the immu-
noglobulins. Immunoglobulins are classified into five groups: IgD, IgG, IgE, IgM and IgA. IgG exists 
as a monomer and is the most abundant with the longest half-life (20-22 days). IgGs are involved 
mainly in increasing the mechanisms of phagocytosis, neutralizing viruses and toxins. IgM repre-
sents a small population of total immunoglobulins, up to 10%. It is both secreted and membrane-
bound on the surface of B cells. IgA is produced as dimers and it represents about 10-15%.  IgA is 
mainly found in secretions. .IgE is a monomer, it comprises only 0.002% of the total Igs and is in-
volved mainly in the allergic reactions. IgD is not well-represented in the blood and has a short 
half-life of only a few days. Its role is still under investigation. Adapted from (Rojas & Apodaca, 
2002).  
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1.2.2 Structure of the T cell receptor 
The main function of T-cell receptors (TCRs) is to recognize peptides derived from 
proteolysis of extracellular antigens in endosomal-type compartments presented by 
MHC class II molecules on an antigen-presenting cell  (APC) or peptides derived 
from intracellular degradation of proteins in the cytosol and presented by MHC 
class I molecules; in addition both classes of MHC molecules must bind to one of the 
two co-receptors, CD4 or CD8 (Wang & Reinherz, 2002).  
TCRs consist of two disulphide-linked polypeptide chains, either a αβ heterodimer 
or a γδ heterodimer, with the αβ heterodimers being more common than the γδ 
heterodimers (the latter are known to respond mainly to bacterial and parasitic in-
fections); nevertheless, only one type is expressed on the T cell surface, non-
covalently bound to the signal-transducing CD3 subunits (CD3εγ, CD3εδ or CD3ζζ) 
(Kim et al, 2012; Pitcher & van Oers, 2003) (Figure 1-13). Similar to Ig molecules, 
both T α and β chains possess variable and constant Ig-like domains, although they 
are not subjected to somatic hypermutation (Chapter 1.2.3).  In addition, they con-
tain a transmembrane domain and a short cytoplasmic tail. 
TCR interaction with peptide–MHC complexes triggers a cascade of signals that 
promotes T-cell differentiation and proliferation. This cascade is initiated by activa-
tion of the Src-family kinases which phosphorylate two tyrosine residues within the 
ITAMs of the TCR ζ and CD3-γ, -δ and ε subunits, rendering the ITAMs high-affinity 
docking sites for the recruitment of the tandem Src homology 2 (SH2) domain-
containing ZAP-70 protein tyrosine kinase (PTK) (Veillette et al, 2002). ZAP-70, in 
turn, initiates the phosphorylation of several substrates which include: LAT (linker 
for activation of T cells), SLP76 (SH2-domain-containing leukocyte protein of 76 kDa) 
and PLC-γ-1 (phospholipase C- γ-1) (Samelson, 2002).  
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Figure 1-13 Components of the TCR activation machinery. 
Top panel: components of the TCR complex (http://www.focisnet.org/). Bottom panel: proximal 
events in TCR signalling. (a) The elements involved in the early stages of T cell signalling in resting 
cells are shown; curved arrows indicate phosphorylation of the tyrosine residues within the ITAMs 
of the CD3 and ζ chains as described in the text. (b) Recognition of MHC–peptide, presented by 
APC, and illustrates molecules involved after ZAP-70 activation; a cascade of phosphorylation 
events triggers the initiation of downstream signalling events leading to T cells activation (Kane et 
al, 2000). 
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1.2.3 Class switch recombination and somatic hypermutation 
Antigen-activated B cells can further diversify their immunoglobulin genes by two 
mechanisms: class-switch recombination (CSR), which occurs only in the IgH chain 
and somatic hypermutation (SHM) that can take place on both the heavy and light 
chains. Both mechanisms greatly increase the variability and affinity of the antibod-
ies repertoire and take place in B cells residing in the germinal centre (GC), a site in 
the secondary lymphoid organs where B cells actively proliferate. 
CSR occurs in B cells which express on their surface a functional IgM receptor, thus 
it take place only in B cells which have completed V(D)J recombination and which 
have migrated to the secondary lymphoid organs where they encounter the anti-
gen. Via CSR, B cells are able to switch between the IgM/IgD and the other class of 
Igs, IgA, IgE or IgG. This recombination event, which consists of a deletion, occurs 
within G-rich tandem repeated DNA sequences found in the switch regions (S), up-
stream of each constant gene segment (Figure 1-14) (Cory et al, 1980; Kataoka et al, 
1980). The reaction is stimulated by secretion of cytokines by activated T cells and 
requires also interaction between CD40 on the surface of B cells and CD40 ligand 
found on T cells. The reaction it is catalysed by the enzyme activation-induced 
cytidine deaminase (AID) which deaminates cytidines to uridines within the S re-
gions and following deletion, DNA breaks are repaired by the NHEJ repair system 
(Manis et al, 1998; Muramatsu et al, 2000; Muramatsu et al, 1999). 
SHM occurs in the rearranged V(D)J segment of both heavy and light. SHM intro-
duces mutations at high frequency (10–3- 10-5 pair bases per generation) and as in 
the CSR, it is catalysed by AID which deaminates cytidines to uridines at V region (V) 
genes to produce C-to-T mutations at the same frequency during transcription of 
the Ig loci. Mutations take place within a specific site called hypermutation domain 
(HYM) found within the promoter of the rearranged VDJ gene segments and en-
compassing the rearranged receptor locus and the intron region. Preferred sites or 
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“hotspots” for mutations are known to reside within the complementarity-
determining regions (CDRs) of the variable segments, the portion of the V region 
where contacts with the antigen occur; indeed, mutation rates are higher in the V 
region and tend to decrease as the JC region is reached. It is now established that 
SHM correlates to transcription and that the intronic enhancer (Ei) and promoter (P) 
are required for SHM (Figure 1-15) (Betz et al, 1994; Fukita et al, 1998). At the end 
of the process, mismatch repair and base excision repair (BER) process uridines in 
an error-prone fashion, leading to significant diversification of the Ig locus. 
 
Figure 1-14 Mechanism of CSR and SHM. 
CSR and SHM take place in the peripheral lymphoid tissues. SHM introduces mutations in the rear-
ranged V exon in both the heavy and light chains. CSR occurs only within the constant region of the 
heavy chain. It switches the Cμ region with another CH region, bringing that constant region close 
the V region. This reaction occurs in the “switch” regions located upstream of each constant region 
(except for Cδ). Deleted DNA is released as a circular DNA. S, switch region; C, constant region. 
Adapted from (Kinoshita & Honjo, 2001). 
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Figure 1-15 Regions in the Ig heavy chain involved in SHM. 
SHM is linked to transcription and efficient loading of RNA polymerases at the immunoglobulin 
promoter is supported by the Ei-MAR region found downstream of the rearranged antigen recep-
tor locus. Mutation frequency is maximal over the V(D)J coding exon and decays at the 3’ end 
approx. 1.5kb downstream from the transcription start site. C, constant region; MAR, matrix at-
tachment region; Ei, intronic enhancer; E3’, 3’ enhancer. Adapted from (Jacobs & Bross, 2001). 
1.2.4 Biochemistry of V(D)J recombination 
V(D)J recombination undergoes a meticulous regulation at different levels to ensure 
that only the right cells will initiate recombination at the right time. The process oc-
curs first at the heavy chain, with the rearrangement of the DH to JH gene segments. 
This occurs on both alleles, while, later rearrangement of DH JH to VH segments oc-
curs on one allele alone. The first recombination event defines the pro-B cell stage, 
while the second characterise the late pro-B cell stage. If successful, this rear-
rangement produces a μ chain and the cells progresses to the pre-B cell stage, oth-
erwise cells are lost at the earlier stage.  
The μ chain forms a complex together with other two proteins to generate what is 
known as the pre-B cell receptor. This complex is formed by the μ chain, λ5 and 
VpreB (“surrogate light chain”). As described earlier (Chapter 1.2), this complex also 
included the heterodimers IgαIgβ, essential to transmits signals from the membrane 
to the cytoplasm. Successful expression of the pre-B cell receptor defines also the 
transition from large pre-B cells to small pre-B cells. At this stage, rearrangement of 
the light chain is completed and signals through various receptors, such Bruton’s 
tyrosin kinases, alt further recombination events.  A successful light chain recombi-
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nation event leads to the expression of a complete immunoglobulin M (IgM) on the 
surface of B cells together with the IgαIgβ heterodimer. Self-reacting B cells are 
eliminated at this stage, while the rest will proceed to complete their maturation. 
The whole process is highly regulated at three main levels: lineage and stage speci-
ficity, allelic exclusion and cell cycle regulation. 
1.2.4.1 Stage and lineage specificity  
Stage-specific regulation of V(D)J recombination ensures that Ig heavy chain rear-
ranges first at the pro-B cell stage followed by Igκ or Igλ light chain at the small pre-
B cells (Ehlich et al, 1993; Yancopoulos & Alt, 1986). Lineage specificity ensures that 
the immunoglobulin loci rearrange only in B cells, while the T cell receptor loci only 
in T cells. These two processes are governed by changes in the accessibility of the 
gene segments to recombinase proteins RAG-1 and RAG-2. RAG1 and RAG2 proteins 
are the only lymphoid-specific factors required for V(D)J recombination: co-
expression of these two proteins triggers recombination of extra-chromosomal sub-
strates in non-lymphoid cells (Oettinger et al, 1990; Schatz et al, 1992) and their ex-
pression is strictly limited to B and T cells. However, the RSSs at each of the rear-
ranging loci in B and T cells are recognized by the same recombinase machinery. 
Therefore a key factor determining expression of the antigen receptor loci either in 
B or T cells is the accessibility of the recombinase to a specific rearranging locus. 
This is known as the accessibility hypothesis which was formulated by Yancopoulos 
and Alt (Yancopoulos & Alt, 1985): in the absence of recombination, the antigen re-
ceptor loci are not accessible to the recombinase machinery. Following chromatin 
changes, loci will be accessible to the RAG proteins in order to start rearrangement. 
Consistent with these findings, in vitro studies showed that when nuclei from RAG-
deficient B and T cells at different developmental stages were incubated with ex-
ogenous RAG proteins, cleavage at the RSSs was dependent on the lineage and de-
velopmental stage of the cells from which the nuclei derived (Stanhope-Baker et al, 
1996). This suggested that accessibility of the antigen receptor loci to the recombi-
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nase machinery in chromatin would determine which segments undergo recombi-
nation. Later studies showed that the basic unit of chromatin structure itself inhibit 
binding of the RAG proteins to the DNA (Golding et al, 1999; Kwon et al, 1998; 
McBlane & Boyes, 2000). Different factors regulate accessibility to RAG1/2, among 
which histone post-translational modifications and the activity of the chromatin 
remodelling factors which can either promote chromatin accessibility or rendering it 
inaccessible by promoting higher level of organization which make chromatin inac-
cessible to the recombinase machinery (Inlay & Xu, 2003; Johnson et al, 2003; Maes 
et al, 2001; McBlane & Boyes, 2000). 
1.2.4.2 Mechanism of allelic exclusion   
Allelic exclusion ensures that each lymphocyte expresses a single receptor encoded 
by only one of its Ig heavy and light chain alleles. Activation of one of the two alleles 
could be a pre-determined regulated process (Yancopoulos & Alt, 1986) or could be 
via a stochastic mechanism (Coleclough, 1983).  
In the first case it is thought that, following productive rearrangement, the pre-BCR 
signals to stop further rearrangements through a feedback inhibition mechanism 
(Chowdhury & Sen, 2004).  This model proposes that at the pro-B cell stage, both 
the Ig heavy and Ig kappa light chain loci are repositioned from the periphery to the 
center of the nucleus. At this stage of development, only the heavy chain rear-
ranges and IgH contracts. Successful rearrangement at the heavy locus triggers 
down-regulation of the RAG proteins by signals sent through the pre-BCR. At the 
pre-B cells stage, when the light chain recombines, the IgH de-contracts and the Ig 
kappa contracts. Because RAGs are re-expressed to allow recombination of the light 
chains, additionally, one allele from both heavy and light loci is sequestered by the 
repressive centromeric heterochromatin, making them inaccessible to the recombi-
nation machinery and leaving only one Ig kappa allele available to rearrange 
(Roldan et al, 2005) . This recruitment coincides with down-regulation of IL-7 signal-
ling in pre-B cells which triggers deacetylation of the VH locus (Chowdhury & Sen, 
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2003; Chowdhury & Sen, 2004) which in turn stops further rearrangements at the 
heavy chain (Figure 1-16).  
The stochastic model instead proposes that rearrangement of both alleles of the 
same gene is a rare event: functional V-to-DJ rearrangement is an event that occurs 
with low probabilities, therefore the probability of functional rearrangement on 
both alleles would be even lower (Liang et al, 2004).  
 
Figure 1-16 Mechanism of allelic exclusion.  
Heavy chain genes rearrange first and if a productive chain gene rearrangement takes place, rear-
rangement of the other heavy-chain allele is prevented while simultaneously light-chain gene rear-
rangement is initiated. In mice the k light chain genes rearrangement normally precedes the 
λ genes. In humans, however, either κ or λ rearrangement might take place if a productive heavy-
chain rearrangement has occurred. Generation of a complete immunoglobulin inhibits further 
light-chain gene rearrangement. If a non-productive rearrangement occurs for one allele, then the 
cell attempts rearrangement of the other allele (Yancopoulos & Alt, 1986). 
1.2.4.3 Cell cycle regulation  
V(D)J recombination is also regulated at the level of the cell cycle. Notably, it starts 
with the introduction of double strand breaks (DSBs) at the RSSs. DSBs cause a delay 
in the transition between the G1 to S phase of the cell cycle to allow repair of the 
DNA before entering the S phase. Therefore it was suggested that V(D)J recombina-
tion is restricted to a specific phase of the cell cycle, namely G0/G1 (Figure 1-17).  
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Because the RAG proteins are the only factors required to initiate V(D)J recombina-
tion, regulation of their synthesis or their degradation could prevent recombination 
in the wrong phase of the cell cycle. Earlier mutational studies on RAG2 suggested 
that, following accumulation in G0/G1 phase, phosphorylation of residue Thr490 
targets RAG2 for degradation in G1/ early S phase via the ubiquitin-proteasome 
pathway (Jiang et al, 2005; Li et al, 1996; Lin & Desiderio, 1993), Therefore, it was 
suggested that V(D)J recombination occurs preferentially during the G0/G1 phase of 
the cell cycle (Lin & Desiderio, 1994). 
 
Figure 1-17 Cell cycle regulation of V(D)J recombination. 
Cyclin A/CKD2 activity control RAG2 turnover during the G1/S transition phase. In the G1 phase of 
cell cycle, p27Kip1 and p21 bind to cyclin A/CKD2 inhibiting their action, thus rendering RAG2 sta-
ble in the nucleus. A. When cells enter the G1/S transition phase, p27Kip1 and p21 are degraded, 
therefore cyclin A/CKD2 are able to phosphorylate RAG2 at Thr-490 residue. B/C. Phosphorylation 
of RAG2 triggers its nuclear export to the cytoplasm where it can bind Skp2 to recruit the SCF com-
plex that retains an E3-ubiquitin ligase activity. D/E. The SCF complex ubiquitinates RAG2 trigger-
ing its degradation by the 26S proteasome (Chao et al, 2014). 
1.2.5 Organization of the immunoglobulin light chains genes in mice 
Immunoglobulin light chain genes can be either κ or λ chain. The ratio between κ 
and λ differs between species. In humans it is 6:4 while in mice it is 10:1.  
The murine κ locus has clustered variable (V), joining (J) and only a single constant 
(Cκ) gene segment, while the λ locus is bipartite as a result of evolutionary gene du-
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plication. It has four JC genes and two V genes (Bernard et al, 1978; Blomberg et al, 
1981; Miller & Tang, 2009): Vλ1 rearranges with Jλ1-Cλ1 or Jλ3-Cλ3, while Vλ2 rear-
ranges with Jλ2-Cλ2. The Jλ4-Cλ4 is thought to be a non-functional pseudogene be-
cause of an inactive RNA splice site and is thus not fully functional during rear-
rangement (Carson & Wu, 1989). Overall V1 to J1 accounts for 60% of the total re-
combination, while V2 to J2 for 30% and V3 to J3 for 10% of the recombination 
process. 
In mice, immunoglobulin light chain expression is under the control of enhancers.  
The kappa locus has two enhancers: the intronic enhancer, κEi, and the 3ˈ enhancer, 
κE3ˈ.  Mutational analysis showed that both enhancers are essential for locus acti-
vation at the pre-B cell stage.  The lambda locus has two B cell specific enhancers, 
Eλ2-4 and Eλ3-1 which are 90% homologous (Eisenbeis et al, 1993; Hagman et al, 
1990) (Figure 1-18 B).  
 
 
Figure 1-18 Organization of the immunoglobulin light chains in mouse.  
A.The immunoglobulin light chain can be either κ or λ. The murine κ locus consists of several V 
gene segments and five J gene segments. Two enhancers regulate the locus: an intronic enhancer, 
Eiκ, and one at the 3ˈ end, 3ˈEκ. (b) The murine λ light chain results from an evolutionary gene du-
plication event. It has two V gene segments and four JC gene segments. Two enhancers regulate 
gene expression: Eλ2-4 found 15.5 kb downstream of JCλ2 and Eλ3-1, 35 kb downstream of JCλ1. 
At the lambda locus, Vλ1 rearranges mostly with JCλ1 while Vλ2 with JCλ2. This is also consistent 
with the large distance between the gene segments: there is about 190 kb between Vλ2 and JCλ3, 
while 55-75 kb separates Vλ2 from JCλ2 and 24 kb separates Vλ1 from JCλ1. 
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1.2.5.1 Immunoglobulin lambda light chain expression in mice 
The lambda locus is a duplicated locus that is mainly regulated by two enhancers, 
Eλ2-4 and Eλ3-1. Initial analyses identified four hypersensitive sites downstream of 
JCλ1 (Eccles et al, 1990): HS1, HS2, HS3 and HS4 where HS1 is equivalent to Eλ3-1. 
Insertion of the 3ˈ half of the lambda locus into a bacterial artificial chromosome 
(BAC) and subsequent deletion of the hypersensitive sites showed that only one of 
them, HS1, is required for functional recombination (Haque et al, 2013). Different 
transcription factors bind to these enhancers to regulate VJ recombination. Earlier 
footprinting studies of Eλ2-4 enhancer identified four protected regions: λA, λB, Eλ1 
and Eλ2. 
Mutational analysis showed that two of them, Eλ1 and Eλ2, confer optimal activity, 
while the other two, λA and λB, are essential for enhancer activity (Eisenbeis et al, 
1993; Rudin & Storb, 1992). Subsequent EMSA studies identified these factors. Of 
these, Eλ1 and Eλ2 were E-box proteins and λA was identified as a member of the 
myocyte enhancer factor 2 (Mef2) protein family. Mef2 protein members belong to 
the MADS (MCM1, Agamous and Deficiens and serum-response factor, SRF), a fam-
ily of transcription factors that also regulates myogenesis through interactions with 
other transcription factors (Shore & Sharrocks, 1995). Vertebrates have four mef2 
genes:  mef2a, mef2b, mef2c, and mef2d located on different chromosomes 
(Pollock & Treisman, 1991). EMSA studies using extracts from the cell line J558L 
showed that more than one member binds to the λA motif (Satyaraj & Storb, 1998). 
The two complexes were identified as JA1 and JA2 and are likely to correspond to 
Mef2C and and Mef2D, respectively. Mef2C is mainly expressed in brain, spleen and 
skeletal muscle while Mef2D is ubiquitously expressed (Martin et al, 1994; Martin et 
al, 1993).  
Whilst E boxes and Mef proteins are ubiquitously expressed, factors binding to λB 
were identified as B cell-specific factors (Eisenbeis et al, 1993). This is a protein 
complex formed by PU.1, a member of the Ets family (Petterson & Schaffner, 1987), 
and PIP (PU.1-interacting partner, also known as IRF4) (Eisenbeis et al, 1995).  Be-
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cause the Eλ2-4 and Eλ3-1 enhancers share 90% homology and the binding site for 
this complex is conserved between the two enhancers,  it can be suggested that the 
PU.1/IRF4 protein complex also binds to the Eλ3-1 enhancer (Rudin & Storb, 1992). 
IRF4 is expressed in B and T cells (Brass et al, 1996; Eisenbeis et al, 1995) and its 
DNA binding domain is highly homologous to the DNA binding domain of the inter-
feron regulatory factors (IRF) family. IRF4 is directly recruited by PU.1 to form a pro-
tein complex. However, it is not able to bind the λB motif on its own (Eisenbeis et al, 
1993; Pongubala et al, 1992): IRF4 is recruited only when interacting with PU.1 and 
only when PU.1 is phosphorylated at serine 148 of the PEST domain (Pongubala et 
al, 1993). The C-terminal regulatory domain of IRF4 is required for ternary complex 
formation with PU.1 and, when IRF4 is not bound to PU.1, the C-terminus functions 
as an auto-inhibitory domain preventing IRF4 binding to DNA (Brass et al, 1996).   
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1.3 Eukaryotic transcription 
The exact number of human genes is still unknown, however it is has been estab-
lished that approx. 20-25,000 genes (less than 2%) are expressed as proteins, with 
the rest of the genome containing non-coding RNA genes, regulatory sequences, 
introns, and non-coding DNA (International Human Genome Sequencing, 2004; 
Pertea & Salzberg, 2010) .  Proteins-coding genes are regulated at several levels in-
cluding transcription initiation and elongation, mRNA processing, transport, transla-
tion and mRNA stability.  
Two different families of cis-acting DNA elements regulate proteins-coding genes by 
controlling gene expression: a promoter together with the proximal promoter ele-
ments, and distal regulatory element such as enhancers and locus control regions 
(LCRs), silencers and insulators. These DNA sequences contain binding siteS for 
trans-acting DNA binding transcription factors whose function is either to enhance 
or repress transcription. 
1.3.1 Chromatin organization  
Eukaryotic genomes are packaged by histone proteins into chromatin, which is 
composed of condensed fibres to fit 2m of DNA into the nucleus, which has a di-
ameter of just 5-10µm. While DNA must be highly packed, this packaging must also 
be able to allow different processes like replication, repair and transcription to oc-
cur and to allow the binding of different factors required for these processes. 
When isolated chromatin is examined by electron microscopy it appears like a 
“beads on string” of about 10 nm diameter, where the “beads” represent the single 
nucleosomes and the “string” the DNA linker (Finch et al, 1975). Further micrococ-
cal nuclease digestion and cross-linking studies have shown that the nucleosome is 
the basic repeating unit of chromatin and it is formed by an octamer of histones 
around which is wrapped approx. 147bp of DNA. A DNA linker joins individual nu-
cleosomes (Luger et al, 1997). The histone proteins involved are: H1, H2A, H2B, H3 
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and H4 (Felsenfeld, 1978; Kornberg, 1977) (Figure 1-19). The octamer is formed by a 
tetramer of two copies each of H3-H4 as well as two H2A/H2B dimers. Histone H1 is 
not part of the main core, it is less conserved compared to the other histones and it 
associates with the nucleosome outside of the main core. It binds to both DNA and 
the core histone octamer and its function is believed to be in the formation of 30 
nm fibres (Robinson & Rhodes, 2006).  
 
Figure 1-19 Levels of chromatin organization.  
DNA is first wrapped around nucleosomes to form the first level of structural compaction, then 
further association of nucleosomes gives the 30nm fibre and higher levels of organization allow 
the generation of the final structure found in chromosomes. Adapted from (Luger et al, 2012). 
The 30 nm fibre represents a higher level of organization and is formed by the asso-
ciation of nucleosomes. How nucleosomes are organized to form the latter level of 
compaction is poorly understood and two main models have been proposed. The 
one start helix (also called the solenoid model) where nucleosomes form a helical 
structure with 6 nucleosomes per turn, and the two start model, where nu-
cleosomes follow a zig-zag pathway and the linker between nucleosomes is straight. 
(Dorigo et al, 2004).  
Higher levels of compaction are still being studied.  Earlier studies showed that by 
removing histones from metaphase chromosomes, DNA is organized into loop do-
mains (Marsden & Laemmli, 1979; Paulson & Laemmli, 1977). These loops are at-
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tached to a scaffold of non-histone chromosomal proteins called scaffold attach-
ment regions (SAR). Similar studies were also conducted on histone-depleted inter-
phase chromosomes and the DNA was organized in loop domains anchored to the 
nuclear matrix. This scaffold is referred to as the matrix attachment region (MAR) 
(Heng et al, 2004). 
                               
Figure 1-20 The solenoid and the zig-zag models. 
A.The solenoid model is characterized by interactions between consecutive nucleosomes: the 
30 nm chromatin fibre a nucleosome in the fibre interacts with its fifth and sixth neighbour nu-
cleosomes. C. In zigzag model the interactions occur between alternate nucleosomes (N1 to N8): 
the chromatin fibre is a two-start helix in which nucleosomes are arranged in a zigzag manner such 
that a nucleosome in the fibre binds to the second neighbour nucleosome. Adapted from (Li & 
Reinberg, 2011). 
1.3.1.1 Activation of chromatin: chromatin modifications 
During transcription, the binding of different proteins to specific DNA sequences is 
essential to ensure correct initiation. This process is however influenced by the 
presence of nucleosomes which create a repressive environment due to the inac-
cessibility of the DNA (nucleosome positioning), as well as some post translational 
modifications, to which histones are subjected, which can create a repressive chro-
matin environment (Berger, 2007; de la Cruz et al, 2005; Strahl & Allis, 2000). Post-
translational modifications occur in some amino acids in the N-terminal tails of his-
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tones and involve acetylation of lysine residues, methylation of lysine and arginine 
residues, phosphorylation, ubiquitination or ADP-ribosylation (Berger, 2002). Spe-
cific enzymes catalyse these reactions that can either create a repressive chromatin 
or an open chromatin structure. Moreover, once these tails are modified, histones 
are able to recruit further proteins that can affect chromatin structure (Jenuwein & 
Allis, 2001; Strahl & Allis, 2000). The combination of the different modifications is 
known as the “histone code” (Figure 1-21).  
Histone acetylation occurs at lysine residues and correlates with gene activation. It 
can affect chromatin structure at two main levels. It can either trigger 30nm fibre 
opening by decreasing interactions between histone tails and adjacent nucleosomes 
or it can help octamer eviction from promoters (Reinke & Horz, 2003). Indeed, ace-
tylation of lysine residue 16 in H4 (H4K16ac) promotes an open chromatin status 
since it inhibits formation of the 30nm fibre (Robinson et al, 2008; Shogren-Knaak et 
al, 2006).  
In contrast, histone methylation is associated with either promotion or repression 
of transcription, depending on the lysine modified. Trimethylation of lysine residue 
4 in H3 (H3K4me3) is associated with gene expression, but trimethylation of lysine 
residue 9 and/or lysine residue 27 in H3 (H3K9me3 and H3K27me3) is associated 
with repression of gene expression. Moreover, the same tail can be subjected to 
one or more modifications on different residues, thus gaining new functions 
(Berger, 2007; Strahl & Allis, 2000). In addition to post-translational modifications, 
chromatin remodelling complexes are required and recruited at the specific site to 
relax chromatin structure. These complexes use the energy derived from ATP hy-
drolysis to modify the interaction between histones and DNA, by displacing the his-
tone octamer or altering the histone core to unwrap the DNA (Clapier & Cairns, 
2009; Vignali et al, 2000).  
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Figure 1-21 Modifications occurring on the histones.  
Histone tails are subject to post-translational modification, namely acetylation, methylation, 
phosphorylation. Acetylation (blue), methylation (red), phosphorylation (yellow) and ubiquitina-
tion (green). The number in grey under each amino acid represents its position in the sequence 
(Portela & Esteller, 2010). 
1.3.2 Promoters and the initiation of transcription 
Promoters are DNA regulatory elements located near and typically upstream of the 
genes they regulate. Eukaryotic promoters are composed of two parts: the core 
promoter (or basal promoter), which includes the TATA box (AT-rich region) for bin-
ding of RNA Pol II and the transcriptional start sites (TSSs), and the upstream pro-
moter element (one or more) which regulate transcription (Figure 1-22). A typical 
promoter also contains short sequence elements which represent binding sites for 
different transcription factors; these are typically found 200-300bp upstream of the 
start site. The importance of the TATA box was demonstrated in mutagenesis stud-
ies where mutations usually reduced or abolished the activity of the promoters, al-
though it was also shown that not all promoters necessarily have a TATA box 
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(Breathnach & Chambon, 1981; Farrell). These include housekeeping genes (ex-
pressed constitutively) and developmentally-regulated genes (Lodish, 2000).  
 
Figure 1-22 Structure of eukaryotic promoters. 
To allow binding of RNA Pol II to the promoter, several transcription factors have to 
find their place within the promoter. These are known as general or basal transcrip-
tion factors (GTFs): TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH and are known to bind 
in an ordered, sequential manner. TFIID is the largest of the transcription factors as 
it consists of the TATA box – binding protein (TBP) and eleven TBP-associated fac-
tors (TAFs) (Lodish, 2000). 
The first factor to bind to the promoter is TFIID (in complex with TAFs and TBP) fol-
lowed by TFIIB and a newly formed complex between Pol II and TFIIF (Figure 1-23). 
One major role played by TFIIF is also to help maintain chromatin at the promoter in 
an uncondensed state due to the histone acetylase activity. Then, TFIIE binds allow-
ing entrance of the next transcription factor, TFIIH (Alberts et al, 2002). This com-
plex is known as the pre-initiation complex or PIC.  
During eukaryotic transcription, a major role is also played by the C terminal domain 
(CTD) tail on the largest subunit of the RNA Pol II which consists of multiple, con-
served repeats of a heptapeptide with the consensus sequence Tyr-Ser-Pro-Thr-Ser-
Pro-Ser and serves as a binding site for several transcription factors.  Which one of 
these factors will bind depends on the phosphorylation state of the CTD during 
gene transcription.  
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Figure 1-23 Assembly of the pre-initiation complex in eukaryotic cells. 
The diagram depicts the ordered assembly of the general transcription factors during eukaryotic 
transcription. 
Phosphorylation occurs mainly on Serine 2 and Serine 5 of the repeats, with the lat-
ter being catalysed by TFIIH that has a protein kinase activity (Figure 1-24). In vivo, it 
was shown that RNA Pol II requires the association of a mediator and a large protein 
complex that includes TFIIB, TFIIH and TFIIF; this association occurs at the CTD of 
unphosphorylated RNA Pol II. 
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Figure 1-24 CTD phosphorylation patterns during the RNAPolII transcription cycle. 
RNA Polymerase II (RNAP II) with hypophosphorylated CTD forms together with general transcrip-
tion factors (GTFs) and the mediator a pre-initiation complex (PIC). During initiation, elongation 
and termination various CTD phosphorylation marks (P) are successively introduced and erased.  
These CTD signatures determine the interaction capacity of RNAP II machinery for different tran-
scription and RNA processing factors (schematically presented by colored ovals). (Heidemann & 
Eick, 2012). 
1.3.3 Enhancers 
Enhancers are relatively short DNA sequences characterised for the first time over 
30 years ago while analysing the β-globin locus using transient reporter gene assays 
in cultured cell lines (Banerji et al, 1981). The activity associated with these se-
quences was first described in viruses and subsequently also in metazoans (Banerji 
et al, 1983; Gillies et al, 1983). These regulatory sequences contain binding sites for 
transcription factors and they can activate their target genes over long distances 
without regard to orientation or location (Bulger & Groudine, 2011). It was also re-
ported that in some cases enhancers can regulate expression of genes located on 
different chromosomes (Williams et al, 2010). Different mechanisms were de-
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scribed to explain how such long regulatory elements control gene expression; 
however the predominant model envisages enhancers looping out the intervening 
DNA, to touch and activate the target promoters (Bulger & Groudine, 1999).  
While localization of promoter sequences is relatively easy to perform (by sequenc-
ing of the 5'-end of its mRNA), identification of DNA sequences corresponding to 
enhancers is more challenging. However, a common feature of most enhancers se-
quences is the exposure of the local chromatin structure to DNase I digestion in vi-
tro. Such regulatory sequences contain sites for transcription factors that can both 
exclude nucleosomes and bend DNA and are therefore marked by such nuclease 
hypersensitivity (Elgin, 1988; Gross & Garrard, 1988; Wu, 1980). DNase I hypersensi-
tivity is therefore considered to be a hallmark of enhancer function in a given DNA 
sequence. With the advent of  microarrays and high-throughput sequencing, further 
studies  have also allowed the genome-wide mapping of nuclease hypersensitivity 
(Crawford et al, 2006).  Another feature of enhancers is that their non-coding se-
quences are highly conserved (implying their regulatory function) compared to less 
conserved sequences which instead tend to accumulate mutations and are there-
fore unlikely to be regulatory elements. A typical example is that of the β-globin lo-
cus where expression of all the genes is under the control of a potent enhancer, 
known as LCR located 20-30 kb upstream of the gene cluster: indeed, the sequences 
of the LCR are well conserved among mammalian genomes (Visel et al, 2009). In 
addition, common to sequences identified as enhancers are some “chromatin signa-
ture” recently discovered by genome-wide studies. These include H3K4Me1 and the 
absence of H3K4Me3 (Birney et al, 2007). Interestingly, studies utilizing embryonic 
stem (ES) cells and multiple primary cell types have suggested that acetylation of 
histone H3K27 in combination with H3K4Me1 is correlated with active enhancers, 
whereas H3K4Me1 alone appeared to mark either inactive or ‘‘poised’’ enhancers 
(Creyghton et al, 2010; Rada-Iglesias et al, 2011). These data, together with ge-
nome-wide mapping of nuclease hypersensitive sites (HSs), have suggested that the 
human genome might harbour as many as 1x106 enhancers (Heintzman et al, 2009). 
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Figure 1-25 Long range chromatin interactions  
Distant enhancers cause DNA to loop and touch the cognate promoters following intervention of 
several transcription factors (https://www.boundless.com). 
1.3.4 Locus control regions (LCRs) 
LCRs are cis-acting regulatory DNA sequences that enable high-level and tissue-
specific gene expression.  
It is known that transcribed genes are more sensitive to nuclease digestion com-
pared to non-transcribed genes. This is referred to as general sensitivity to differen-
tiate it from the DNase I hypersensitivity found at active promoters and enhancers 
(Forrester et al, 1986). One of the well-characterized LCRs is the human β-globin, 
which was the first to be identified (Grosveld et al, 1987). In the β-globin cluster 
these hypersensitive sites at the LCRs are required for the correct activation of the 
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genes and they bind a number of different transcription factors (Grosveld et al, 
1993; Orkin, 1995). 
1.3.4.1 The β-globin LCR 
The β-globin LCR is located 6 to 22 kb 5ˈ to the first embryonic globin gene (ε) in the 
locus which consists of five developmentally regulated genes (, G, A,, ) organ-
ized and expressed at different times during development. The  gene is the first to 
be expressed, it is then silenced and expression of the foetal  genes takes place. At 
birth, expression of  genes starts to decrease and  and  genes are activated 
(Dean, 2004) (Figure 1-26). The LCR has four erythroid, tissue-specific DNase I–
hypersensitive sites, HS1 to HS4 (starting from the 5'-end), while in non-erythroid 
cells, there are three additional HSs, HS5 to HS7 (Dean, 2006; Li & 
Stamatoyannopoulos, 1994). Moreover,  it was shown that enhancer activity of the 
β-globin LCR depends on HS2, 3, and 4, but not on HS1 or 5 (Fraser & Grosveld, 
1998).  Experiments in which the cores of HS2 and HS3 were mutated or deleted 
respectively, showed a decreased level of expression of the ε-globin as well as the 
β-globin gene suggesting that these sites are essential for full expression of the lo-
cus, while deletion of HS2-5 resulted in complete loss of gene expression (Bungert 
et al, 1999; Reik et al, 1998). However the contribution of individual HSs for full 
gene activation is still poorly understood and debate about the function of a single 
HS is still open. In the absence of the LCR, transcription of the human β-globin gene 
represents less than 1% of the endogenous murine β-globin mRNA in transgenic 
mice (Magram et al, 1985; Townes et al, 1985), suggesting that the LCR has strong 
enhancer activity. 
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Figure 1-26 Organization of the human β-globin locus. 
The human β-globin locus has five genes arranged in order of their developmental expression, 5'-ε-
Gγ-Aγ-δ-β-3'. Expression is under the control of the LCR located 5' between 6 and 22kb upstream 
the distal  gene. The LCR is composed of five hypersensitive sites (HS1 to HS5) required for high 
level expression of the genes. The first gene to be expressed is the ε-globin gene in the yolk sac; 
this is then silenced and the Gγ- andAγ-globin genes are expressed in the foetal liver. After birth 
the γ-globin genes are silenced and the β-globin gene and δ-globin gene are activated in the bone 
marrow. The HSs 5′HS1 through 5′HS7 are located −6, −11, −15, −18, −22, −28, and −35 kb relative 
to the ε-globin gene, respectively.  
1.3.5 Insulators can block enhancer-promoter interaction 
Specific elements are able to block the interaction between enhancers and promot-
ers. An insulator is a DNA sequence that is able to interfere with the interaction be-
tween enhancer and promoter, thus preventing inappropriate gene expression. The 
best characterized insulators are Gypsy in Drosophila and the chicken β-globin 5'-
HS4 (cHS4), both associated with specific proteins which mediate their activity:  
Su(Hw) and CTCF (CCCTC-binding proten), respectively (Brasset & Vaury, 2005). Two 
mechanisms describe their action. An insulator can be an enhancer-blocking insula-
tor found between the enhancer and promoter preventing any association or it can 
act as a barrier insulator by preventing the spread of repressive heterochromatin.  
In the first mechanism it is thought that the insulators might form chromatin loops 
to physically separate the enhancer and promoter. The exact mechanism by which 
this happens is poorly understood; however, it was proposed that an insulator could 
block specific signals from the enhancer from reaching the promoter (Gaszner & 
Felsenfeld, 2006; West et al, 2002; Zhao & Dean, 2004). The action of these ele-
ments relies on the models proposed to explain long-range enhancer-promoter in-
teractions. Historically three different models were proposed to explain this interac-
tion: the linking, tracking and looping models (Figure 1-27).  
βε Gγ Aγ δ
3′ HSs
5′ HSs
5  43   2 1
HSs-111
10 Kb
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Figure 1-27 Models to describe long-range chromatin interactions. 
In the linking model, interaction between distant elements is mediated by a protein complex that 
forms a link between the distant elements and the promoter. The tracking model, also called the 
scanning model, is based on the ability of enhancer and protein complexes bound to it to scan the 
DNA to find a promoter. If the right promoter is found, then a more stable complex is formed.  In 
the looping model, generation of chromatin loops brings the distant enhancer close to its cognate 
promoter.  
1.3.6 Linking, tracking and scanning models 
Long-range interactions between distant regulatory elements and promoters have 
been documented in different systems. The following models explain how these in-
teractions may occur. 
The linking model is based on the hypothesis that interaction between distant ele-
ments is mediated by a protein complex that forms a link between the distant ele-
ments and the promoter (Bulger & Groudine, 1999; Dorsett, 1999; Morcillo et al, 
1996). The idea for this hypothesis comes from the activity of some insulators. Be-
cause these elements block the signal between enhancer and promoter, it was pro-
posed that what an insulator is blocking is the signal transmitted by specific proteins 
dispersed along the chromatin, between the distant regulatory element and the 
promoter (Morcillo et al, 1997). Mutation studies conducted on Drosophila Cut 
gene, which is regulated by the Chip protein, suggest that Chip could be essential 
for enhancer-promoter communication. The same is believed to happen for its ver-
tebrate homologues interacting with the LIM (Lin11, Isl-1 & Mec-3) domains of nu-
clear proteins. The LIM domains are zinc-finger motifs involved in different protein-
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protein interactions and proteins with these motifs also possess a homeodomain 
DNA binding motif (HD); therefore it was proposed that the Chip protein (as well as 
the vertebrate homologues) could promote interactions between the LIM proteins 
located at the enhancer and HD proteins found along the chromatin between en-
hancer and promoter generating in this way a sort of chain of proteins that con-
nects the two distant elements (Bulger & Groudine, 1999; Morcillo et al, 1996). 
However to date, there is no strong experimental evidence to support this model.  
The tracking or scanning model is based on the ability of enhancer and protein 
complexes bound to the DNA and their ability to to scan the DNA to find a pro-
moter. If the right promoter is found, then a more stable complex is formed (Hatzis 
& Talianidis, 2002; Travers, 1999). Like the linking model, the evidence for this idea 
comes from the activity of some insulators. Since these elements are able to block 
signals between enhancer and promoter, the idea is that these elements interrupt 
the communication by blocking the complex from reaching the promoter during the 
scanning of the DNA (Figure 1-27). Good evidence for this model comes from the 
protein CTCF in vertebrates with its binding site for the insulator cHS4 in the chicken 
β-globin genes. Using minichromosome constructions carrying the ε globin gene 
and HS2, it was found that this insulator was able to interrupt the communication 
between HS2 and promoter by altering the pattern of chromatin modification at the 
promoter (Zhao & Dean, 2004). Positioning of cHS4 between HS2 and the ε globin 
gene blocked the spreading of histone acetylation that was attributed to the activity 
of CBP and p300, two proteins required for haematopoietic differentiation (in the 
case of CBP, acetylation decreased when the insulator was between, outside or in-
side the enhancer- gene unit). These results were confirmed by creating a cHS4 lo-
cus mutated in the sequence that corresponds to the CTCF binding.  In this con-
struct, transcription was restored, confirming the role played by this insulator and 
the two proteins involved (Zhao & Dean, 2004).  
The looping model is based on the theory that the generation of loops is the main 
mechanism by which a distant enhancer reaches its own promoter (Figure 1-27). 
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This model is supported by results obtained using the Chromosome Conformation 
Capture (3C) technique (Dekker et al, 2002). The 3C is a powerful technique to de-
termine whether interactions occur in vivo; this methodology is based on the ability 
of formaldehyde-induced cross-links to detect links between regions of chromatin 
that are interacting with each other (Figure 1-28). Following digestion with a restric-
tion enzyme, the ends of the cross-linked fragments are ligated. Following reversal 
of the cross-links, PCR is used to analyse ligation frequencies of the fragments 
(Dekker, 2006).  Using the 3C technique to analyse interactions in the human  glo-
bin cluster, several loops were generated, collectively identified as “active chroma-
tin hub”, a complex network of different loops coming in and out. However a limit-
ing factor for the 3C technique is that it does not explain how the two distant ele-
ments “find each other” since it is supposed that the two elements find each other 
by collision (Bulger & Groudine, 1999; Engel & Tanimoto, 2000). Thus, it is possible 
that both looping and scanning models are valid.  
Two other techniques have been developed to analyse chromosome interactions 
based on the same theory of 3C, the 4C (Circular chromosome conformation cap-
ture or 3C-on chip) and the 5C (Chromosome conformation capture carbon copy). 
Both techniques detect interaction between genomic regions without prior knowl-
edge of the fragments involved. The 4C technique includes a circularization step to 
analyse chromatin interaction of all genomic regions with a given gene, while the 5C 
copies and amplifies parts of the 3C library to obtain many copies of a unique liga-
tion product (Dostie & Dekker, 2007; Ohlsson & Gondor, 2007; Simonis et al, 2007; 
Zhao et al, 2006). Thus these techniques are useful to detect previously unpredicted 
interactions. 
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Figure 1-28 Chromosome conformation capture technique.  
a) Genes (blue rectangles) and regulatory elements (red circles) are linearly organized along chro-
mosomes (top), but as a result of specific interactions between elements (indicated by arrows, 
both in cis and in trans) a complex three-dimensional network is formed inside the cell (bottom).  
(b) Schematic representation of the 3C assay.  Chromatin is cross-linked, digested with a restriction 
enzyme and then ligated.  Specific ligation products can be detected by PCR. Adapted from 
(Dekker, 2006). 
1.3.7 Role of transcription factors in mediating long range chromatin in-
teractions 
Although different studies showed that enhancer and promoters interact, they do 
not show how the specificity of this interaction is achieved.  Different studies were 
conducted on the globin genes and evidence was found in favour of specific tran-
scription factors in mediating long range interactions between regulatory elements 
and promoters. An example is given by GATA-1, a transcription factor required for 
erythroid cell development and which activity depends on FOG-1 (friend of GATA-
1). A mouse cell line was generated that expressed GATA-1 fused to the oestrogen 
receptor ligand-binding domain (GATA-1-ER). This hybrid protein, in the presence of 
either oestrogen or tamoxifen (the results were the same) was able to bind to DNA 
allowing careful control of GATA-1 binding to the LCR. 3C analysis revealed that in 
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Chromosome conformation capture
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the absence of the ligand, loop formation between the genes and the LCR was de-
creased. However, subsequent introduction of the hormone allowed recruitment of 
GATA-1 to the hypersensitive sites (HS2 and HS3) of the LCR and interaction of the 
LCR with the promoter by looping, confirming that it is only GATA-1 activity (with 
the co-factor FOG-1) that promotes this close interaction. Moreover, it was ob-
served that loop formation coincided with RNA Pol II recruitment to the promoter 
site, suggesting that GATA-1 is also responsible for the recruitment.  
The involvement of transcription factors was also investigated in the α-globin locus. 
In this study Vernimmen et al. used cells at different stages of erythropoiesis to in-
vestigate the order in which GTFs, RNApol II, mediator and elongation factors were 
recruited at the HS regulatory elements (and consequently to the promoter site) 
and the role played by some transcription factors in regulating this process. The hy-
pothesis is that these genes are kept in a “poised” state (starting from the multipo-
tent haematopoietic cells stage) until full activation, which occurs in mature eryth-
roblasts. During this time, specific transcription factors are recruited by the HSs to 
start transcription (Anguita et al, 2004; Vernimmen et al, 2007). 
The transcription factors involved include GATA-1, GATA-2 and Sp/X-KLF factors. 
They are bound to the HSs sites at the pro-erythroblast stage by forming a complex, 
which was then able to recruit the pre-initiation complex. Indeed, 3C analysis con-
firmed the presence of chromatin looping which was connecting to the distant regu-
latory elements to the promoter of the α globin genes and also that the PIC complex 
was recruited at the HS site by looping at the promoter site, but only in the final 
stages of cell development (primary erythroblasts). Therefore the role of these 
transcription factors, which are highly specific, is also to ensure that the PIC com-
plex is recruited at the promoter site at the right time of cell development. In the 
absence of these transcription factors bound at the HSs, PIC is not recruited at these 
sites, since only the interaction between HSs and these transcription factors facili-
tate the recruitment.  In addition, chromatin modifications are also associated with 
recruitment of these transcription factors. For example GATA-1 recruits histone ace-
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tyltransferase (HAT) whose activity is related to the generation of open chromatin, 
which in turn facilitate binding of other different proteins (Letting et al, 2003). 
More evidence for the role of enhancers in mediating long range interactions comes 
from studies conducted on the protein p300, a transcriptional co-activator as well 
as an acetyltransferase also required for correct haematopoietic development 
(Zhao & Dean, 2004). In this study, ChIP analysis and sequencing (ChIP-seq) of the 
genome distribution of p300 associated with the enhancer, showed that the pres-
ence of this protein (referred as “peaks”) in some mouse embryonic forebrain, mid-
brain and limb was an evidence for enhancer activity in these tissues (Visel et al, 
2009); in contrast, the absence of p300 was found to be correlated with a lack of 
enhancer activity. Therefore p300 binds to the enhancer to drive the interaction 
with the promoter. Since this protein is widely distributed and associated with en-
hancer activity, this could explain how enhancers deliver the modification to pro-
moters. 
1.3.8 bHLH proteins in Ig genes rearrangement  
Strong evidence exists that both rearrangement at a particular locus and Ig class 
switch recombination are preceded by transcriptional activity of the respective 
germ-line gene segments (Engel et al, 1999; Lennon & Perry, 1990; Schlissel & 
Baltimore, 1989). It has been established that cis-regulatory elements physically 
contact the promoter to drive transcription of the target genes, but how the speci-
ficity of this interaction is achieved is poorly understood. Different factors may in-
fluence this interaction: chromatin modifications (Chapter 1.3.1.1), the interactions 
between specific transcription factors and boundary elements that interfere with 
the interaction between enhancers and promoters.  
In the next paragraph, the role of transcription factors in mediating long-range in-
teractions in the immunoglobulin chain genes is examined.  
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At the immunoglobulin lambda light chain locus, enhancer-promoter interactions 
are driven by B cell specific transcription factors. Of these, the helix loop helix pro-
tein, E47 is of particular interest. 
The helix-loop-helix transcription factor family are key regulators of different devel-
opmental processes such as neurogenesis, myogenesis, and haematopoiesis (Bain 
et al, 1994; Zhuang et al, 1994). These proteins recognize specific, conserved DNA 
sequences termed E-box sites. E-box sites were first discovered at the promoter and 
enhancer regions of both B and T lineage specific genes by in vivo methylation pro-
tection assays that identified a number of sites which were specifically protected. 
The protected DNA sequence consisted of the core hexanucleotide sequence, 
CANNTG (in which N denotes any nucleotide), and was named E box binding protein 
(Ephrussi et al, 1985). This sequence was subsequently identified at the enhancers 
of the immunoglobulin heavy chain locus (IgH: μE1, μE2, μE3, μE4, and μE5.), at the 
immunoglobulin kappa light chain locus (Igκ: κE1, κE2, and κE3), the T cell receptor 
α and  β loci, the promoters of the mb-1, λ5, and pre-Tα genes (Ahmad, 1995; Ernst 
& Smale, 1995; Ho et al, 1989; Kee & Murre, 2001; Nelsen et al, 1993; Reizis & 
Leder, 1999; Sigvardsson et al, 1997). Subsequent studies have also identified E-box 
elements in promoter and enhancer elements that control muscle-, neuron-, and 
pancreas-specific gene expression (Buskin & Hauschka, 1989; Chaudhary et al, 
1997).  
1.3.8.1 E-box proteins 
Based on structural characteristics, dimerization properties and tissue distribution, 
E-box binding proteins have been classified into 6 classes (I to VI) (Murre et al, 
1994). E12, E47, HEB, E2-2 belong to the Class I HLH proteins. These transcription 
factors regulate gene expression in different tissues and can form either homo- or 
heterodimers (Murre et al, 1989b).  
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Class II HLH proteins are tissue-restricted and include: NeuroD/BETA2, MyoD, myo-
genin and the achaete-scute complex. Compared to class I proteins, these transcrip-
tion factors are usually unable to form homodimers, preferring instead het-
erodimerization with other E proteins. Class III HLH proteins include the Myc family 
of transcription factors, TFE3, SREBP-1, and the microphthalmia-associated tran-
scription factor, Mi. Transcription factors belonging to this group are characterized 
by the presence of a leucine zipper motif (LZ) adjacent to the HLH motif.  Class IV 
HLH proteins include Mad, Max, and Mxi that are capable of dimerizing with the 
Myc proteins.  Class V HLH proteins includes proteins that lack the basic region 
which are called Id proteins, inhibitor of differentiation. Id proteins heterodimerize 
with E proteins from class I and class II, however, because they lack the DNA binding 
domain, they regulate E proteins activity by sequestering them as non-functional 
heterodimers (Benezra et al, 1990).  Class VI HLH proteins are characterized by the 
presence of a proline in the DNA-binding domain and include the Drosophila pro-
teins Hairy and Enhancer of split (Davis & Turner, 2001; Klambt et al, 1989). Class VII 
is characterised by the presence of the bHLH-PAS domain; members of this class 
include the aromatic hydrocarbon receptor (AHR), the AHR nuclear-translocator 
(Arnt), hypoxia-inducible factor 1α, and the Drosophila Single-minded and Period 
proteins (Crews, 1998). 
E proteins are broadly expressed and many of them from the different classes can 
bind DNA as homo- or heterodimers. In B cells, the predominant E box binding 
complex is comprised of E47 homodimers: E47 is one of the two products of the 
E2A gene and it plays a key role during B cell development. In thymocytes E47/HEB 
heterodimers are found predominately (Bain et al, 1993; Murre et al, 1991; Sawada 
& Littman, 1993; Shen & Kadesch, 1995). In non-B cells, E47 forms heterodimers 
with other members of the E protein family proteins (class II) such as the muscle-
specific bHLH protein MyoD (Lassar et al, 1991; Wendt et al, 1998)  and NeuroD1, a 
key regulator of neuronal development (Lassar et al, 1991; Longo et al, 2008; 
Mehmood et al, 2009; Murre et al, 1989b; Naya et al, 1995). 
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1.3.8.2 Structural properties of the E-box binding protein E47 
The transcription factor E2A is encoded by the Tcfe2a gene and belongs to the class 
I family of HLH transcription factors (Murre, 2005). E2A gives rise to E47 and E12 by 
differential pre-mRNA splicing of the exon encoding both the DNA binding and 
dimerization domains (Murre et al, 1989a). E12 and E47 share 80% sequence iden-
tity within the bHLH domains and they only differ in usage of the exon encoding the 
bHLH domain (basic helix-loop-helix), however E12 has a lower affinity for DNA due 
to an inhibitory region nearby the bHLH domain (Sun & Baltimore, 1991). This could 
explain the major use of the E47 homodimer in B cells, rather than the E12. 
The helix-loop-helix motif of the E47 is highly conserved and consists of two amphi-
pathic α-helices separated by a loop structure (Murre et al, 1989b). This domain is 
common to all E-box binding proteins and is responsible for dimerization. The E47 
dimer forms a parallel, four-helix bundle (two dimeric alpha-helical structures) 
which allows the basic region to contact the major groove of the DNA. In addition to 
the basic region, residues in the loop and helix 2 also make contact with DNA 
(Ellenberger et al, 1994). 
Structurally, alongside the DNA-binding and the dimerization domains, E12 and E47 
also share two conserved transcriptional activation domains known as the activa-
tion domain 1 (AD1) and loop-helix (LH) or AD2 domains (Aronheim et al, 1993; 
Massari et al, 1996; Quong et al, 1993). Both activation domains are helical struc-
tures; AD1 is found at the N terminus within the first 99 amino acids (Massari et al, 
1996), while AD2 is downstream of the N terminus within residues 349-406 (Figure 
1-29). Further analysis of these two transcription factors region identified additional 
highly conserved regions named E proteins homology domains (EHD1, EHD2 and 
EHD3). Mutational studies within both the AD and EHD domains have shown that 
transcriptional activity of E47/E12 decreases remarkably. In particular, point muta-
tions in either AD1 or AD2 cause about 50% reduction of transcriptional activity. 
EHD1 and EHD2 mutation led to 30-40% decrease, while deletion of the EHD3 do-
main trigger only slight decreases in transcriptional activity (Massari et al, 1996). 
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Further studies confirmed that this domain is responsible for E47 regulation by the 
Notch family via MAPK phosphorylation of the residues within the EHD3 domain 
(Massari et al, 1996). 
 
Figure 1-29 Domain structure of the E12/47 proteins. 
AD1, activation domain 1; AD2, activation domain 2; bHLH, basic helix-loop-helix, EHD, E protein 
homology protein.  
1.3.8.3 Regulation of E47 activity 
E47 is widely expressed and together with other E-proteins plays key roles in pro-
moting commitment to and differentiation of the B- and T-cell lineages from the 
early stages to the generation of the immunoglobulins and TCRs. To this end, its ac-
tivity is highly regulated. E47 is regulated by association with Id proteins and, 
among others, by p300 (adenoviral E1A-associated protein, 300 kDa) while its turn-
over is controlled by Notch/MAPK signalling pathway. P300 is a histone acetyltrans-
ferase, which acetylates the ε-amino group of lysine residues in different proteins 
by regulating their functions, and it works in association with CREB (cAMP-
response-element binding protein)-binding protein (CBP). It is now known that E47 
contains an acetylation site for p300/CBP within the AD1 domain and that this in-
teraction is responsible for E2A transcription activity and localization in the nuclear 
compartment (Bradney et al, 2003). 
1.3.8.3.1 Regulation of E47 activity by Id proteins 
E47 and Id proteins are widely expressed throughout the haematopoietic system 
and they have crucial roles in cell fate decisions, differentiation and proliferation of 
lymphocytes as well as in other tissues (de Pooter & Kee, 2010; Engel & Murre, 
2001; Greenbaum & Zhuang, 2002; Massari & Murre, 2000). In B lymphocytes E 
1 99 349 406 549 607 654
AD1 bHLH
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protein activity is strictly regulated by association with Id proteins (Rivera & Murre, 
2001). Id proteins are class V HLH proteins, however they lack the basic DNA binding 
domain, therefore when they dimerize with E47 and other E proteins, they prevent 
DNA binding and thus inhibit E protein function, acting as dominant-negative HLH 
proteins (Benezra et al, 1990; Ghil et al, 2002). There are four known Id proteins 
(Id1, Id2, Id3 and Id4) and a recent study has showed that E47 interacts with all 4 
classes (Teachenor et al, 2012a). In the absence of E-box binding proteins, Id pro-
teins are distributed in the cytoplasm/perinuclear region. Although Id proteins are 
very small proteins (all four Id proteins range from 13 to 18 kDa) and this implies 
that they can enter and exit the nucleus by passive diffusion, numerous studies 
have suggested that other pathways may regulate their subcellular localization. 
Upon binding with the E proteins, Id proteins relocate to the nuclear compartment 
(Deed et al, 1996). Because Id proteins lack a nuclear localisation signal, E47 and 
other E proteins, which are nuclear proteins and therefore possess a classical nu-
clear localization signal, function as nuclear chaperones (Deed et al, 1996). More-
over, association of Id/E47 protein complex regulates the half-life of both proteins: 
Id proteins have a half-life of about 1h, while E47 turnover is slower, about 24 
hours. Following formation of the dimer, the half-life of Id proteins is increased to 3 
hours, while E47 is decreased to 16 hours (Deed et al, 1996). 
1.3.9 Importance of E47- IRF4 interaction  
The PU.1/IRF4 complex binds the Eλ3-1 enhancer and an interesting question is 
what mediates the interaction with the promoter of sterile transcription upon 
chromatin looping. While transcription factor binding to the enhancer site has been 
widely characterized (such as the E2A protein complex), the transcription factors 
that bind to the promoter have not been determined. Engel et al. (1999) mapped 
the promoters of sterile transcription for JCλ1, JCλ2 and JCλ3 (Engel et al, 2001). Ini-
tiation of transcription was observed at 293 bp, 116 bp and 79 bp upstream of the 
Jλ gene segment, respectively. Previous studies showed that IRF4 interacts with E47 
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at the κE3' enhancer and that this interaction enhanced E2A (E12 and E47) DNA 
binding and resulted in a strong E2A/IRF4 transcriptional synergy (Nagulapalli & 
Atchison, 1998; Nagulapalli et al, 2002). However, in this study, the two transcrip-
tion factors lay immediately adjacent to each other. Therefore it is not known if 
these factors interact when bound to separate sites on the chromosome. However, 
by performing an internet database search for E2A binding sites, it was possible to 
highlight E2A binding sites at the Jλ1, Jλ2 and Jλ3 promoters as well. These were 
60bp upstream and 35bp downstream of the start site of sterile transcription of the 
Jλ1 promoter, 110bp upstream and 50bp downstream of the Jλ2 promoter and 
15bp downstream of the Jλ3 promoter. Therefore, a possible E2A-IRF4 interaction 
was investigated in this study. 
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1.4 Human papillomaviruses: general considerations 
Human papillomaviruses (HPVs) are small, non-enveloped, DNA viruses that belong 
to the Papillomaviridae family which display a particular tropism for the stratified 
squamous or cutaneous epithelium (zur Hausen, 2009). To date, at least 180 HPV 
genotypes have been cloned from clinical lesions and they have been numbered 
sequentially (Bernard et al, 2010). These have been categorized into five genera 
based on their genomic sequence and subdivided based on the ability to infect the 
skin (cutaneous) or the mucosal epithelium: α, β, γ, μ and ν (Bernard, 2013; de 
Villiers et al, 2004). HPVs infect the basal cells and their infectious life cycle is closely 
related to the differentiation of the stratified epithelium.  HPVs that infect the geni-
tal mucosa are divided into groups: high risk (HR), such as HPV16, 18, 31 and 33 and 
low risk (LR), such as HPV6 and 11 that cause benign warts that do not progress to 
malignancy (Table 1-2).  HPV16 and HPV18 are the major causative agents of cervi-
cal cancer, accounting for 50% and 20% of all cervical cancer cases, respectively. 
Cutaneous HR-HPVs that infect the skin include HPV5 and 8 that cause flat lesions of 
the skin. HPVs are also the major causative agents of head and neck carcinomas.  
Cervical cancer is the third-most common cancer in females worldwide, with ap-
proximately 275,000 deaths each year (Ferlay et al, 2010; 2008) and the second 
most common cancer in women worldwide, with over 450 000 new cases of cervical 
cancer being diagnosed annually (WHO, 2008).  In most cases, the infection is 
cleared by the immune system after a period of 12-24 months (Richardson et al, 
2003; Steben & Duarte-Franco, 2007), however, in a few cases (at least 10%), some 
virus particles will persist and keep multiplying and the persistence of this infection, 
together with viral genome integration, can potentially lead to cancer (Munger et 
al, 2004; Stanley, 2008).  
Transformation of normal stratified squamous or cutaneous epithelium to cancer 
occurs in multiple steps. In cervical cancer these are: carcinoma in situ (stage 0, 
strictly confined to the cervix), and stage I, II, III and IV, with the latter being carci-
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noma that has extended to different organs surrounding the cervix (pelvis, uterus). 
The immune response is quite weak in the cervix, and in addition, HPVs use differ-
ent strategies to evade immune recognition. CD4+ T helper cells are found mainly 
during regression of cervical intraepithelial neoplasia (CIN) lesions, while CD8+ cyto-
toxic T cells are dominant in invasive carcinoma (Stanley, 2009).  
 
Table 1-2 HPV type and disease association.  
Disease HPV  Type * 
Plantar warts  1, 2, 4, 63 
Common warts  2, 1, 7, 4, 26, 27, 29, 41, 57, 65, 77, 1, 3, 4, 10, 28 
Flat warts  3, 10, 26, 27, 28, 38, 41, 49, 75, 76 
Other cutaneous lesions (e.g., epi-
dermoid cysts, laryngeal carcinoma)  
6, 11, 16, 30, 33, 36, 37, 38, 41, 48, 60, 72, 73 
Epidermodysplasia verruciformis  2, 3, 10, 5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 
38, 47, 50 
Recurrent respiratory papillomatosis  6, 11 
Focal epithelial hyperplasia of Heck  13, 32 
Conjunctival papillomas/carcinomas  6, 11, 16 
Condyloma acuminata (genital 
warts)  
6, 11, 30, 42, 43, 45, 51, 54, 55, 70 
Cervical intraepithelial neoplasia:  
Unspecified  30, 34, 39, 40, 53, 57, 59, 61, 62, 64, 66, 67, 68, 69 
Low risk  6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 51, 52, 74 
High risk  16, 18, 6, 11, 31, 34, 33, 35, 39, 42, 44, 45, 51, 52, 56, 58, 66 
Cervical carcinoma  16, 18, 31, 45, 33, 35, 39, 51, 52, 56, 58, 66, 68, 70 
*Orders indicate relative frequency; bold: most frequent associations. Adapted from(Burd, 2003).  
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Figure 1-30 Worldwide cervix cancer incidence rate. 
The diagram depicts worldwide cervical cancer incidence. Colours indicate the relative percentage 
distribution within the countries taken in consideration for the analysis, with red indicating the 
highest rate and dark green the lowest incidence rate (Cobo, 2012). 
1.4.1 HPV Structure 
HPV is a small, non-enveloped, double stranded DNA virus of 55 nm diameter. The 
encapsidated circular viral genome of only 8kb is associated with cellular histones to 
form a minichromosome (Danos et al, 1982; Favre, 1975).  
The outer surface of the capsid is comprised of 360 molecules of the major capsid 
protein L1 organized into 72 capsomeres, each made up of a pentamer of L1 pro-
teins which is important to the structure of the HPV capsid (Baker et al, 1991) 
(Figure 1-31).  Each capsomere is composed of β-strands whose connecting loops 
were shown to be different in various HPVs (Ludmerer et al, 1996; Ludmerer et al, 
1997; Roth et al, 2006). This is taken into consideration when formulating types of 
vaccines (Bishop et al, 2007; Carter et al, 2006). On the other hand, the minor cap-
sid protein L2 varies from strain to strain suggesting that it is not involved in the de-
termination of the capsid structure of HPV (Bordeaux et al, 2006; Florin et al, 2002).  
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Figure 1-31 Structure of VLPs assembled from the L1 protein  
The picture represents the case of HPV16. Adapted from (Chen et al, 2000). 
1.4.2 HPV genes: transcription from early and late promoters 
HPVs replicate and assemble in the nucleus of keratinocytes where genes are ex-
pressed in a temporal and highly regulated manner which is tightly linked to kerati-
nocytes differentiation (Howley & Lowy, 2006). The genome is divided into three 
regions: a 4 kb early (E) region that encodes non-structural proteins (E1, E2, E4, E5, 
E6, E7) and a 3-kb late (L) region that encodes the two capsid proteins, L1 and L2 
involved in virus particles assembly and capsid generation; these two regions are 
separated by two polyadenylation sites (pA): early and late pA sites. Both early and 
late ORFs are encoded on the same DNA strand. A third region encompasses a 400–
1000 bp non-coding long control region (ncLCR) that contains the p97 core pro-
moter and different cis-regulatory elements important for viral replication and gene 
expression (Figure 1-32). 
L1 capsomere x 72
(pentamer)
L1 monomer x 5
Individual L1 proteins
VLPs
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Transcription is initiated from different promoters: transcription from the early 
promoter p97 generates mRNA containing all six early ORFs and, via alternative 
splicing, gives rise to the different forms of mRNA (Rosenberger et al, 2010; Stacey 
et al, 1995; Tan et al, 1994). As the viral life cycle progresses, the late promoter 
p670 is activated in terminally differentiated cells and generates a polycistronic RNA 
with three exons and two introns which, gives rise to L1 and L2 by RNA splicing 
(Schwartz, 2013). In addition to promoter switch, transcription of the later genes 
requires a change of polyA signal and derepression of two alternative splice sites 
(Figure 1-32).  
The expression of early and late genes is regulated at both the level of primary tran-
scription and RNA processing (Bernard, 2002; Graham, 2008; Thierry, 2009; Zheng & 
Baker, 2006). The six non-structural early viral regulatory proteins are transcribed in 
undifferentiated or intermediately differentiated keratinocytes while the two genes 
encoding the viral capsid proteins are transcribed only in keratinocytes undergoing 
terminal differentiation. An exception is the early protein E4 that is continuously 
expressed and is also synthetized in terminally differentiated cells (Peh et al, 2002). 
Functions of early and late viral proteins 
E1 is a protein of 73 kDa that plays a key role in viral DNA replication. This protein 
binds to the origin of DNA replication (ori) in the 3'-LCR as a double hexamer, one 
for each strand. The E1 protein has a helicase activity (3'-5' directionality) that un-
winds the DNA in an ATP-dependent manner (Hughes & Romanos, 1993); this func-
tion is supported by the E2 protein, which binding sites are also found within the 3'-
LCR. E2 proteins main function is to recruit E1 to the origin of replication site, acting 
as a molecular tether. The resultant ternary DNA-protein complex, E1-E2-ori, has 
the helicase activity necessary to unwind the supercoiled viral DNA. To stabilize the 
newly generated single-stranded DNA, E1 interacts with the replication protein A 
(RPA) (Loo & Melendy, 2004). 
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Figure 1-32 Organization of the HPV16 genome and regulation of gene transcription. 
Control of early gene transcription and replication is mediated by the upstream regulatory region 
(URR), which contains promoter and enhancer elements as well as the viral origin of replication; 
early and late regions are separated by two polyadenylation (A) sites: early, AE and late AL sites. 
Two promoters, p97 and p670 drive the expression of early and late viral proteins via alternative 
splicing. Yellow and blue circles represent splice factors-binding sites. Adapted from (Johansson & 
Schwartz, 2013; Stanley, 2012).  
E2 is a 40-45 kDa DNA-binding protein that plays a key role during replication of the 
viral genome by loading the E1 protein onto the origin of replication in the viral DNA 
sequence. E2 is the main transcriptional regulator of viral genome, as such it inter-
acts with a broad range of proteins, and among these is Brd4, a chromatin remodel-
ling protein. The interaction, which occurs between the amino terminal transactiva-
tion domain (TAD) of E2 and the carboxy-terminal domain of Brd4, is known to be 
crucial in tethering of viral episomes to cellular chromosomes during mitosis, main-
taining viral genomes in an active conformation for transcription as well as tran-
scriptional repression (Jang et al, 2009; Wu et al, 2006; You et al, 2004). In cells in 
which the viral genome is integrated, the E2 gene is frequently disrupted with con-
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sequent loss of the protein (Hamid et al, 2009) and unregulated transcription of E6 
and E7 in cervical carcinoma cells (Schwarz et al, 1985).  
E4 is translated from a spliced transcript as a fusion protein with E1 (the first 5 
amino acids) generating a fusion protein called E1^E4 (Chow et al, 1987; Doorbar et 
al, 1990) which has little sequence homology between HPV types. E1^E4 proteins 
are known to associate with the keratin intermediate filaments and in HPV16 they 
induce collapses of the keratin networks. Keratins constitute the major structural 
proteins in epithelial cells. This occurs via a domain at the amino terminus of the 
protein that contains a conserved sequence motif, LLXLL (Roberts et al, 2008). In 
addition, a proline-rich region is located at the C-terminus which confers upon 
E1^E4 the ability to interfere with G2-M progression of the cell cycle (Davy & 
Doorbar, 2007; Knight et al, 2004). 
E5 is a small membrane-bound oncoprotein of only 83 amino acids (HPV16). Al-
though HR-HPV E6 and E7 are known to play major roles in malignant transforma-
tion of cervical cells, several studies in HPV16 and BPV1 have shown that E5 also is 
an important mediator for cellular transformation. This occurs via different mecha-
nisms which include up-regulation of EGFR signalling pathway (Pim et al, 1992; 
Rodriguez et al, 2000), MAPK activation via tyrosin kinase-mediated and protein 
kinase C (PKC)-dependent pathways modulating cell proliferation, angiogenesis, and 
anti-apoptosis  (Chen et al, 1996; Crusius et al, 1997; Gu & Matlashewski, 1995), dis-
ruption of cell-cell communication via down-regulation of Cx26 (BPV1) and Cx43 
(HPV16) (Oelze et al, 1995), immune evasion through down-regulation of MHC class 
molecules (Ashrafi et al, 2005; Zhang et al, 2003). 
L1 and L2 are the major and minor capsid proteins, respectively. They are translated 
from the late promoter and play a key role during the infectious process. L1 is a pro-
tein of 55 kDa which self-assembles into virion-like particles (VLP), potent immuno-
gens currently used to formulate VLPs-based vaccine. L1 proteins are highly con-
served and form 72 pentamers, each composed of a pentameric L1 capsomer (360 
L1 proteins). The minor capsid protein L2, (55 kDa) is mainly located inside the cap-
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sid beneath the L1 pentamers and it is not capable to form VLPS like L1. It has been 
estimated there are approx. 72 L2 proteins/capsid (1:5 L2 to L1 proteins ratio) (Buck 
& Trus, 2012). Because of L2 location, during virus entry into the host cells, interac-
tion of HPVs with heparan sulphate proteoglycans triggers a conformational change 
in L2 necessary to expose the amino terminal portion of the protein for cleavage by 
the pro-convertase enzyme furin which is required for endosome escape (Day & 
Schiller, 2009; Richards et al, 2006). Both proteins are detected in the nuclei of the 
terminally differentiated cells and they are required for efficient assembly of infec-
tious virions in the upper layer of the epithelium. During active infection, they both 
relocate from the cytoplasm to the nucleus and assemble into icosahedral capsids 
into which the viral genomes are packaged (Conway & Meyers, 2009). 
 
 
Figure 1-33 Spatial distribution of viral proteins in stratified epithelium.  
The viral genomes are replicated in synchrony with cellular DNA replication. Differentiation of 
HPV-positive cells induces the productive phase of the viral life cycle, which requires cellular DNA 
synthesis machinery. Blu circles: E1, E2; Red circles: E6, E7; green circles: E4; violet circles: L1 and 
L2. Adapted from (Lazarczyk et al, 2009).  
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1.4.3 E6 
HPV E6 molecules are small proteins of only 150 amino acids. They are character-
ised by the presence of two zinc-finger motifs  (Cys-X-X-Cys), which are well con-
served among various types of HPVs (Howie et al, 2009) (Figure 1-34). The main cel-
lular target of both low and high risk HPV E6 is p53, a tumour suppressor protein 
involved in maintaining cellular stability by inducing apoptosis in those cells that 
cannot transit into the S-phase. 
When cell cycle regulators are affected by E7, levels of the tumour suppressor pro-
tein p53 tend to increase and induce apoptosis in E7-expressing cells that the virus 
has to counteract in order to maintain its replication in those cells. To this end, high 
risk HPV E6 proteins recruit a cellular E3 ubiquitin ligase, the E6-associated protein 
(E6AP) to form a trimeric complex with p53, triggering ubiquitination and protea-
somal degradation of p53, thus inhibiting programmed cell death (Demers et al, 
1994; Jones et al, 1997; Lechner & Laimins, 1994).   
While p53 degradation represents one of the main targets of E6, other cellular 
mechanisms triggered by E6 proteins impact in the maintenance of cellular stability, 
such as the ability of E6 to activate the catalytic subunit of the telomerase, hTERT, a 
key determinant of the enzymatic activity of human telomerase (Klingelhutz et al, 
1996). Normal cells undergo only a limited number of cell divisions, until they even-
tually stop dividing. This process is known as cellular senescence and it is a conse-
quence of the loss of telomeres associated with each round of DNA replication. 
However, malignant cells are able to induce cell division by activation of telom-
erase, the enzyme that synthesizes the telomeric repeat DNA (which is lost during 
division of normal cells). In HPV-positive human keratinocytes cells, the HPV16 E6 
protein up-regulates the hTERT promoter activity inducing telomerase activity in 
these cells and it is thought that E6AP may also be involved in this process (Gewin & 
Galloway, 2001).  
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E6 proteins from HR-HPVs have been extensively studied and their role in cellular 
transformation has been established; however, very little is known about the role of 
LR-HPVs E6 and why they fail to cause malignant disease, triggering only non-
invasive lesions. E6 from LR-HPV are known to interact with p53, however they are 
unable to trigger its degradation; instead it was shown that interaction with p53 (to 
a different binding site from the one used by HR-HPVs E6) triggers cytoplasmic 
translocation of p53, binding of p53 to BAK (Bcl2 antagonist killer), leading ulti-
mately to apoptosis (Sun et al, 2008). 
p53-independent activities of HR-HPVs E6  (in particular HPV16) that are important 
for immortalization of keratinocytes are characterised by their interaction with PDZ 
(PSD-95/Dlg/ZO-1) domain proteins which are known to be involved in the mainte-
nance of cell polarity in epithelial cells (Thomas et al, 2008). Apico-basal and planar 
cell polarity is regulated at many levels and several proteins are involved, namely 
the Scribble, the partitioning defective (PAR) and Crumbs (CRBS) complexes; these 
complexes ensure correct cell-cell junctions development (Assemat et al, 2008). 
However, the C terminus of HR-HPV16 and 18 E6 proteins contains a well conserved 
PDZ domain motif (PBM) which interacts with the PDZ domain proteins with delete-
rious consequences on cell polarity establishment. Among the well-established in-
teractions are those occurring between hDlg (human homologue of Drosophila 
Disks large) MAGI-I (membrane-associated guanylate kinase), ZO-I (zonula oc-
cludens I), MUPP-l (multi-PDZ domain protein-I) and hScrib (Javier, 2008).  
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Figure 1-34 Schematic representation of the actions of HPV16 E6. 
A.HPV E6 conserved regions and their target proteins (Wise-Draper & Wells, 2008). B. High-risk E6 
proteins inhibit p53-dependent growth arrest and apoptosis in response to aberrant proliferation 
through several mechanisms, resulting in the induction of genomic instability and the accumula-
tion of cellular mutations. Formation of an E6–E6-associated protein (E6AP)–p53 trimeric complex 
results in p53 degradation, and the interaction of E6 with the histone acetyltransferases p300, 
CREB binding protein (CBP) and ADA3 prevents p53 acetylation (Ac), inhibiting the transcription of 
p53-responsive genes (Moody & Laimins, 2010). 
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1.4.4 E7 
E7 protein is a small protein of only 100 amino acids in length (18 kDa) character-
ised by the presence of three conserved regions (CR) called CR1, CR2 and CR3. 
These conserved regions are crucial for the oncogenic activities of HR-HPVs. In par-
ticular, CR2 is known to contain a conserved motif, namely LXCXE, important for vi-
ral maintenance and binding to pRb, the main target of E7 proteins (Munger et al, 
1989b). In normal cells, pRb exists in a complex with E2F and its main function is to 
repress cell cycle progression into S-phase. The G1/S-phase transition is under the 
control of cyclins, cyclin dependent kinases (cdks), and the inhibitors of cdk (CDKi), 
which are known to negatively regulate the activity of the cdks. When cells are 
ready to progress to the S phase following extracellular signals, pRb is phosphory-
lated by cdks, dissociating it from E2F and thus it is free from the complex and cells 
are able to enter the S-phase (Dyson, 1998; Zerfass et al, 1995). During HPV infec-
tion, E7 proteins bind to the hypo-phosphorylated form of pRb, sequestering it from 
E2F and triggering cells to enter the S-phase. This interaction is coupled with pRb 
degradation by the calcium-activated cysteine protease, calpain, which cleaves pRb, 
as well as other Rb members which are targeted by E7 for degradation via the ubiq-
uitin proteasome family (Boyer et al, 1996). Although all E7 proteins bind to pRb, 
those from the HR-HPVs have a higher binding affinity (Longworth & Laimins, 2004).  
Figure 1-35 also shows additional mechanisms adopted by E7 to induce genomic 
instability in infected cells, such as the ability of E7 to trigger abnormal centrosome 
synthesis by interacting with γ-tubulin and to  induce DNA damage and activation of 
the ATM–ATR pathway (ataxia telangiectasia-mutated–ATM and RAD3-related DNA 
damage response) (Moody & Laimins, 2010). In addition, it has been shown that E7 
proteins can induce cells to enter the S-phase independently of pRb interaction. 
This is achieved by E7 interaction with HDAC (histone deacetylase) to deacetylate 
E2F factors. This interaction is known to occur via a site on E7 different from that 
used by pRb, which also interacts with HDAC in normal cells to repress the tran-
scription of E2F genes (Harbour & Dean, 2000). 
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Figure 1-35 Schematic representation of the actions of HPV16 E7. 
A. HPV E7 conserved regions and their target proteins (Wise-Draper & Wells, 2008). B. High-risk 
human papillomavirus (HPV) E7 proteins subvert G1–S arrest and induce hyperproliferation 
through inhibition of retinoblastoma (Rb) family members and constitutive activation of E2F-
responsive genes. E7 also affects cellular gene expression through interaction with histone deace-
tylases (HDACs) and E2F6. E7 further deregulates cell cycle control through inhibition of cyclin-
dependent kinase inhibitors (such as p21 and p27), stimulation of cyclins and through direct acti-
vation of cyclin-dependent kinase 2 (CDK2) (Moody & Laimins, 2010).  
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1.4.5 HPV life cycle: virus/host cell interactions 
Being an obligatory intracellular parasite, HPV must be able to transfer its own ge-
netic material into the host cell in order to replicate using the host cell replication 
machinery (Pelkmans & Helenius, 2003). To follow these steps in experimental stud-
ies has been difficult due to the fact that the replication of papillomaviruses is 
linked to the differentiation programme of keratinocytes, making propagation of 
the virus difficult: to date, HPVs have been propagated using xenograft and  raft cul-
ture systems developed in the early 1990’s (Kreider et al, 1985; Meyers et al, 1992) 
followed by subsequent use of DNA-free virus-like particles and pseudovirions 
(Roden et al, 1996; Rossi et al, 2000; Unckell et al, 1997), both of which have been 
produced in large scale using packaging cell lines such as 911 and 293 (Buck et al, 
2004).  Further studies also suggested that pseudovirions needed to be activated in 
order to infect organotypic raft cultures or primary keratinocytes in vitro (Day et al, 
2008). 
HPV-host cell interactions have been studied using virus-like particles (VLPs) which 
are produced by synthesis of the L1 and L2 capsid proteins (Kirnbauer et al, 1992; 
Rose et al, 1993; Volpers et al, 1994; Zhou et al, 1991) since HPVs do not grow in 
standard submerged cell cultures. Using this system it was established that HPV 
may use either cell surface heparan sulphate proteoglycans (HSPGs) or α-integrins 
as their primary attachment receptor (Evander et al, 1997; Giroglou et al, 2001; 
Joyce et al, 1999; Patterson et al, 2005; Shafti-Keramat et al, 2003). It was also re-
ported in in vitro studies that laminin-5 may be involved in the initial interaction 
with the host cell (Culp et al, 2006).  
HSPGs are cell surface and extracellular matrix molecules that are ubiquitously ex-
pressed. They are involved in cell adhesion, migration, proliferation, and differentia-
tion and they serve as major attachment molecules for many viruses (Knappe et al, 
2007).  HSPGs include sydecans and glypicans which are molecules with attached 
glycosaminoglycan chains, mainly heparan sulphate (Bernfield et al, 1992; Fransson, 
2003). These can be subjected to post-translational modifications such as sul-
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phation and acetylation, generating a large variety of molecules (Knappe et al, 
2007).  Evidence that heparan sulphate plays a critical role in HPV-host cell surface 
interaction comes from elegant studies where removal of HSPG by addition of 
heparanase or heparinitase resulted in significant reduction of HPV11 VLPs binding 
(Joyce et al, 1999). Heparin was also effective in inhibiting HPV16 and HPV33 by 
pseudovirus infection. Similarly, the ability of different HPV VLPs such as HPV16, 18, 
31 (classified as high risk) to enter COS-7 cells was successfully inhibited with hepa-
rin (Combita et al, 2001). Among the different HSPGs, syndecan-1 is believed to be 
the main attachment molecule for HPV since it is highly expressed in epithelial tis-
sue and it is up-regulated during wound healing in target cells (Elenius et al, 1991; 
Gallo et al, 1994), suggesting that in the presence of a microtrauma, these mole-
cules would allow the uptake of virus particles (Sapp & Day, 2009; Selinka et al, 
2002).   
However, not all HPVs use HSPGs as attachment molecules, such as HPV31 
(Patterson et al, 2005). As mentioned above, HPVs are also known to interact with 
integrins to enter host cells.  Integrin are cell-surface heterodimeric proteins which 
span the phospholipid bilayer and are composed of α and β subunits (Hu & Luo, 
2013). HPVs have been shown to interact mainly with the α-integrin subunit (Letian 
& Tianyu, 2010; McMillan et al, 1999; Yoon et al, 2001). Even though several studies 
focused on the role of integrins in virus interaction and entry, whether the latter 
can be considered a primary or secondary receptor is still controversial. Neverthe-
less, several studies have shown that efficient interaction requires co-receptors and 
that it is unlikely that the virus will enter the host cell only following interaction 
with HSPGs. 
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Figure 1-36 HPV/host cell interactions. 
The ECM consists of collagens, elastins, fibronectins and laminins. HPV16 interacts with HSPGs 
either through laminin 332 (formerly laminin 5), the basement membrane or the epithelial cell 
surface. Following this interaction, the virion undergoes a conformational change facilitated by 
cyclophilin B (CyPB); therefore, HPV16 binds to α6 integrin, which in turn triggers a second intra-
cellular signalling. Following a series of conformational changes and signaling, the HPV16 capsid 
binds to A2, which triggers clathrin-, caveolin-, lipid raft-, flotillin-, cholesterol-, and dynamin-
independent endocytosis of HPV16; vesicle closure and actin scission is promoted by PI3K. Follow-
ing the initial attachment to to HSPGs, the epidermal growth factor receptor (EGFR) and/or kerati-
nocyte growth factor receptor (KGFR) may also become activated and may initiate intracellular 
signalling cascades that include the activation of the phosphoinositide 3-kinase (PI3K) pathway 
(Raff et al, 2013). 
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1.4.6 HPV life cycle: mechanism of virus entry  
HPV L1/L2 virus-like particles will not bind or infect primary cultured epithelial cells 
or epithelial tissue in vivo (Roberts et al, 2007). The primary site of HPV infection in 
vivo is the basement membrane which is the site with actively dividing cells and the 
virus will only enter after the tissue is damaged/micro-wounded (Sapp & 
Bienkowska-Haba, 2009). During mitosis of basal cells, one will become a new basal 
cell while the other daughter cell will migrate away from the basal layer to com-
plete differentiation: this cell will exit the cell cycle and eventually die by apoptosis 
(desquamation). Because the basement membrane is the primary site of infection, 
it was suggested that a secreted form HSPG must be involved (Roberts et al, 2007). 
The entry mechanism requires L1 interaction with HSPG-1, triggering a conforma-
tional change in L1 that allows interaction with a secondary receptor, HSPG-2. These 
two interactions are responsible for the conformational change observed in L1 and 
L2 capsid proteins: the L2 N-terminus (amino acids 17–36) becomes accessible and 
prone to cleavage by furin (Day & Schiller, 2009; Richards et al, 2006). This cleavage 
step is essential for successful infection, suggesting that the N-terminus of L2 is im-
portant to lead the necessary conformational changes observed. Consequently, the 
virus will be transferred and associated stably with a receptor on the epithelial cell 
surface. Following interaction, the virus is internalized either via endocytosis, 
clathrin-or cavelolin- mediated (or both) (Hindmarsh & Laimins, 2007; Laniosz et al, 
2008; Smith et al, 2007).  It has been shown that certain HPVs might be internalised 
by a new mechanism involving tetraspanin-enriched domains (Spoden et al, 2008). 
1.4.7 Viral genome: episomal and integrated 
Following internalization, HPVs capsids are thought to be lost due to their size, 
which will not allow the virus entry through the nuclear pores (Nelson et al, 2000). 
It is known that L2 is not essential for the uncoating, but mainly to free the viral 
DNA from the endosomes (Kamper et al, 2006).  
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Once in the nucleus (by mechanisms which are not well understood), the virus ge-
nome can exist as episome (circular extra chromosomal element) or integrate into 
the host cell genome.  The latter constitutes a key step in cancer progression after 
infection by HR-HPVs.  
In the nucleus, the virus is replicated and amplified through three different stages: 
establishment, maintenance, and productive stages. Initially, the virus will replicate 
in the host cell to establish around 100 episomal copies/cell (Moody & Laimins, 
2010). The E2 proteins that ensure that episomes are not lost during cell division 
maintain this function. In the following stages, the virus will replicate as the basal 
layer keratinocytes enter the cell cycle. E2 also cooperates with E1 to allow virus 
replication, while E6 and E7 modulate host cell cycle regulators to accommodate 
long term replication. In the last stage, episomes are amplified exponentially in 
terminally differentiating keratinocytes and finally packaged into new progeny viri-
ons. 
In basal cells that are not undergoing differentiation, overall HPV proteins are ex-
pressed at very low levels. When the cells start differentiating, viral proteins are ex-
pressed at very high levels allowing the virus to escape the immune response that is 
lower in the differentiating cells destined to die (Frazer, 2009). By doing so, the vi-
rus ensures a long-term infection, however since it does not encode its own replica-
tion enzymes and the cells undergoing differentiation withdraw from the cell cycle, 
it will not replicate. To face this problem, HPVs force the cells to re-enter the cell 
cycle: to this end, a key role is played by the E7 proteins that bind and inactivate 
pRb. By producing high levels of viral proteins, the virus is able to increase the ge-
nome copy number from the initial to up 100 thousands of copies per cell (Bedell et 
al, 1991; Fehrmann et al, 2003; Ozbun & Meyers, 1998). Because the viral particles 
are released as consequence of desquamation, in the absence of lysis/necrosis, 
there will be no sign of evident inflammation (i.e. no immune response).  
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1.4.8 Immune response against HPVs 
Human papilloma viruses (HPVs) attempt to escape the immune system by limiting 
viral protein synthesis in terminally differentiated cells, and due to the absence of a 
cell lysis event, they reduce their exposure to the immune response (Stanley, 2009). 
The presence of HPV should be detected by intraepithelial dendritic cells (DCs); fol-
lowing entry of most viruses into host cells, the capsid proteins are recognised by 
DCs which are then activated, however it seems that DCs are not activated by the 
uptake of HPV capsids, suggesting a limited role in the host's response to HPV infec-
tion (Fausch et al, 2003; Fausch et al, 2002). Indeed in 2009, Einstein MH stated that 
“…these escape mechanisms have enabled HPV to become one of the most com-
mon sexually transmitted infections worldwide” (Einstein et al, 2009)”.  Despite this, 
the immune system, both innate and adaptive, does act in order to limit the infec-
tion since most of the infections are cleared within a couple of years (Steben & 
Duarte-Franco, 2007). In particular, the key role played by T cells, and thus cell-
mediated immune response, is clear in suppressed patients such as HIV-positive pa-
tients, where clearance of HPV infection is significantly compromised (Koshiol et al, 
2006; Scott et al, 2001). 
1.4.8.1 From infection to cancer of the cervix 
HPV-infected patients are able to clear the infection within a period of 24 months; 
however, persistence of this infection and viral genome integration probably near 
fragile sites, leading to genomic instability, can cause abnormal cell growth and 
changes in the cervix; these changes are identified through a pap smear test which 
is interpreted as atypical squamous cells of undetermined significance (ASCUS). This 
process of transformation of the cervical tissue takes usually 10-20 years and sug-
gests that HPVs have evolved a mechanism to evade the immune system and induce 
cancer (Feller et al, 2010; Koutsky et al, 2002) (Refer to Chapter 1.4 for detailed in-
formation about HPVs). It is widely accepted that HPV infection is linked to cancer 
of the cervix (Walboomers et al, 1999). However, currently there are no therapeutic 
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vaccine strategies available to defeat the infection and eradicate cervical cancer.  
The closest achievement has been the development of virus-like particles (VLP) 
composed of the L1 viral capsid protein being engineered as a tool for new prophy-
lactic vaccination strategies to prevent HPV infection (Koutsky et al, 2002).  In re-
cent years, the development of two FDA-approved drugs, Cervarix and Gardasil, 
have been also administrated to girls as vaccine prevention against HPV infection.  
Both vaccines are highly effective in preventing infections with HPV types 16 and 
18, the two major high risk HPVs, which cause nearly 70% of all the HPV infections. 
However, the current vaccines do not protect against all HPV infections that might 
cause cancer. The first drug, Cervarix is produced by GlaxoSmithKline (GSK) and in 
the UK, its administration started in 2008. Cervarix was used in females’ aged 9 to 
25 to prevent cervical cancer caused by HPV types 16 and 18. However, after a 4 
year trial and 4 million doses administrated, it was replaced by Gardasil in 2012,  
due to adverse reactions registered among the patients (MHRA, 2010). Gardasil is 
manufactured by Merck & Co., Inc. and it is a quadrivalent vaccine as it protects 
against HPV6, 11, 16, and 18. Gardasil is administrated to girls aged 9-26.  
HPVs infect cells in the basal layer of stratified squamous epithelia which are ex-
posed to the virus following micro wounds; synthesis of new virions following HPV 
infections occurs after these cells undergo mitosis and one of the infected daughter 
cells has differentiated. Basal cells are the only proliferating cells in normal epithe-
lia, while the differentiated cells in the suprabasal layers have exited the cell cycle. 
Initially, the virus genome is found in episome copies (extrachromosomal elements).  
To this end, one of the virus proteins, E2, regulates episome copy number by re-
pressing gene expression of the early proteins (Stubenrauch et al, 1998). If the im-
mune system does not clear persistent HPV infections, these can trigger the devel-
opment of cervical cancer over several decades. The route from infection to tumour 
initiation involves not only evasion from the immune system and persistent infec-
tion. In addition, integration of the viral genome disrupts the E2 gene and its ex-
pression, consequently up-regulating expression of the early genes, E6 and E7. Ac-
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cordingly, most HPV16- and 18-positive malignancies contain integrated HPV ge-
nomes, suggesting that integration may be a crucial event in cancer development 
and progression. Furthermore it has been shown that cells that have integrated 
copies of the virus have a selective growth advantage over cells that harbour only 
episomal copies of the viral genome (Jeon et al, 1995; Jeon & Lambert, 1995). It has 
also been suggested that the coexistence of HPV episomes with integrated copies 
might be a crucial step in carcinogenesis (Kadaja et al, 2009). 
1.4.8.2 Role of E6 and E7 in cancer development  
The major viral proteins involved in the initiation and progression of cervical cancer 
are the high risk HPV (HR-HPVs) E6 and E7 (McLaughlin-Drubin & Munger, 2009), 
two small proteins which mainly localize in the nucleus, although a recent study has 
shown that high cell confluence or density might result in E7 and E6 localization in 
the cytoplasm (Laurson & Raj, 2011). Both proteins are able to interact with cellular 
transcription factor complexes, thus altering their activities, but the most important 
targets are represented by the cellular tumour suppressors pRb and p53. Interest-
ingly, only E7 proteins from the HR-HPVs such as HPV16 and HPV18 can immortalize 
human keratinocytes on their own, while HR-HPV E6 does not have such an activity. 
In addition, transformation of cells with E7 and E6 was found to be more efficient 
than the two oncogenes alone, suggesting that cell immortalization requires the ac-
tivity of both viral proteins (Hawley-Nelson et al, 1989; Munger et al, 1989a). Ele-
gant experiments using both organotypic raft cultures and transgenic mice have 
shown that while E7 alone can immortalize cells and cause high grade cervical dys-
plasia, co-expression of E6 leads to more extensive  cervical cancers (McCance et al, 
1988; Riley et al, 2003). However, since most people infected with HPV do not nec-
essarily develop cancer, co-expression on the two oncogenes may be necessary but 
not sufficient for tumour progression, suggesting that other oncogenes or factors 
might be involved. Genome instability plays a crucial role in tumour progression and 
maintenance as shown by the number of chromosomal abnormalities (such as those 
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involving centromeres) found in HPV-positive patients. The two oncogenes can also 
induce genomic instability by inducing DNA damage via ATM pathway activation 
(Duensing et al, 2000; Moody & Laimins, 2009). 
1.5 Role of gap junctions in cell communication 
Cell-cell communication is essential to maintain homeostasis and coordination 
within the cellular environment; in eukaryotic cells tight junctions (TJs) and gap 
junctions (GJs) are responsible for the correct functioning of cell-cell communica-
tion processes. This chapter will primarily focus on GJs as they are of particular in-
terest for the results presented in Chapter 5.  
GJs are a group of ubiquitously expressed proteins with a half-life of only a few 
hours. They are involved in direct intercellular exchange of small molecules (< 1 
kDa) and metabolites, second messengers, electrical signals and ions and they play 
a key role in the homeostasis and controlled growth and differentiation of the cells 
(Laird, 2006). GJs are composed of connexin proteins and so far 21 connexins have 
been discovered in humans and 20 in mice (named based on their molecular 
weight), whose combinations give rise to a vast array of GJs (Sohl & Willecke, 2004). 
The basic unit of a GJ is a connexin protein that forms hexamers with other connex-
ins to form a connexon (Figure 1-37). All connexins share a common structure con-
taining four transmembrane domains, an N-terminus and C-terminus intercellular 
domains, and 3 extracellular loops. Their cytoplasmic domain is often subject to 
post-translational modifications, such as phosphorylation by protein kinases (PKA, 
PKC, PKG and mitogen-activated protein kinase among others) with the exception of 
Cx26 that does not have a long cytoplasmic tail and is thus less of a target for post-
translational modifications.  
Lower levels or lack of expression of connexin within a tissue is considered to be a 
sign of tumorigenesis and cell transformation (Czyz, 2008; Naus, 2002). Connexins 
are therefore considered to be tumour suppressor genes, despite their role in cell 
transformation being still unclear. In experimental studies, transfection of a con-
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nexin is known to down-regulate cell growth (Fujimoto et al, 2005; Fujimoto et al, 
2007). For instance, Cx26 was shown to be a tumour suppressor gene in HeLa cells 
and breast cancer cells as well as in lung cancer cells (Hirschi et al, 1996; McLachlan 
et al, 2006; Mesnil et al, 1995; Plante et al, 2011) , although deafness is the most 
frequent disorder due to mutations in this gene. Tumorigenesis might be driven ei-
ther because of loss of connexin gene transcription or aberrant trafficking of con-
nexin proteins to the plasma membrane.  
 
Figure 1-37 Structural organization of gap junction proteins.  
Adapted from (Maeda et al, 2009). 
1.5.1 Regulation of connexin protein expression  
Connexins are expressed in a tissue- or cell-specific manner and several organs or 
cell types express more than one connexin; for example, keratinocytes express 
Cx26, Cx30, Cx30.3, Cx31, Cx31.1 and Cx43 (Goliger & Paul, 1994; Wiszniewski et al, 
2000). Studies on the expression of connexins during keratinocyte differentiation 
have shown that Cx26 is expressed in both the basal and spinous layers, while Cx43, 
one of the most abundant connexins, is also found in the granular layer (Figure 
1-38). This pattern of expression is controlled via regulation of connexin proteins at 
different levels. 
Connexin expression can be regulated at the transcriptional, post-transcriptional 
and translational levels. Knowledge of their gene structures is essential to under-
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stand these mechanisms. All connexin proteins share a basic gene structure com-
prising a 5'-untranslated region (5'-UTR) on exon 1 separated by the coding region 
and a 3'-UTR. The coding region is generally found within the second exon where 
the 3'-UTR is also found (Figure 1-39). The basal promoter is approx. 300 bp up-
stream of the TSS (which is located in exon 1) and contains the binding sites for the 
TATA binding protein and transcription factors such as Sp1/Sp3 and AP-1, which 
have been described to be important for the transcriptional activity of connexin 
genes, as is the case for Cx26, although AP-1 binding sites have not yet been found 
(Tu & Kiang, 1998). While the activity of several other factors is undoubtedly essen-
tial for cell- and tissue-specific expression of the connexin proteins, an interesting 
aspect of transcriptional control is represented by methylation of connexin promot-
ers that triggers gene silencing.  Epigenetic inactivation through promoter hyper-
methylation was shown for several connexin proteins, included Cx26. Tan et al. 
showed that the Cx26 promoter was frequently methylated in breast cancer cells 
and treatment with 5'-aza-2'-deoxycytidine resulted in re-expression of Cx26 mRNA 
(Tan et al, 2002), although other groups failed to find a correlation between Cx26 
promoter hypermethylation and protein expression as observed in mammary 
epithelial and oesophageal cancer cell lines (Loncarek et al, 2003; Singal et al, 2000). 
 
Figure 1-38 Pattern of expression of connexin proteins in the epidermis.  
Adapted from (Martin et al, 2014). 
In addition to transcriptional control, connexin protein expression was found to be 
modulated by post-translational events. Earlier studies on Cx26 and Cx43 have iden-
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tified internal ribosome entry sites (IRESs) within the 5'-UTR of the transcript. Trans-
lation of most eukaryotic cells proceeds from a translational start codon at the 
capped 5'-UTR and ends at a stop codon found near the beginning of the 3'-UTR. 
However, in some genes, such as Cx26 and Cx43, a cap-independent translation 
mechanism was discovered, where translation occurred using an IRES rather than 
the canonical 5'-cap structure, which means that higher levels of proteins were pro-
duced. In an elegant experiment, Lahlou and colleagues showed that increased lev-
els of Cx26 and Cx43 proteins in density-inhibited human pancreatic cancer cells 
(BxPc-3) were dependent on translation from the IRES and that subsequent genera-
tion of GJs was essential to counteract the density-inhibition of BxPC-3 cells trig-
gered by the anti-proliferative somatostatin receptor 2 (sst2)(Lahlou et al, 2005). 
This shows that, while transcriptional controls regulate mRNA levels that in turn 
might reflect low or high protein levels, the latter can be achieved via alternative 
translational routes.  
 
Figure 1-39 Splicing patterns of connexin gene transcripts. 
Connexin genes have a similar structure, which comprises between 1 and 3 exons. The coding re-
gion is generally confined within exon 2 (or 3 where present; violet), although some connexin 
genes might have the coding region in two separated exons (d), have exons transcribed from dif-
ferent promoters that generate alternative first exons (b) or have splice variants (c). UTR, untrans-
lated region; Ex, exon. Adapted from (Bosco et al, 2011). 
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1.6 DNA sequencing 
DNA sequencing has become an invaluable tool in molecular biology allowing scien-
tists to sequence long genomes in a relatively short period of time and reduced 
costs.  
The first DNA sequencing methodology was developed by Sanger in 1975 (Sanger & 
Coulson, 1975). This method called “plus and minus” was a simple method based on 
the comparison between polynucleotide lengths extended with (plus) or without 
(minus) specific nucleic acids (A, C, T, or G) in order then to reconstruct the original 
sequence. However it was only possible to determine about 50 bases per reaction. 
In the following years Maxam and Gilbert in Harvard, and around the same period 
Sanger in Cambridge, developed two methodologies for DNA sequencing (Maxam & 
Gilbert, 1977; Sanger et al, 1977) (Figure 1-40). The Maxam-Gilbert method was 
based on the chemical modification of DNA and subsequent cleavage at specific 
bases but due to the extensive use of radioactivity it was subsequently modified by 
Sanger who introduced the chain termination method. This new method still uses 
toxic chemicals and radioactivity, but in lower amount (this is known today as “first 
generation sequencing”).  The Sanger methodology synthesized a new DNA mole-
cule on a template strand with its synthesis being stopped when one of four dide-
oxy nucleotides (lacking a 3’ hydroxyl group) was incorporated, thus stopping the 
overall reaction of chain growth. These molecules were then run on an electropho-
resis gel and based on their size they were put in order, reconstituting the original 
molecule by reading the last (known) nucleotide added.  
The Sanger method represents the basic methodology used in later sequencing 
technologies. Rather than radiolabelled nucleotides, the DNA molecule are fluores-
cently labelled, with each of the nucleotides represented by a different colour and 
then separated based on their size using glass capillaries where the fluorescent dye 
is detected and recorded following laser excitation. 
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Figure 1-40 Maxam-Gilbert and the Sanger sequencing methods.  
The picture depicts the main difference between the two methodologies 
(www.oxbridgebiotech.com). 
1.6.1 Microarrays and other transcriptome sequencing assays 
Microarrays made their entry into the market in the mid-1990s, with the first report 
appearing in Science in 1995 (Schena et al, 1995). The technology is based on the 
principle of DNA and RNA hybridization: a target sample (DNA or cDNA) is hybrid-
ised against a large set of probes attached to a solid support (Miller & Tang, 2009). 
Microarrays are used to measure changes in gene expression levels, i.e. between a 
normal and a cancer cell, to analyze chromosomal aberrations, to observe genomic 
gains and losses via microarray Comparative Genomic Hybridization (CGH) or ana-
lyze mutation in DNA samples.  
In brief, a plate made of glass (or silicon) is prepared so that it contains imprinted all 
the probes for the genes (these are represented as “spots”). Target samples are 
properly prepared depending on the downstream application. In case of gene pro-
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file expression, mRNA will be isolated and reverse transcription will be performed to 
generate cDNA; a mix containing oligoT, primers and fluorescently labeled oligonu-
cleotides will be used (green for the control sample, red for the test sample, for ex-
ample) (Figure 1-41). In this way, the complementary strand being generated will 
incorporate the labeled oligonucleotides. This cDNA is hybridized with the probes 
(ssDNA) on the microarray plate. Following laser excitation, the hybrid bonds will 
fluoresce and a camera connected to a computer will record the images (Schena et 
al, 1998). Results are then analyzed: given the colors used, if the spot is green it 
means the control sample hybridized more than the test sample, if it is red the test 
sample hybridized more than the control sample and if is yellow then both samples 
hybridized equally to the target DNA. Some area will show up black meaning neither 
sample hybridized to the target DNA. 
 
Figure 1-41 Overview of microarrays technology. 
For gene expression analysis, probes are prepared by PCR amplification of the target genomic re-
gion; for transcript expression levels total RNA is isolated and reverse transcribed; cDNA is labelled 
using fluorescent dyes; two different colours can be used for the two conditions being studied. The 
labelled target is placed onto a DNA microarray where it will hybridise to the DNA probe previ-
ously synthetized. The microarray is then scanned to quantitate the signal and differences be-
tween the samples analysed (Miller & Tang, 2009).  
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Microarrays were a breakthrough in biology. The simplicity of the assay and the 
possibility to analyse thousands of genes on a single chip simultaneously made mi-
croarrays a powerful tool for over two decades, representing the main tool for sev-
eral studies in cancer research. Microarrays revealed information about genes that 
were expressed in certain conditions and their relative magnitude, reflecting the 
cellular response to the condition being studied.  
One of the first studies of microarrays applied to human gene expression levels was 
published in 1999, investigating fibroblasts response to serum: since addition of FBS 
triggers proliferation of the fibroblasts, microarray were the ideal tool to study the 
parallel change of gene expression (Iyer et al, 1999). Since then, microarrays have 
been used in a vast number of studies including gene expression in lymphomas 
(Alizadeh et al, 2000; Alizadeh & Staudt, 2000), breast cancer (Chou et al, 2013), co-
lorectal cancer (Hegde et al, 2001; Koga et al, 2014; Moura Franco et al, 2013), oral 
cancer (Alevizos et al, 2001; Sumino et al, 2013), prostate cancer (Luo et al, 2001), 
melanoma (Clark et al, 2000) as well as cervical cancer (Jang et al, 2011; Srivastava 
et al, 2014) and ovarian carcinomas (Bayani et al, 2002; Mok et al, 2001), reaching 
over 25,000 publications since their first appearance in 1995. In addition, DNA mi-
croarrays have been used for the detection of single nucleotide polymorphisms 
(SNPs), microRNAs analysis as well as CpG islands of target genes.   
In recent years, however, next generation sequencing (NGS) technologies have be-
gun to rival microarrays. There are several reasons for this, e.g the higher sensitivity 
and specificity for NGS, and the fact that microarrays are dependent on previous 
knowledge of the gene probes, thus covering fewer genes than NGS. Yet, both 
technologies need robust bioinformatics and statistical approaches to analyse the 
large amount of information generated, a problem still persisting in both technolo-
gies.  
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1.6.2 Next generation sequencing 
Next generation sequencing is a term used to describe technologies that have the 
ability to massively parallel sequence millions of DNA templates. “Second-
generation” and “third-generation sequencing” are terms used to differentiate the 
newly developed sequencing technologies from the Sanger methodology defined as 
“first-generation sequencing”. Next generation sequencing gives a more complete 
analysis of the genome by generating larger amounts of data, within a compara-
tively shorter period of time and at lower costs (compared to the first generation 
sequencing technologies), being more comprehensive than microarrays (Ledford, 
2008). Most of the second generation platforms were developed during the Human 
Genome Project, but since then, the applications have been numerous, going be-
yond simple DNA sequencing.  Based initially on the use of bacterial artificial chro-
mosomes (BAC), the complete genome was assembled by “pasting” together the 
clones based on known transcripts and overlaps. Due to the difficulty encountered 
in assembling the sequence, several genome annotations were developed such as 
the UCSC Genome, NCBI Map viewer and Ensembl Genome browser (Hubbard et al, 
2002; Kent et al, 2002; Wheeler et al, 2001). Today, these tools are still in use when 
analysing sequencing data, and have evolved over time. BACs are no longer in use 
and in the following years several companies launched their sequencing platforms 
starting with Roche/45 FLX in 2004, followed by the Illumina/ Solexa Genome Ana-
lyzer in 2006, Applied Biosystems (ABi) in 2007 (Table 1-3). Developed initially for 
small genome analysis they were soon competing with microarrays and other se-
quencing technologies, giving a broader range of use which went beyond simple 
sequencing, such as ChIP-Seq (Chromatin Immunoprecipitation Sequencing) to look 
at genome-wide measurements of protein-DNA interactions, CNV-Seq (Copy num-
ber variation) and RNA-Seq. The latter gives the possibility not only to look at the 
expression levels of transcripts within a cell, but also splicing events, alleles expres-
sion and fusion events. 
  
111 
 
Table 1-3 Comparison between various sequencing platforms. 
 
http://www.sequencing.uio.no
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1.6.3 Advantages of RNA-Seq over other transcriptome methodologies 
Whole transcriptome analysis by total RNA-Seq is used to analyse gene and tran-
scripts expression changes in both coding and non-coding RNA species. In addition, 
RNA-Seq can be used for transcript discovery and annotation, allele specific expres-
sion (SNPs or mutations), mutation discovery and fusion-gene detection. Identifying 
patterns of gene expression and molecular pathways, in particular for certain tu-
mors, can enable tailored therapies to be developed, based on the transcriptome 
profile. RNA-Seq analyses the expression level of mRNAs, thus the different tran-
scripts and isoforms of a protein. 
RNA-Seq seems to advance on microarray technology. Microarrays are less sensi-
tive; they give information only about the selected probes and being based on hy-
bridization, they are prone to generate non-specific signals, part of the reasons why 
other technologies such as DNA and RNA-Seq were developed. To overcome the 
limitations of microarrays, initially several groups developed other methodologies 
such as serial analysis of gene expression (SAGE) where tagged cDNA fragments are 
cloned and sequenced. SAGE relies on the tag being present uniquely within the 
transcript of interest, allowing easy identification of the target. The tag sequences 
are ideally linked together to form serial long molecules and then sequenced: the 
number of times the tag is sequenced would provide an estimate of the transcript 
abundance (Velculescu et al, 1997; Zhang et al, 1997). 
RNA-Seq presents considerable advantages also against SAGE as well as whole ge-
nome sequencing. First of all, while the whole genome is known to be constant cer-
tain conditions might have an effect on gene expression (drugs for example), thus 
only RNA-Seq might reveal these differences. Secondly, isoforms and fusion tran-
scripts, together with RNA editing, can only be observed if the RNA is studied since 
these are not characteristic of the DNA molecule. However, modifications occurring 
at the transcript level do not allow mapping back to the original sequence, which 
can cause issues with downstream analysis. 
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Among the various available platforms, RNA-Seq on the Illumina platform is highly 
reproducible, with virtually no need for technical replicates (Marioni et al, 2008); 
biological replicates will be however required to confirm the robustness of the re-
sults and to quantify noise in the data for biologically relevant signals and be ascer-
tained. In addition, fold changes observed in RNA-Seq are similar to those observed 
in arrays, validating the new methodology (Marioni et al, 2008). 
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1.7 Aims of the project 
1. To the test the hypothesis that specific transcription factors drive the inter-
action between enhancer and promoter at the mouse immunoglobulin 
lambda light chain locus: 
 To identify via bioinformatic searches B cell-specific transcription fac-
tors that bind the mouse immunoglobulin lambda light chain locus; 
 To test if any of the above transcription factors bind any of the pro-
moters analysed, notably Jλ1, Jλ2, and Jλ3, via DNase I footprinting 
and EMSA. Particular focus will be given to E47; 
  To test the hypothesis that the promoter-bound E47 interacts with 
the enhancer-bound IRF4 to drive enhancer/promoter looping, trig-
gering sterile transcription through the J lambda gene segments; 
 To test if particular residues are crucial for this interaction via 
mutagenesis studies. 
2.  To analyse RNA-Seq data from seven HPV-positive tumour biopsies and 
three HPV-positive cell lines to identify possible biomarkers for cervical can-
cer: 
 To identify differentially expressed cell surface transcripts between 
the samples analysed; 
 To generate recombinant adenoviruses expressing either the HPV16 
E6 or E7 oncoproteins to be used to test any putative candidate as 
biomarker; 
 To test whether one of the differentially-expressed cellular tran-
scripts, connexin 26, might be considered a putative biomarker by 
studying expression levels in normal HaCaT keratinocytes cells trans-
duced with adenovirus expressing HPV16 E6 or E7 oncoproteins.
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Chapter 2. MATERIALS AND METHODS 
2.1 Chemicals and equipment  
0.2 cm electroporation cuvettes Cat.Z7006086-50EA, Sigma-Aldrich (Dorset, UK). 
100mM dNTPs Cat.10297018, Invitrogen (Paisley, UK). 
1kb Plus DNA ladder Cat.10787-018, Invitrogen (Paisley, UK). 
2′ deoxygalactose Cat.D4407, Sigma-Aldrich (Dorset, UK). 
2-log DNA Cat.N3200S, NEB (Hertfordshire, UK). 
6 well dishes  Cat. BC010, Appleton Woods (Birmingham, UK) 
Acrylamide 30% Cat.20210010, Thistle Scientific (Uddigston Glas-
gow, UK)  
Agar bacteriological Cat.LP0011, Oxoid Ltd (Hampshire, UK). 
Agarose electrophoresis grade Cat.MB1200, Melford (Ipswich UK). 
Ampicillin Cat.A5354, Sigma-Aldrich (Dorset, UK).  
BioRad DC Protein assay (B) Cat.500-0114, BioRad (Hertfordshire, UK). 
BioRad DC Protein assay (C) Cat.500-0113, BioRad (Hertfordshire, UK). 
BioRad DC Protein assay (S) Cat.500-0115, BioRad (Hertfordshire, UK). 
BSA Cat.A4503, Sigma-Aldrich (Dorset, UK). 
Cell scrapers Cat.BC323, Appleton Woods (Birmingham, UK). 
CellBIND® flasks Corning (Corning, USA). 
Cesium chloride Cat.15507-023, Invitrogen (Paisley, UK). 
Chloramphenicol Cat.C0378, Sigma-Aldrich (Dorset, UK) 
Custom primers  Life Technologies (Paisley, UK). 
DAPI Cat.D9542, Sigma -Aldrich (Dorset, UK). 
D-biotin Cat. L8912, Sigma-Aldrich (Dorset, UK). 
D-galactose Cat.1287700, Sigma-Aldrich (Dorset, UK). 
DH5α cells Cat.18263-012, Invitrogen (Paisley, UK). 
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Dialysis tubing  Cat.D100, Biodesign Inc.(Carmel, NY, USA). 
DMEM  Cat. D6546, Sigma -Aldrich (Dorset, UK). 
DNase/RNase-free water Cat.10977035, Invitrogen (Paisley, UK). 
ECL Western blot detection reagents Cat.RPN2235, GE Healthcare (Buckinghamshire, 
UK). 
Expand HiFi DNA Polymerase Cat. 11732650001, Roche (Burgess Hill, UK). 
Foetal calf serum GE Healthcare (Buckinghamshire, UK). 
Formalin Cat.HT501128-42, Sigma-Aldrich (Dorset, UK). 
Glass capillaries tubing  Cat. 640766, OD 1.0 nm, ID 0.5 mm, G-100-4  
Glycogen Cat.FQ-R0561, Thermo Scientific Pierce 
(Rockford, USA) 
Halt proteinase inhibitor cocktail Cat.78429, Thermo Scientific Pierce (Rockford, 
USA) 
IPTG   Cat.MB1008, Melford (Ipswich, UK). 
L-glutamine solution Cat. 67513, Sigma-Aldrich (Dorset, UK). 
Lipofectamine 2000  Cat.11668027, Life Technologies (Paisley, UK). 
L-Leucine Cat.L8000, Sigma-Aldrich (Dorset, UK). 
Lucifer yellow CH dilithium salt Cat.L0259, Sigma -Aldrich (Dorset, UK). 
Magic marker Cat.LC5602, Invitrogen (Paisley, UK). 
Mini slide-A-lyzer Cat.69550, Thermo Scientific Pierce (Rockford, 
USA). 
Nitrocellulose membrane 0.45 μM Cat.1620094, BioRad (Hertfordshire, UK). 
NucleoBond BAC 100 DNA  Cat.N2740579, Thermo Scientific Pierce 
(Rockford, USA) 
Optimem-1 Cat.11058021, Invitrogen (Paisley, UK). 
PBS tablets Cat.BR0014, Oxoid Ltd (Hampshire, UK). 
PCR and gel extraction kits Qiagen (Hilden, Germany). 
Penicillin/Streptomycin Cat.4458, Sigma-Aldrich (Dorset, UK). 
Petri dishes 92X16 mm Cat. 821473, CAT. 62.547.254, Sarstedt (Leices-
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ter, UK) 
Phenol-Chlorophorm Cat.77617, Sigma-Aldrich (Dorset, UK). 
Phusion  DNA polymerase NEB (Hertfordshire, UK). 
Plasmid purification kits Qiagen (Hilden, Germany). 
Prestained protein ladder Cat.10748-010, Life Technologies (Paisley, UK). 
Protein G agarose Cat. 20398, Thermo Scientific Pierce (Rockford, 
USA) 
Proteinase inhibitor tablets Cat.88665, Thermo Scientific Pierce (Rockford, 
USA) 
Proteinase K Cat.P2308, Sigma-Aldrich (Dorset, UK). 
PVDF microporous membrane 0.45 
μM 
Cat.IPVH00010, Merk (New York, US) 
Restriction enzymes NEB (Hertfordshire, UK). 
Riboruler HR RNA ladder Cat.SM1821, Thermo Scientific Pierce (Rockford, 
USA). 
RPMI-1640 Cat.R0083, Sigma -Aldrich (Dorset, UK). 
RQ1 RNase-free DNase Cat.M6101, Promoega (Madison, USA) 
Subcellular proteome extraction Cat.539790-1KIT, Calbiochem (Darmstadt, Ger-
many). 
SYBR green Cat.59430, SLS (East Riding of Yorkshire, UK) 
T4 polynucleotide kinase NEB (Hertfordshire, UK). 
Taq DNA polymerases NEB (Hertfordshire, UK). 
Thick blot paper Cat.1703960, BioRad (Hertfordshire, UK). 
Transcriptor first strand cDNA Synthe-
sis 
Cat.048968-66001, Roche (Burgess Hill, UK). 
Transfection reagents Cat.11668030, Life technologies (Paisley, UK). 
Trizol Cat.15596-018, Invitrogen (Paisley, UK). 
Trypsin-EDTA Cat.25200056, Invitrogen (Paisley, UK). 
Ultraclear centrifuge tubes, 13x51 mm Cat.344060, Beckman Coulter VWR (High Wy-
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combe, UK) 
Ultraclear centrifuge tubes, 14x95 mm Cat.344057, Beckman Coulter VWR (High Wy-
combe, UK) 
Vectashield mounting medium Cat.H1000, Vector Laboratories (California, USA) 
X-gal Cat.MB1001, Melford (Ipswich, UK). 
Zero Blunt cloning kit Cat.K275040, Invitrogen (Paisley, UK). 
All other chemicals used to prepare buffers and solutions, unless stated, were pur-
chased from Sigma-Aldrich (Dorset, UK). 
2.2 Buffers and solutions 
2.2.1 Agarose gel electrophoresis 
 10x TAE buffer, 1 l: 48.4 g Tris base, 17.4 M glacial acetic acid, 3.7 g EDTA, 
disodium salt. 
 10x TBE buffer, 1 l : 108 g Tris base, 55 g Boric acid, 40 ml 0.5 M EDTA (pH 
8.0). 
 10x Orange Gel Loading Buffer (20 ml): 5 g Ficoll 400, 2 ml 1 M Tris-HCl (pH 
7.4), 4 ml 1 M EDTA (pH 8.0), 0.04 g Orange G. 
 DNA loading buffer: 2.5% ficoll, 0.025% bromophenol blue, 0.025% xylene 
cyanol. 
 Ethidium bromide solution: 5g/ml in TE buffer. 
 SYBR green: 1/10 000 dilution of stock solution in water. 
 TE: 1 mM EDTA, 10 mM Tris-HCl pH 7.5. 
 PBS: 1 tablet/500 ml sterile water. Autoclaved before use. 
2.2.2 Protein extraction buffers 
 Buffer A: 10 mM Hepes-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
DTT. 
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 Buffer C: 20 mM Hepes-KOH pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT. 
 Buffer D: 20 mM Hepes- KOH pH 7.9, 20% glycerol, 0.1 M KCl, 0.2 mM EDTA, 
0.5 mM DTT. 
 Lysis buffer (whole cell extract) : 20 mM Hepes- KOH, 0.4 M KCl, 2 mM DTT, 
20% glycerol, 0.5 mM PMSF (PMSF was prepared in isopropanol). 
2.2.3 DNase I footprinting buffers 
 Binding buffer: 10 mM Tris-HCl pH 7.5, 80 mM NaCl, 1 mM DTT, 1 mM EDTA 
and 5% glycerol. 
 Formamide loading buffer: 80% formamide, 10 mM NaOH, 1 mM EDTA, 
0.1% xylene cyanol, 1% bromophenol blue. 
 Polyacrylamide sequencing gel: 7 M urea, 8% 19:1 acrylamide, 250 μl 10% 
APS, 50 μl TEMED, 5 ml 10x TBE. 
 Stop buffer: 0.3 M sodium acetate pH 5.2, 0.1 mM EDTA, 100 μg/ml yeast 
tRNA. 
2.2.4 Western blot and Co-Immunoprecipitation solutions 
 10x Tris-Gycine-SDS buffer (TGS): 25 mM Tris, 192 mM glycine, 0.1% SDS. 
 10x TBS: 60.6g Tris, 87.6g NaCl (1l, adjust pH to 7.5 with concentrated HCl), 
bring up the volume to 1L with ddH2O. 
 Transfer buffer: 25mM Tris, 192 mM glycine, 20% (v/v) methanol, adjust pH 
to 8.3. 
 TBST: 1x TBS in 0.1% Tween-20. 
 TBST (for E6 antibody): 1x TBS in 0.1% Triton-X100 
 Blocking solution: 5% dry milk in TBST (10% milk for Cx26). 
 Blocking solution for HPV16 E6: 1x TBST (E6), 2.5% dry milk, 1% BSA. 
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 Stripping solution: 10 ml 20% SDS, 6.25 ml 1M Tris pH 6.8, 700 μl β-
Mercaptoethanol, increase volume to 100 ml with ddH2O. 
 SDS-PAGE, resolving gel: 1.5 M Tris-HCl, pH 8.8, 10% APS, 10% SDS, TEMED, 
acrylamide (amount change depending on gel concentration). 
 SDS-PAGE, stacking gel: 1 M Tris-HCl, pH 6.8, 10% APS, 10% SDS, TEMED, 
acrylamide (amount change depending on gel concentration). 
 Co-Ip buffer : 10 mM Hepes-KOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.1% 
NP-40, 150 mM NaCl. 
 Buffer E: 10 mM Hepes pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.1% NP40 
 Buffer F: 10 mM Hepes pH 7.9. 
 RIPA buffer: 50 mM Tris-HCl pH8, 150 mM NaCl, 1% NP-40, 0.5% sodium de-
oxycholate, 0.1% SDS. Supplement with protease inhibitor. 
 Supplemental lysis buffer to RIPA: 5% SDS, 0.15 M Tris-HCl, pH 6.7, 30% 
glycerol. Supplement with protease inhibitor. 
 Lysis buffer for mass spectrometry samples: 50 mM Hepes-NaOH, pH 7.4 
(4°C), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 0.1-0.5% NP40. 
 2x SDS sample buffer: 100mM Tris-HCl (pH 6.8), 200mM DTT, 4% SDS, 20% 
glycerol, 0.2% bromophenol blue. 
2.2.5 Buffers for bacterial and virus experiments  
 DNase I solution: 20 mM Tris-HCl (pH 7.4), 50 mM NaCl, 1 mM DTT, 0.1 
mg/ml BSA, 10 mg/ml bovine pancreatic DNase I, 50% glycerol. 
 CsCl gradient solutions for virus purification:  
o 1.5d – 90.8 g CsCl, 109.2 g 10 mM Tris-HCl pH 8.0. 
o 1.35d – 70.4 g CsCl, 129.6 g 10 mM Tris-HCl pH 8.0. 
o 1.25d – 54.0 g CsCl, 146.0 g 10 mM Tris-HCl pH 8.0. 
 Luria-Bertani (LB) medium: 10 g/l tryptone, 5 g/l yeast extract, 10 g/l salt, 
volume was adjusted to 1L with ddH2O. 
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 Low salt LB: 10g/L tryptone, 5 g/L yeast extract, 5 g/l salt. Volume was ad-
justed to 1 l with ddH2O. 
 LB-Agar: 10 g/l tryptone, 5 g/l yeast extract, 10g/l salt, 15g/l agar. Volume 
was adjusted to 1 l with ddH2O. 
 M63 minimal media (5X): 10 g/l (NH4)2SO4, 68 g/l, 2.5 mg/l FeSO4.7H20 vol-
ume was adjusted to 1 l with ddH2O and pH to 7 with KOH. 
 M9 salts (2X): 25.6 g/l Na2HPO4, 6 g/l KH2PO4, 2 g/l NH4Cl, 1 g/l NaCl. Volume 
was adjusted to 1 l with ddH2O. 
 GalK positive selection agar plates: 1X M63 medium,  1 mM MgS04 , 1 mg/l 
D-biotin , 45 mg/l L-leucine,  0.2% galactose,  12.5 μg/ml Chloramphenicol,  
15 g/l agar dissolved in SQ H2O.  
 GalK negative selection agar plates: 1X M63 medium,  1mM MgS04, 1 mg/l 
D-biotin, 45 mg/l L-leucine,  0.2% 2´-deoxgalactose,  0.2% glycerol,  12.5 
μg/ml chloramphenicol,  15 g/l agar dissolved in SQ H2O. 
 AdZ selection cassette plates: 10 g/l tryptone,  5 g/l Yeast extract,  50 g/l Su-
crose,12.5 μg/ml Chloramphenicol, 80 μg/ml X-gal,  0.2mM IPTG,  15 g/l agar 
dissolved in SQ H2O. 
 Antibiotic concentrations used: Ampicillin (50 μg/μl), Chloramphenicol (12.5 
mg/ml), X-gal (1:500 of 40 mg/ml stock), IPTG (1:500 of 100 mM stock). 
2.2.6 Calcium phosphate transfection reagents 
 10x Hepes-buffered saline (HBS): 8.18% (w/v) NaCl, 5.94% (w/v) Hepes, 0.2% 
(w/v) Na2HPO4. A working solution of 2x HBS was made; the pH was adjusted 
to 7.12 with 1 M NaOH and stored at 4°C. 
 2 M CaCl2: this was filter-sterilised and stored at 4°C. 
 15% glycerol/HBS: 30 ml 50% glycerol (w/v), 50 ml 2x HBS, (pH 7.12),  20 ml 
ddH2O. This was filter-sterilised and stored at 4˚C. 
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2.3 Cell lines 
 122-1 cell line is a mouse pro-B cell line transformed with A-MuLV and was 
used to make cell extracts for both DNase I footprinting and EMSA experi-
ments. These cells were cultured in RPMI 1640 medium supplemented with 
10% heat inactivated FCS (foetal calf serum), 5,000 U/ml penicillin, 5,000 
μg/ml streptomycin, 2 mM L-glutamine and 0.05 mM 2-β-mercaptoethanol 
and maintained at 37°C, in a humidified atmosphere containing 5% CO2.  
 Cos-7 cells are a simian virus 40-transformed African green monkey epithe-
lial cell line. They were used for transfection experiments to study enhancer-
promoter interactions (Jensen et al, 1964). 
 CaSki and SiHa cells are human cervical cancer cell lines containing inte-
grated copies of HPV16  (Friedl et al, 1970; Pattillo et al, 1977) while HeLa is 
an HPV18 positive cervical cancer adenocarcinoma cell line (Scherer et al, 
1953). 
 911 is a human retinoblastoma cell line used to amplify the recombinant 
adenovirus. The cell line provides the Adenovirus 5 E1 region in trans, neces-
sary for adenovirus replication (Fallaux et al, 1996). 
 Normal human foreskin keratinocytes (NHK) were a kind gift of Ms Rosie 
Doble, (University of Leeds, Leeds, UK). These were cultured in keratinocyte 
growth medium (Promo Cell) and maintained at 37°C, in a humidified at-
mosphere containing 5% CO2. 
 HaCaT is an immortalised human keratinocyte cell line (Boukamp et al, 
1988). These cells were transduced with the recombinant adenovirus to in-
vestigate the expression of Cx26. Extracts derived from HaCaT cell lines in 
which hDlg and hScribble were ablated were kind gifts of Dr Paola Massimi, 
ICGEB, Trieste, Italy. 
122-1 pro-B cells and Cos-7 cells were cultured in RPMI-1640 using the same condi-
tions as described above. CaSki, SiHa, HeLa, 911 and HaCaT cell lines were grown in 
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DMEM supplemented with 10%  heat-inactivated FCS, 5,000 U/ml penicillin, 5,000 
μg/ml streptomycin, 2 mM L-glutamine and maintained at 37°C, in a humidified at-
mosphere containing 5% CO2. The HaCaT cell lines in which hdlg and Scribble were 
ablated were maintained at 37°C in a humidified atmosphere containing 10% CO2. 
The identities of CaSki, SiHa, HeLa and HaCat cells were established by STR (finger-
printing) analysis (Dr Claire Taylor, CRUK Genomics facility, SJUH, Leeds). 
2.4 Bacterial strains 
 E. coli DH5α: non-expression vector used for propagation and storage of 
plasmids.  
 DY380 cells:  these cells contained the 3'-half of the duplicated lambda locus 
which was used for V(D)J recombination studies. 
 SW102: DY380 cells previously modified to contain a full galactose operon, 
which have had a deletion of the galK gene. Genotype: as DY380 plus 
gal+ΔgalK. These were used for recombineering studies and were a kind gift 
of Dr James Findlay, University of Leeds, UK. 
2.5 Adenovirus constructs 
 AdZ-5F35-CV5: E1-and-E3-deleted Ad5 vector with a selection cassette in 
place of the E1 region under the control of a CMV promoter with the Ad5 fi-
bre replaced with the Ad35 fibre. A kind gift of Dr James Findlay, University 
of Leeds, Leeds, UK. 
 AdZ-5F35-ECFP: an AdZ-5F35-CV5 vector with an ECFP transgene under the 
control of the CMV promoter in place of the E3 region. Ampicillin and 
chloramphenicol resistant. This construct was made in this study. 
 AdZ-5F35-ECFP/E6: an AdZ-5F35-CV5 vector with an ECFP transgene in place 
of the E3 region and HPV16 E6 N-terminal HA-tagged ORF in place of the E1 
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region, both under control of the CMV promoter. Chloramphenicol resistant. 
This construct was made in this study. 
 AdZ-5F35-ECFP/E7: an AdZ-5F35-CV5 vector with an ECFP transgene in place 
of the E3 region and HPV16 E7 C-terminal Myc-tagged ORF in place of the E1 
region, both under control of the CMV promoter. Chloramphenicol resistant. 
This construct was made in this study. 
2.6 Plasmids  
 pUC19: plasmid cloning vector (New England Biolabs, Hertfordshire, UK).  
 pBluescriptK+: plasmid cloning vector used to clone the mutants constructs 
used in Chapter 4. 
 pEF3-99 (pEF-HPV16-W12E): plasmid containing the entire HPV16 genome, 
including the E6 and E7 open reading frames (ORFs) (Flores et al, 1999). 
 pGL3-Basic: promoter-less firefly luciferase reporter gene. A kind gift of Dr 
Ian Wood. 
 pCMV-RL: Renilla luciferase reporter gene under the control of the Cy-
tomegalovirus promoter (CMV). A kind gift of Dr Ian Wood. 
 pGL3/Jλ1: pGL3-Basic vector containing the Jλ1 promoter within the Xho I 
and HindIII restriction sites. This construct was made in this study. 
 pGL3/Jλ1/Eλ3-1: pGL3-Basic vector containing the Jλ1 promoter within the 
XhoI/HindIII  restriction sites and the Eλ3-1 enhancer within the SalI/BamHI 
restriction sites. This construct was made in this study. 
 pCS2Myc/E2A_Myc: plasmid containing the E2A ORF N-terminallly Myc 
tagged. A kind gift of Dr Sarah Bevington.  
 pEF-cx/E2A_Myc: plasmid containing the E2A ORF N-terminallly Myc tagged. 
This construct was made in this study and used in mutational studies de-
scribed in Chapter 4. 
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 pCMV/IRF4: plasmid containing the IRF4 ORF. A kind gift of Dr Sarah Beving-
ton. 
 pEF-PU.1_Flag: plasmid containing the PU.1 ORF N-terminallly Flag tagged. A 
kind gift of Dr Sarah Bevington. 
2.7 Protein methods  
2.7.1 Preparation of nuclear extracts 
Nuclear extracts were prepared according to the method of Dignam et al (Dignam 
et al, 1983). 122-1 pro-B cells (to reach up to 20-30 pellets from T175 flasks) were 
harvested by centrifugation at 2000 rpm for 10 minutes at 4°C and washed twice 
with ice-cold PBS to remove the medium. The packed cell volume (PCV) of the pellet 
was measured. It was then re-suspended in five PCVs of hypotonic buffer A and the 
cells were allowed to swell on ice for 20 minutes. The cell lysate was centrifuged at 
2000 rpm for 10 minutes at 4°C and the pellet was re-suspended in two PCV of 
buffer A. The cells were homogenised using a Dounce homogeniser with a type B 
(loose) pestle with 10 strokes to lyse the cells. This was checked using a phase con-
trast microscope and the nuclei were recovered by centrifugation in a small Sorvall 
plastic centrifuge tube at 2500 rpm, at 4˚C for 10 minutes. The nuclear pellet was 
re-suspended in 1.3 volumes buffer C (to remove proteins bound to DNA) by ho-
mogenisation in a Dounce homogeniser type C (tight) pestle (10-20 strokes) to lyse 
nuclei. The nuclear homogenate was transferred into a beaker and stirred slowly in 
a cold room for 30 minutes. The homogenate was centrifuged at 15000 rpm at 4°C 
for 30 minutes and the supernatant was transferred into a fresh sterile beaker. 
Ground (NH4)2SO4 (0.33 g/ml) was added slowly to precipitate proteins, followed by 
neutralization of the pH with 40 µl of 1 M NaOH per g (NH4)2SO4. The extract was 
left stirring in the cold room for 1 hour to “salt out” the proteins. The extract was 
centrifuged at 15000 rpm for 30 minutes at 4°C and the pellet was re-suspended in 
0.1 volumes of buffer D. The nuclear extract was dialysed against two changes of 
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buffer D for 1.5 hours. Following a final centrifugation at 10000 rpm for 10 minutes 
at 4°C, the extract was divided into aliquots in siliconised Eppendorf tubes and 
stored at -80°C. Protein concentration was determined by the Bradford assay (Bio-
Rad) according to the manufacturer’s instructions. Approximately 100 μg of extract 
were used per lane in footprinting reactions. 
2.7.2 Preparation of whole cell extracts 
Whole cell extracts were prepared using the method developed by Kumar and 
Chambon (Kumar & Chambon, 1988). The cells were harvested by centrifugation for 
6 minutes at 1800 rpm. The cell pellet was washed twice in 50 ml ice cold PBS to 
remove traces of the medium and re-suspended in 200 μl lysis buffer per 2x107 cells 
supplemented with protease inhibitors (Roche, complete cocktail). The cell suspen-
sion was immediately placed on dry ice and allowed to thaw on ice to break cell 
membranes. The cell lysate was centrifuged at 14000 rpm in a bench top centrifuge 
for 15 minutes at 4˚C and the supernatant divided into aliquots and stored at -80°C. 
Protein concentrations were determined by the Bradford assay according to the 
manufacturer’s instructions and approximately 20-30 μg protein was used per lane 
in EMSA experiments. 
2.7.3 Co-Immunoprecipitation assays 
Co-Immunoprecipitation (Co-Ip) assays were performed to investigate protein-
protein interactions in vitro.  
To investigate interactions between E47, IRF4 and PU.1, 122-1 pro-B cells (1x108 
cells) were centrifuged at 1800 rpm for 2 minutes and the pellet was washed in 500 
μl ice-cold PBS. The pellet was re-suspended in buffer E, supplemented with prote-
ase inhibitors (Roche, complete cocktail). An 18 μl aliquot of 5M NaCl was added 
and the sample vortexed for about 5-10 seconds. Following addition of 25 μl 40% 
glycerol, the samples were left rotating for 20 minutes in the cold room. The cell 
lysate was centrifuged for 15 minutes at 14000 rpm in a bench top centrifuge at 4˚C 
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and the supernatant removed. Following addition of 300 μl of buffer F and 15 μl 
protein G beads to pre-clear the lysate, the samples were left rotating in the cold 
room for 20 minutes. Following a brief centrifugation at 2400 rpm for 2 minutes, 
the clarified supernatant was divided into aliquots in siliconised Eppendorfs and 
1/10 of the volume was retained as input. Antibodies against E47 or IRF4 (5 μl) were 
added and the samples were left rotating overnight in the cold room. Following ad-
dition of 20 μl protein G beads, the samples were rotated for 2 hours at 4°C and the 
immunoprecipitation complex was washed by centrifugation three times with Co-Ip 
buffer. The pellets were re-suspended in protein loading buffer, boiled for 2 min-
utes, centrifuged for 10 seconds and the supernatant loaded on a 10% SDS poly-
acrylamide gel. The gel was subjected to electrophoresis at 125V for 2 hours in 1X 
TGS. To prevent E47 degradation, two inhibitors were used: MEK inhibitor and 
MG132 (a proteasome inhibitor), each at a final concentration of 10 μM. The MEK 
inhibitor was added 3 hours prior to harvesting the cells and MG132 was added 6 to 
8 hours prior harvesting. Both inhibitors were also added to buffers E and F. 
2.7.4 Sample preparation for mass spectrometry 
HaCaT cells were transduced as described in 2.9.7 and samples prepared for mass 
spectrometry to confirm the expression of HPV16 E6, due to the difficulty found in 
Western blots. The reagents and protocol was kindly provided by Dr Lawrence 
Banks. In brief, the HA-conjugated beads (EZnew Red αHa affinity gel, Sigma 
SLBG7153) were prepared by washing them in the lysis buffer and left rotating at 
4˚C. After 45 minutes the antibody-conjugated beads were washed twice in 1ml ly-
sis buffer and left in ice until use. HaCaT cells (confluent 10 cm dishes) were washed 
twice with cold PBS and lysed with 0.5 ml of lysis buffer supplemented with 0.1 
mg/ml dextran, directly on the dish, on ice. Cells were scraped, the lysate was trans-
ferred into a cold microcentrifuge tube and centrifuged for 10 minutes at 13,000 
rpm. An aliquot was removed to be kept as input to run a co-immunoprecipitation 
parallel to the mass spectrometry analysis. The remaining lysate was added to the 
  
128 
 
washed beads and incubated for 3 hours at 4˚C. The complex was washed three 
times with the lysis buffer (without dextran) and re-suspended in the same lysis 
buffer and transferred into a new cold fresh micro centrifuge tube. Because the 
samples were used for co-immunoprecipitation, to improve the stringency of the IP, 
a glycerol step gradient was performed. In brief, an aliquot of the lysis buffer was 
supplemented with glycerol to 20% and 200 μl was transferred at the bottom of a 
microcentrifuge tube. The beads were placed on top of the lysis buffer-glycerol mix 
and centrifuged for 30 seconds at 13,000 rpm. The supernatant was carefully re-
moved and the beads washed twice with 1 ml of lysis buffer. The pellet was washed 
three times with PBS and samples split equally for immunoprecipitation and mass 
spectrometry, respectively. Samples were kept at -80˚C until further use. 
2.7.5 Determination of protein concentration 
Protein concentration was determined using the BioRad DC assay system (Bio-Rad 
Inc.) according to the manufacturer‘s instructions. In brief, 20 µl of reagent S were 
added to each ml of reagent A (this mix will be called A'). The required dilutions of a 
protein standard (BSA, range 0.2-1 mg/ml) were prepared and 100 µl of standards 
and samples were pipetted into a clean test tubes. 500 µl of reagent A' was added 
to each of the tube and quickly vortexed, followed by addition of 4.0 ml reagent B 
into each test tube and vortexed immediately. Following an incubation of 15 min-
utes, absorbances were read at 750 nm. 
2.7.6 Western blot analysis 
Cells of interest were grown in Petri dishes or flasks depending on the experiments. 
The medium was discarded and cells washed twice with cold PBS prior to lysis in 
RIPA buffer. The lysate was left on ice for 30 minutes, centrifuged for 10 minutes at 
13,000 rpm and the supernatant loaded for Western blot analysis. Where required, 
protein concentration was determined using either the Bradford assay as described 
in above or a Nanodrop UV Spectrophotometer with absorbance set at Abs280 
  
129 
 
(Thermo Scientific, Nanodrop 1000).  Following electrophoresis, proteins were 
transferred to polyvinylidine fluoride (PVDF) membrane that had been pre-soaked 
in 100% methanol and equilibrated in transfer buffer, except for detection of HPV16 
E7 and Westerns from the cell fractionation assays where proteins were blotted on 
0.22μ nitrocellulose membranes. The proteins were transferred for 1 hour at 0.068 
mA/cm2 or at 5mA/cm2 using the Biometra semidry blotting apparatus (Biometra 
Fastblot B33/34). For detection of proteins following the cell fractionation assay, 
wet transfer of gels was with the following settings: 250 mA constant current for 3.5 
hours or overnight at 120 mA at room temperature with constant stirring. For de-
tection of HPV16 E7, following transfer, nitrocellulose membranes were fixed in 
0.5% glutaraldehyde in 1XTBS for 30 minutes at room temperature. The membrane 
was washed extensively with ddH2O before blocking. Membranes were blocked for 
1 hour at room temperature with 5% non-fat dried milk (Marvel) in TBST or in 10% 
milk in TBST for 30 minutes at 37˚C for proteins derived from the cell fractionation 
assay, and incubated with the primary antibody for 1 hour at room temperature or 
overnight in the cold room (Table 2-2). The membrane was washed in TBST for 1 
hour and incubated with the secondary antibody for 1 hour at room temperature or 
overnight in the cold room. Following another wash for 1 hour in TBST, the mem-
branes were exposed to a chemiluminescent detection reagent according to the 
manufacturer's instructions, followed by autoradiography or detection using the 
Raytek Fujifilm LAS-3000 Imager, according to the manufacturer’s instructions.  
  
130 
 
Table 2-1 List of primary antibodies used in this study. 
Antibody Specificity Species and Isotype Source 
N-649 Mouse E47 Rabbit polyclonal IgG Santa Cruz 
G-2 Mouse E2A Mouse monoclonal IgG1 Santa Cruz 
N-18 Mouse  IRF4 Goat polyclonal IgG Santa Cruz 
B-9 Spi Mouse PU.1  Mouse monoclonal IgG1 Santa Cruz 
NM2 HPV16 E7  Mouse monoclonal IgG2a Santa Cruz 
HA-7 HA-tag   Mouse monoclonal IgG1 Sigma 
sc-807 Flag-tag Rabbit polyclonal IgG Santa Cruz 
BS1715-R Human Cx26  Rabbit polyclonal IgG Bioss 
Z-Z8 Human Cx26  Rabbit polyclonal IgG Zymed 
CX-1E8 Human Cx26 Mouse monoclonal  IgG2a-kappa Zymed 
C65 Human GAPDH Mouse monoclonal IgG1 Calbiochem 
GTU-99 Human γ-tubulin Mouse monoclonal IgG1 Sigma 
TUB2.1 Human  β-tubulin Mouse monoclonal IgG1 Sigma 
H-2 Human α-actinin  Mouse monoclonal IgG1 Santa Cruz 
 
Table 2-2 Antibodies concentration for Western blots (WB) or immunofluorescence (IF). 
Primary antibody Dilution Secondary antibody  Dilution 
E47 1:500 (WB) anti-rabbit 1:10000 
IRF4 1:500 (WB) anti-goat 1:10000 
PU.1  1:500 (WB) anti-mouse  1:10000 
HPV16 E7  1:50 (IF) 
1:100 (WB) 
anti-mouse  
anti-mouse 
1:1000 
1:10000 
HA-tag  1:200 (IF) anti-mouse  1:1000 
Cx26 (Bioss) 
Cx26 (Zymed) 
Cx26 (Zymed) 
1:200 (IF) 
1:200 (WB) 
1:50 (WB) 
anti-rabbit 
anti-rabbit  
anti-mouse  
1:3000 
1:10000 
1:10000 
GAPDH 1:5000 (WB) anti-mouse 1:2000 
Tubulin 1:5000 (WB) anti-mouse 1:10000 
α-actinin  1:1000 (WB) anti-rabbit 1:10000 
β-galacotsidase  1:2000 (WB) anti-mouse 1:10000 
 
 
2.7.7 Immunofluorescence microscopy 
HaCaT cells (1x105) were grown on glass coverslips for 24 hours, transduced with 
the recombinant adenovirus as described in Chapter 2.9.7 and incubated for 24 
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hours to allow expression of viral proteins. Cells were washed three times with PBS 
and fixed with 10% formalin for 10 minutes at room temperature. Cells were 
washed three times with PBS and treated for 1 hour at room temperature with 2% 
fish skin gelatin (Sigma, a kind gift of Gareth Howell) to block non-specific protein 
binding. The cells were washed with PBS and incubated overnight with the primary 
antibody in 0.1% Triton in PBS. Coverslips were washed with PBS and incubated 
with the secondary antibody the species-specific Alexa Fluor-labelled secondary an-
tibody for 1 hour at room temperature, in the dark. The secondary antibody was 
removed with three washes of PBS and cells were stained with DAPI (4-6-diamidino-
2-phenylindole 1:5000 of 5 mg/ml) to stain the nuclei for at least 1 minute. Cells 
were washed again three times with PBS and left to dry before mounting with Vec-
tashield hard-set mounting medium. The coverslips were viewed using an AxioPlan 2 
Imaging Fluorescent microscope equipped with an AxioCam MR camera and images 
processed using the AxioVision 4.3 or Zen 2011 software.  
Table 2-3 List of secondary antibodies used in this study. 
Antibody Specificity  Species  Label  Source  
A-11070  Rabbit IgG  Goat  Alexa Fluor-488  Invitrogen  
A-21206  Rabbit IgG  Donkey  Alexa Fluor-488  Invitrogen  
A-11020  Mouse IgG  Goat  Alexa Fluor-594  Invitrogen  
A-21203  Mouse IgG  Donkey  Alexa Fluor-594  Invitrogen  
A-6782  Mouse IgG  Sheep  HRP  Sigma Aldrich  
A-6154  Rabbit IgG  Goat  HRP  Sigma Aldrich  
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2.8 DNA methods 
2.8.1 Standard PCR reactions 
Amplification of DNA segments of interests was carried out using Taq Polymerase in 
a final volume of 25 or 50 μl. The following components were mixed in PCR tube: 1x 
Taq Buffer, 0.2 mM dNTPs, 0.1 μM primers, 0.625 U Taq DNA polymerase, DNA 
template, DEPC H2O to 25 or 50 μl. PCR cycling conditions and primers used for all 
PCR reactions are listed in the following tables: 
 
Table 2-4 Cycling conditions used for standard PCR reactions. 
Temperature (˚C) Time (seconds) Cycles 
95 300 1 
95 30  
35-40 55 30 
72 30/kb 
72 600 1 
All PCR reactions were performed with heated lid at 110˚C prior to beginning of the PCR cycles. 
 
Table 2-5 Cycling conditions used for Pfx DNA polymerase PCR reactions. 
Temperature (˚C) Time (seconds) Cycles 
98 300 1 
98 30  
35 55 30/kb 
72 60/kb 
72 300 1 
 
Table 2-6 Cycling conditions used for site directed mutagenesis PCR reactions. 
Temperature (˚C) Time (seconds) Cycles 
95 60 1 
95 50  
18 60 50 
68 60/kb 
68 420 1 
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Table 2-7 Cycling conditions used for HiFi
PLUS 
PCR reactions. 
Temperature (˚C) Time (seconds) Cycles 
94 120 1 
94 15  
10 55 30 
72 60 
94 15  
20 55 30 
72 60/kb ((+ 5 seconds/cycle) 
72 420 1 
 
Table 2-8 Primers used to generate the recombinant adenoviruses. 
hr = homology region 
Table 2-9 Primers used to generate the PCR products for DNase I footprinting reactions. 
DNA fragment Primers (5' to 3') 
Jλ1 BamHI F CGGATCCGCTGATCCCAGAATTTATATCTTGTTAG 
Jλ1 HindIII R GGAAGCTTCCACCAGCTGTGTAAAGTCTATGC 
Jλ2 BamHI F CGGATCCCACTCAGCCTGTAAAATCAAGCC 
Jλ2 HindIII R GGAAGCTTTGTTCTCTCACAGCTGAGCTGAATCA 
Jλ3 BamHI F CCATTTGTTTCATAACTTCTGTTAGAGTCATTGT 
Jλ3 HindIII R GAGCTGTGACCTCACTTGAAGTG 
DNA fragment Primer sequence (5' to 3') 
E3 GalK hr F CTGCTAGTTGAGCGGGACAGGGGACCCTGTGTTCTCACTGTGATTTGCAACTG
TCCTAACCTTGGATTACATCCTGTTGACAATTAATCATCGGCA 
E3 GalK hr R TAACTGATTTTAAGTAAGTGATGCTTTATTATTTTTTTTTATTAGTTAAAG 
E7 hr F (CterMyc) TCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCG
GGACCGATCCAGCCTGGATCCACCATGCATGGAGATACACCTACAT 
E7 hr R (CterMyc) TTATTGAGTAGGATTACAGAGTATAACATAGAGTATAATATAGAGTATACAATA
GTGACGTGGGATCCTTACAGATCTTCTTCAGAAATAAGTTTTTGTT 
E6hr F (NterHA) GTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACC
GGGACCGATCCAGCCTGGATCCCCTACCATGTACCCATACGACGTC 
E6 hr R(NterHA) GCGTGACACGTTTATTGAGTAGGATTACAGAGTATAACATAGAGTATAATATA
GAGTATACAATAGTGACGTGGGATCCTTACAGCTGGGTTTCTCTACG 
ECFP hr  F CTGCTAGTTGAGCGGGACAGGGGACCCTGTGTTCTCACTGTGATTTGCAACTG
TCCTAACCTTGGATTACATTAGTTATTAATAG TAATCAATTACGG 
ECFP hr R TGATTTTAAGTAAGTGATGCTTTATTATTTTTTTTTATTAGTTAAAGGGAATAAG
ATCTTTGAGACACAGGGTTAAGATACATT GATGAGTTTGGAC 
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Table 2-10 Primers used for standard PCR for amplification of genes of interest. 
DNA fragment Primer sequence (5' to 3') 
Jλ1 F BamHI CGGATCCGCAACACCAACACACATTTTTACCTGG 
Jλ1 R HindIII GGAAGCTTCCACCAGCTGTGTAAAGTCTATGC 
Jλ2 F BamHI CGGATCCCACTCAGCCTGTAAAATCAAGCC 
Jλ2 R HindIII GGAAGCTTGTTCTCTCACAGCTGAGCTGAATCA 
Jλ3 F BamHI CGGATCCCATTTGTTTCATAACTTCTGTTAGAGTCATTG 
Jλ3 R HindIII GGAAGCTTGAGCTGTCAGCTCACTTGAGTG 
Eλ3-1 PU.1 F GAGAAATAATAGGAACTGCAACCAAGTCCATTAGCAGCAAGGC 
Eλ3-1 PU.1 R GCCTTGCTGCTAATGGACTTGGTTGCAGTTCCTATTATTTCTC 
Eλ3-1 IRF4 F GAGAAATAATAGGAACTGCAACCAAGTCCATTAGCAGCAAGGC 
Eλ3-1 IRF4 R GCCTTGCTGCTAATGGACTTGGTTGCAGTTCCTATTATTTCTC 
HPV16 E6 F CACCAACCGAGAACTGCAATG 
HPV16 E6 R CAGCTGGGTTTCTCTACG 
HPV16 E7 F ATGCATGGAGATACACCTAC 
HPV16 E7 R TTATGGTTTCTGAGAACAGA 
ECFP F TAGTTATTAATAGTAATCAATTACGG 
ECFP R TAAGATACATTGATGAGTTTGGAC 
HPV16 E6 N_ter HA F ACCATGTACCCATACGACGTCCCAGACTACGCTATGCAC 
HPV16 E6 N_ter HA R TTACAGCTGGGTTTCTCTACGTGTTCTTGA 
HPV16 E7 C_ter Myc F ACCATGCATGGAGATACACCTACATTG 
HPV16 E7 C_ter Myc R TTACAGATCTTCTTCAGAAATAAGTTT TTGTTCTGGTTT 
Cx26 F TTCCTCCCGACGCAGAGCAA 
Cx26 R GGGCAATGCGTTAAACTGGC 
GAPDH F CTCAACTACATGGTTTACATGTTC  
GAPDH R GCAAATGAGCCCCAGCCTT  
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Table 2-11 Oligonucleotide sequences used for gel retardation assays. 
Probe Sequences (5' to 3') 
E47 (Jλ1) F GTGTTCTCCAACTGCTCTCTCCT 
E47 (Jλ1) R AGGAGAGAGCAGTTGGAGAACAC 
E47(Jλ2) F ATCTACTACACAGCTGTCAG 
E47(Jλ2) R CTGACAGCTGTGTAGTAGAT 
E47(Jλ3) F TTCAGTGCAGCTGTGAGA 
E47(Jλ3) R AAGTCACGTCGACACTCT 
Pou1F1a (Jλ1) F GATCCTTCAGTGTTTAGTATAATA 
Pou1F1a (Jλ1) R TATTATACTAAACACTGAAGGATC 
IRF1/IRF2 (Jλ1) F AGTTTTCTTCAATAACTAGTGAAGATAAAG 
IRF1/IRF2 (Jλ1) R CTTTATCTTCACTAGTTATTGAAGAAAACT 
Table 2-12 Unlabelled competitors used for gel retardation assays. 
Unlabelled competitor Sequences (5' to 3') 
AML F GAATTCACCACATCTAGA 
AML R TCTAGATGTGGTGAATTC 
EBF F TCTAGAATTCCCNNGGGAATGAATTC 
EBF R GAATCCATTCCCNNGGGAATTCTAGA 
Oct factor F TCTAGAATGCAAATGAATTC 
Oct factor R GAATCCATTTGCATTCTAGA 
E47 F CAAACACCACCTGGGTAATC 
E47 R GATTACCCAGGTGGTGTTTG 
E2A F CCTTAGGCACATCTGTTGCTTTCG  
E2A R CGAAAGCAACAGATGTGCCTA AGG 
PU.1/IRF4 F CTTTGAGGAACTGAAAACAGAACCT  
PU.1/IRF4 R AGGTTCTGTTTTCAGTTCCTCAAAG 
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Table 2-13 Primers used for site directed mutagenesis. 
DNA fragment Primer sequence (5' to 3') 
Jλ1 E47mut F TGACTGTGTATGTGTTCTCTGACTGCTCTCTCCTGAAGTGCCT 
Jλ1 E47mut R AGGCACTTCAGGAGAGAGCAGTCAGAGAACACATACACAGTCA 
Eλ3-1 /IRF4 mut F GAGAAATAATAGGAACTGCAACCAAGTCCATTAGCAGCAAGGC 
Eλ3-1/IRF4 mut R GCCTTGCTGCTAATGGACTTGGTTGCAGTTCCTATTATTTCTC 
Internal primer 1 AATTTCTCACCTGCCCCCTCAACGC 
Internal primer 2 GCGTTGAGGGGGCAGGTGAG 
E47 NheI primer  TGGCACCGCTAGCGATCTCCATGGGC 
E47 Acc65I  primer GGTCGCGGCGCTTCCGGAGCAA 
IRF4 L368Ala R ATGGTGAGCAAACACTTGCGCCTCTGAAAACTGCTGTGT 
IRF4 L368Ala F ACACAGCAGTTTCTATCAGAGGCGCAAGTGTTTGCTCACCAT 
IRF4 K399Ala F GACCCTCAGAGACAGAGGGCGCTCATCACAGCTCAT 
IRF4 K399Ala R ATGAGCTGTGATGAGCGCCCTCTGTCTCTGAGGGTC 
Eλ3-1 IRF4/PU.1 mut F AAGAGAAATAATACCGACTGCAACCAAGTCCATTAGCAGCAAGGC 
Eλ3-1 IRF4/PU.1 mut R GCCTTGCTGCTAATGGACTTGGTTGCAGTCGGTATTATTTCTCTT 
2.8.2 Recombineering PCR reactions 
All primers used for recombineering studies are listed in Table 2-8. 
To generate fragments to be used for recombineering reactions the following com-
ponents and PCR conditions were used. The following components were mixed in a 
PCR tube: 1x Pfx Buffer, 0.3 mM dNTPs, 0.3 μM primers, 2 mM MgCl2, 1.25 units Pfx 
DNA polymerase, DNA template, DEPC H2O to 25 μl. The PCR products were re-
solved by electrophoresis on a 1% agarose gel and the band of interest excised and 
gel purified using the Qiagen PCR purification kit according to the manufacturer’s 
instructions. The settings in Table 2-5 were used to run the Pfx DNA polymerase PCR 
reactions.  HiFi DNA Polymerase was used to generate the GalK, ECFP, HPV16 E6 or 
E7 fragments with the homology regions for recombineering reactions. The follow-
ing component were mixed:  1x Expand HiFiPLUS, 10x reaction buffer 2, 0.2 mM 
dNTPs, 0.4 μM primers, DNA template, 1.25 units HiFiPLUS DNA polymerase, DEPC 
H2O to 25 ul. The cycling conditions are listed in Table 2-7. The resulting PCR prod-
ucts were resolved by electrophoresis on a 1% agarose gel and the band of interest 
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extracted and purified using the Qiagen PCR purification kit according to the manu-
facturer’s instructions. 
2.8.3 Site-directed mutagenesis  
All mutants except E47 were prepared using the site-directed mutagenesis kit ac-
cording to the manufacturer’s instructions (Agilent Technologies). The Jλ1 promoter 
was mutated in the E47 binding site that was found to be protected in DNase I foot-
printing experiments.  The Eλ3-1 enhancer was mutated in the PU.1 and IRF4 bind-
ing sites.  The IRF4 expression construct was mutated in the amino acids involved in 
the interaction with E47 and PU.1. In brief, for the mutant strand synthesis reaction 
two complementary oligonucleotides containing the desired mutation were synthe-
sized. These primers were gel purified and two reactions, a control and a sample 
containing the mutated primers were prepared. The control reaction contained the 
following components:  5 μl of 10× reaction buffer, 2 μl (10 ng) of pWhitescript 4.5-
kb control plasmid (5 ng/μl), 1.25 μl (125 ng) of oligonucleotide control primer #1 
[34-mer (100 ng/μl)] ,  1.25 μl (125 ng) of oligonucleotide control primer #2 [34-mer 
(100 ng/μl)], 1 μl of dNTP mix, 3 μl of QuikSolution reagent, 36.5 μl of double-
distilled water (ddH2O) to a final volume of 50 μl, 1 μl of PfuUltra HF DNA poly-
merase (2.5 U/μl), 10 QuikChange II XL Site-Directed Mutagenesis Kit. For the sam-
ple reaction containing the primers with the desired mutations the following reac-
tion was prepared in a final volume of 50 μl: 5 μl of 10× reaction buffer, X μl (10 ng) 
of dsDNA template, X μl (125 ng) of oligonucleotide primer #1 , X μl (125 ng) of oli-
gonucleotide primer #2 , 1 μl of dNTP mix , 3 μl of QuikSolution , 1 μl of PfuUltra HF 
DNA polymerase (2.5 U/μl), where X detonates the amount of DNA  template or 
primers required for the specific site directed mutagenesis reaction. The PCR condi-
tion in Table 2-6 were applied for both control and sample reactions. The reactions 
were placed on ice for 2 minutes and 1 μl of the Dpn I restriction enzyme (10 U/μl) 
was added directly to each amplification reaction and mixed by pipetting the solu-
tion up and down several times and incubated at 37°C for 1 hour to digest the pa-
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rental (i.e., the non-mutated) supercoiled dsDNA.  To proceed with the transforma-
tion into competent cells, 45 μl of XL10-Gold Ultracompetent Cells (tetracycline and 
chloramphenicol-resistant) were aliquoted into a pre-chilled 14-ml BD Falcon poly-
propylene round-bottom tube and 2 μl of the β-ME mix was added to the cells. Cells 
were incubated on ice for 10 minutes, swirled gently every 2 minutes and 2 μl of the 
Dpn I-treated DNA from each control and sample reaction were mixed with the 
competent cells and the reaction was incubated on ice for 30 minutes. The samples 
were heat-pulsed in a 42°C water bath for 30 seconds and the tubes were incubate 
on ice for 2 minutes to recover the cells. 0.5 ml of preheated (at 42°C) NZY+ broth 
was added to each tube followed by incubation at 37°C for 1 hour with shaking at 
225–250 rpm. The reaction was plated into agar plates containing the appropriate 
antibiotic for the plasmid vector and incubated at 37°C for >16 hours. The resulting 
clone was isolated and the fragment of interest subjected to PCR and sequenced to 
confirm the identity of the mutations. 
2.8.4 Overlap extension PCR 
E47 mutants were prepared by overlap extension PCR. A set of primers (internal 
primer 1 and internal primer 2) complementary to the sequences containing the 
mutation of interest were designed. A second set of primers (Acc65I primer and 
NheI primer) were designed upstream and downstream of the internal primers 1 
and 2, respectively. A first round of PCR was carried out by using internal primer 2 
and Acc65I, while a second PCR reaction used internal primer 1 and NheI.  
pCS2Myc/E2A was used as a template (Table 2-13). Each PCR product was se-
quenced to verify the accuracy of the fragment generated, gel-purified by electro-
phoresis on a 1.5% agarose gel and the PCR products were mixed. This mixture was 
used as a template for a further PCR using Acc65I and NheI as primers. The resulting 
PCR product was sequenced and gel-purified. Because E47 contained several GC-
rich regions, the PCR reaction was performed in the presence of 5% DMSO using a 
high fidelity Taq polymerase (HiFi). The final PCR products were then digested with 
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Acc65I/NheI and cloned into the Acc65I and NheI sites of pCS2Myc/E2A, previously 
double-digested and CIP-treated according to the manufacturer’s instructions 
(NEB). The resulting clone was eventually sequenced to confirm the identity of the 
mutation. 
2.8.5 Gel electrophoresis and DNA elution 
PCR fragments were separated by agarose gel electrophoresis for 30- to 45 minutes 
at 75V constant in 1x TAE or 1X TBE buffer. For purification of PCR products, the gel 
containing the band of interest was cut and purified either using the Quiagen gel 
purification kit according to the manufacturer’s instructions or electroeluted. For 
the latter, DNA fragments were subjected to electrophoresis in the presence of the 
intercalating agent ethidium bromide and the band of interest visualised by brief 
exposure to ultraviolet light. The band was excised using a scalpel blade and elec-
troeluted at 100V for 1 hour using dialysis tubing with a molecular weight cut off of 
8 kDa in the presence of 1 ml 1x TAE. Electreluted DNA was cleaned by two phenol 
chlorophorm extractions and precipitated in 2 volumes 100% ethanol and 1/10th 
volume of 3M sodium acetate (pH 5.2), followed by two washes in 70% ethanol.  
2.8.6 RNA extraction  
Cells were grown in T75 flasks and washed twice in cold PBS and scraped. Following 
a centrifugation at 1800 rpm for 3 minutes, the pellet was washed twice with cold 
PBS. One ml of TRIzol reagent was added to the pellet and samples mixed vigorously 
with additional vortexing. The cell suspension was incubated for 8 minutes at room 
temperature and centrifuged at 11500 rpm for 15 minutes at 4˚C. The aqueous 
phase was transferred to a fresh Eppendorf tube and RNA was precipitated by addi-
tion of 0.5 ml isopropanol. Samples were mixed by gentle inversion and incubated 
for 10 minutes at room temperature. Following centrifugation at 11500 rpm for 15 
minutes at 4˚C, the supernatant was discarded and the pellet re-suspended in 400 
μl TE and RNA was precipitated by addition of 40 μl 3M sodium acetate pH 5.2 and 
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880 μl 100% ethanol. After incubation at room temperature for 10 minutes, sam-
ples were centrifuged at 11500 rpm for 10 minutes at 4˚C and pellets washed with 
ice-cold 80% ethanol. Samples were centrifuged at 9500 rpm for 5 minutes at 4˚C 
and the pellets left to air dry on ice and re-suspended in 50 μl ddH2O. For certain 
further analyses, the RNA was treated using RQ1 RNase-Free DNase I according to 
the manufacturer’s instructions (Promega).  
2.8.7 Generation of cDNA  
To generate cDNA (complementary DNA), the Roche transcriptor first strand cDNA 
synthesis kit was used according to the manufacturer’s instructions (Roche). In 
brief, 2 μg of extracted RNA was mixed with 2 μl Random hexamer primers to a final 
volume of 13 μl. This was subjected to a PCR cycle for 10 minutes at 65˚C, with 
heated lid. After 10 minutes, the following components were added to the reaction: 
4 μl 5x buffer, 2 μl dNTP (10 mM stock), 0.5 μl reverse transcriptase (20 U/μl) and 
0.5 μl RNA Protect (40 U/μl) to a final volume of 20 μl. The reaction was subjected 
to another PCR cycle: 55ºC for 30 minutes, 85ºC for 5 minutes and 4ºC for 4 min-
utes. The cDNA was then analysed by electrophoresis gel (1-1.5% depending on the 
size of the cDNA segment of interest) to identify the band of interest. 
2.8.8 DNA Ligation  
PCR products of the gene of interest were generated and digested with the appro-
priate restriction enzyme. Plasmid vector DNA was digested with the same restric-
tion enzymes. PCR products were ligated to the vector using T4 DNA ligase enzyme 
(NEB) using a 3: 1 ratio of insert to vector. In brief, in a microcentrifuge tube the fol-
lowing were mixed: vector DNA, PCR product, 1x ligase Buffer, 0.5-1μL T4 DNA li-
gase and ddH20 to a total of 10μL. The PCR-plasmid mix was incubated for 1 hour 
(or overnight) at 16°C in the cold room and used for bacterial transformation.   
  
141 
 
2.8.9 Transformation of E. coli DH5α cells  
In a microcentrifuge tube, 1 to 5 μl of DNA (usually 10pg to 100ng) was mixed with a 
20-50 μl aliquot of chemically-competent E. coli DH5α cells which had previously 
been thawed on ice. Following incubation for 30 minutes on ice, cells were heat-
shocked at 42˚C for 45 seconds to allow uptake of the plasmid DNA containing the 
insert of interest into the competent cells. Cells were cooled on ice for at least two 
minutes and SOC or LB medium at room temperature was added to the cells which 
were incubated at 37˚C for one hour in a shaking incubator and subsequently plated 
on LB agar plates supplemented with the required antibiotic. Plates were incubated 
at 37˚C overnight or until single colonies were visible. To identify plasmids contain-
ing the required insert, colonies were shaken overnight in 5 ml LB medium supple-
mented with the required antibiotic and plasmid isolated as described below (Chap-
ter 2.8.10). A restriction digest was performed on the isolated plasmid to determine 
the size of the insert. 
2.8.10 Plasmid purification 
Colonies containing the desired plasmid were grown in a larger volume, typically 5-
10 ml (miniprep) or 250-500 ml (maxiprep) of LB medium supplemented with the 
required antibiotic, at 37˚C overnight and plasmids purified using Qiagen Miniprep 
Spin Kit or NucleoBond BAC DNA kits according to the manufacturer’s instructions. 
2.8.11 Determination of nucleic acid concentration 
To determine the concentration of DNA and RNA a conventional Nanodrop (Nano-
drop ND-1000, Thermo Scientific, UK) or spectrophotometer were used according to 
the manufacturer’s instructions. Quantification was performed measuring the opti-
cal density (OD) at 260nm and 280nm wavelengths (OD260nm and OD260nm) according 
to the Lambert-Beer’s law that relates absorbance to concentration using the path 
length of the measurement and an extinction coefficient: 
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Where A is the absorbance, ε the molar extinction coefficient, c the concentration 
of the solution and l the length in cm of the solution the light passes through (using 
a standard 10 x 10 cuvette, the light path length is fixed at 1 cm). For 1 cm path 
lenght standard the extinction coefficient will correspond to: 50 (dsDNA), 40 
(ssRNA) or 33 (ssDNA). The OD260/OD280 ratio is an indication of the purity of the 
sample: if the ratio of DNA OD260/OD280 is between 1.8 and 2.0, the DNA purity 
(meaning free from protein contaminants) is approx. 90% or better. If the ratio of 
RNA OD260/OD280 is approx. 2.0, the RNA purity is approx. 90% or better. 
2.8.12 Transient transfections 
Cos-7 cells were transfected by the calcium phosphate co-precipitation method. In 
brief, 250 μl 2x HBS were transferred into polystyrene tubes and in a second tube 
the plasmid DNA of interest was mixed at the concentration required with 20 μl of 
2M CaCl2. The mixture was added to the 2x HBS and incubated for 20 minutes at 
room temperature. In the meantime, cells were washed twice with PBS and, follow-
ing incubation, the mix was added drop-wise to the cells. Cells were covered with 
complete medium and incubated at 37˚C for 4 hours. Cells were washed with se-
rum-free DMEM and 500 μl 15% glycerol/HBS was added to the cells and quickly 
removed. Cells were washed twice with serum-free DMEM and incubated with 
complete medium for at least 48 hours prior to harvesting.   
911 and HaCaT cells were transfected with the recombinant adenovirus constructs 
using Lipofectamine 2000 (Invitrogen) for generation of viruses according to the 
manufacturer’s instructions. 
2.8.13 Cx26 siRNA transfection 
siRNA for Cx26 was purchased from ThermoScientific  (L-019285-00-005, 5nmol 
stock concentration, SMART pool on target). siRNA transfection were performed 
according to the manufacturer’s instructions (Life Technologies). In brief, for each 
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siRNA transfection, 125 μl of serum- and antibiotic-free DMEM was mixed with 4 μl 
of siRNA and in a second tube, 125 μl of serum- and antibiotic-free DMEM was 
mixed with 8 μl of RNAMax transfection reagent. The two solutions were mixed and 
incubated for 20 minutes at room temperature. HaCaT ells were washed twice with 
PBS and the mixture added carefully to the cells and volume increased to 5 ml with 
serum- and antibiotic-free DMEM. After 5 hours, the medium was changed with an-
tibiotic-free DMEM in the presence of serum. Cells were incubated for 72 hours 
prior to harvesting for further analysis. 
2.8.14 Probe preparation for Deoxyribonuclease I (DNase I) footprinting 
reactions 
A DNA fragment of approx. 300-400 bp encompassing the region around the start 
site of sterile transcription of Jλ1, Jλ2 and Jλ3 was amplified by PCR. The bacterial 
artificial chromosome Rp23-24i11 covering the 3 half of the lambda locus was used 
as a template to amplify the Jλ1-3 gene segments. Mouse kidney genomic DNA was 
used as a template for Jλ2. The PCR products and the vector were digested with 
HindIII and BamHI and ligated into pBluscript expression plasmid. The ligation reac-
tion was prepared on ice in a final volume of 10 μl using T4 DNA ligase and incu-
bated at 16°C in the cold room using a 3:1 molar ratio of insert to vector. Half of the 
ligation products were chemically transformed into competent DH5α E.coli cells and 
shaken in LB at 37°C overnight. The cultures were plated on LB agar plates supple-
mented with ampicillin and incubated for 1-2 days at 37°C. Discrete colonies (5-10) 
were picked and grown in 2 ml of LB supplemented with ampicillin. Following plas-
mid isolation, a test digest was performed to confirm the presence of the insert.  
Positive clones were expanded by growing in 500 ml cultures in the presence of 
ampicillin in a shaking incubator at 37°C overnight. Maxipreps were performed ac-
cording to the alkaline lysis procedure using QIAGEN columns, according to the 
manufacturer’s instructions. The final DNA was re-suspended in 500 μl TE. The con-
centration of plasmid DNA was determined by spectrophotometry (OD260) and 100 
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μg of DNA was double-digested with SacI/ClaI to generate the Jλ1, Jλ2 and Jλ3 lower 
strands, and with XbaI/KpnI to generate the Jλ1, Jλ3 upper strands, and XbaI/ApaI 
to generate the Jλ2 upper strand. Following digestion, samples were separated by 
electrophoresis in 1% agarose gels at 90V for 1 hour, the DNA fragment was excised 
and electroeluted at 90V for 1 hour using dialysis tubing with a molecular weight 
cut off of 6-8 kDa in the presence of 1-1.5 ml of TE. The fragment was purified by 
two phenol/chloroform extractions and re-suspended in 100 μl TE followed by pre-
cipitation in the presence of 10 μl 3 M sodium acetate (pH 5.2) and 200 μl 100% 
ethanol. The DNA was further purified with two washes of 70% ethanol to remove 
the salts, re-suspended in TE and quantified by spectrophotometry as described 
above.  
2.8.15 DNA labelling with the Klenow fragment 
Purified DNA fragments (1.3 μg) were digested with the appropriate restriction en-
zymes and labelled using [α-32P]-dCTP and Klenow DNA polymerase by filling in of 
3'-recessed ends. The reaction was prepared in a final volume of 50-60 μl depending 
on the concentration of the DNA.  DNA fragments, 10x E.coli polymerase buffer, 30 
μCi [α-32P]-dCTP and 10 U of Klenow DNA polymerase were incubated for 15 min-
utes at 12°C. Unlabelled deoxyribonucleoside triphosphatess (dNTPs, 0.2 mM) were 
added and incubated at room temperature for 10 minutes. To remove unincorpo-
rated dNTPs, the reaction was purified using a G-25 spin column (GE Healthcare) 
according to the manufacturer’s instructions. Eluted [α-32P]-dCTP -containing frac-
tions were increased to 200 μl by addition of TE and the samples incubated at 56°C 
for 30 minutes in presence of 5 μl 20% SDS and 5 μl 0.4 mg/ml proteinase K (PK) to 
inactivate the Klenow enzyme. The probes were then extracted with two phenol 
chloroform extractions and ethanol precipitated as described above. The pellets 
were re-suspended in 100 μl TE and counted using a scintillation counter. Approxi-
mately 10000-30000 cpm (counts per minute) were used for each lane on a foot-
printing gel and for each G+A ladder. 
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2.8.16  DNase I footprinting 
Reactions were performed in a final volume of 40 μl in which the binding buffer, 
0.5-1 mg/ml polydI-dC, 100 μg/lane of extract and 10000-30000cpm of the [32P]- α-
dCTP labelled probe were incubated for 20 minutes on ice. After incubation, 3.3 μl 
of 30 mM MgCl2 and 10 mM CaCl2 were added to the samples. Between 0.5 μl -1.0 
μl of 0.005 U DNase I were added to the free extract sample used as a control, while 
0.8 μl to 3.0 μl 0.25 U DNase I were used in the presence of the extract. In both 
cases, reactions were incubated for two minutes at room temperature. The cleav-
age reaction was stopped by addition of 5 μl of 100 mM EDTA and then the volume 
was increased to 100 μl by addition of 10 mM EDTA. Following two to four phenol-
chloroform extractions to remove proteins and ethanol precipitation, the pellets 
were re-suspended in formamide loading buffer and boiled for 2 minutes. The sam-
ples were loaded on a pre-run 8% polyacrylamide urea sequencing gel next to a size 
marker and a G+A ladder (Chapter 2.8.17) for 4-5 hours at 1800V/38mA in 1x TBE. 
The gels were dried on Whatman 3MM paper using a vacuum assisted gel drier 
prior to autoradiography using a phosphorimager LAS 5000. Captured images were 
analysed using the AIDA software. 
2.8.17 Guanine plus adenosine (G+A) ladder. 
A G+A ladder generated by Maxam-Gilbert chemical sequencing was applied next to 
the DNase I footprinting samples to identify the footprinted sequences. The radio-
labelled probe was incubated with 25 μl formic acid for 3 minutes to catalyze base-
specific modification. The reaction was stopped by addition of 200 μl hydrazine stop 
buffer and 750 μl 100% ice cold ethanol. The samples were left on dry ice for 5 min-
utes and centrifuged at 14000 rpm for 5 minutes at 4˚C. Following two washes with 
70% ethanol, the samples were dissolved in 200 μl dH2O and precipitated in the 
presence of 20 μl 3M sodium acetate (pH 5.2) and  400 μl 100% ethanol. After 
washing the samples in 70% ethanol to remove traces of formic acid, the samples 
were incubated with 70 μl 10% piperidine at 90°C for 30 minutes to allow the strand 
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scission reaction. The samples were then dried in a Speedvac evaporator and the 
pellet was washed twice in 30 μl and 20 μl dH2O respectively, to remove traces of 
piperidine. The pellets were re-suspended in formamide loading buffer, boiled at 
90°C for 2-3 minutes and loaded on a pre-run 8% polyacrylamide urea sequencing 
gel and separated by electrophoresis at 1800V/38mA as described above (Chapter 
2.8.16).  
2.8.18 Electrophretic shift assay (EMSA) 
EMSA is based on the retardation of DNA in protein/DNA complexes when sepa-
rated by electrophoresis under non-denaturing conditions. One strand of the duplex 
oligonucleotide probe was end-labelled with [γ-32P] ATP by T4 Polynucleotide kinase 
(PNK) and annealed to the complementary unlabelled strand. Labelling of one 
strand was performed by incubation of 100 pmol of the oligonucleotide with 1x T4 
PNK buffer, 15 μCi [γ-32P] ATP and 10 U of T4 PNK in a 15 μl reaction for 30’ at 37˚C. 
Unincorporated radiolabelled ATP was removed using a G-25 spin column (GE 
Healthcare) according to the manufacturer’s instructions. The end-labelled DNA was 
annealed with 120 fmol/μl of the complementary strand in the presence of 2 μl of 5 
M NaCl in a final volume of 100 μl. The samples were boiled for 2 minutes to allow 
denaturation of the DNA and left to cool overnight to anneal the strands. Unla-
belled double-stranded DNAs used in competition assays were prepared as follows: 
100 pmol of each strand, 2 μl  5M NaCl, 28 μl TE were combined in  a final volume 
of 100 μl and boiled for 2 minutes. The samples were cooled overnight to allow an-
nealing of the strands. A 1000- to 4000-fold excess of each competitor DNA was 
used in each competition assay.  For EMSA experiments, the reactions containing 
binding buffer, 0.5-2 μg/μl poly(dI-dC,) 20-30 μg protein extract and 10 fmol 32P- 
labelled probe, were incubated for 10-30 minutes on ice in a final volume of 25-40 
μl. The samples were separated by electrophoresis on a native polyacrylamide gels 
for 2 hours at 150V in 0.25x TBE (Table 2-14). The gels were dried onto Whatman 
3MM paper using a vacuum assisted gel drier prior to autoradiography.  For anti-
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body competition experiments, 3 to 10 μl of antibody was added to the binding re-
actions for 10 minutes on ice prior to addition of the extract, while for competition 
assays 1000 to 4000 fold excess of unlabelled competitor DNA was added prior to 
the addition of extract. For relative affinity experiments, between 30- to 1000-fold 
excess of unlabelled E2A competitor DNA was used prior to addition of the extract. 
Table 2-14 Incubation and electrophoresis conditions for gel retardation assays. 
Probe 1X Binding buffer % gel Incubation 
E47 25 mM Hepes-KOH (pH 7.9), 1 mM MgCl2, 1 
mM DTT, 1 mM EDTA, 10% glycerol 
7% for Jλ1 
6%  for Jλ2 
10 minutes on 
ice 
IRF1/2 10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 50 
mM NaCl, 0.5 mM EDTA, 20% glycerol 
6%   20 minutes on 
ice 
Pou1F1a 20 mM Hepes-KOH (pH 7.9), 10 mM MgCl2, 
50 mM KCl, 1 mM DTT, 4% Ficoll 
5% 30 minutes on 
ice 
2.8.19 Luciferase assay 
For luciferase assays, Cos-7 cells were seeded in 6-well plates at a density of 1.2x105 
cells/well one day prior to transfection. Constructs in which either the Jλ1 promoter 
or the Eλ3-1 enhancer drove the expression of the luciferase gene were used. Both 
constructs were cloned into the pGL3-basic reporter plasmid (promoter-less). The 
activity of both the promoter and the enhancer was determined in the presence of 
plasmid vectors expressing E47, PIP and PU.1 (a kind gift of Dr SL Grange). The pRL-
TK Renilla vector (a kind gift of Dr Ian Wood) was used as an internal control to 
monitor transfection efficiency. Cos-7 cells were harvested after 48 hours of trans-
fection and treated with passive lysis buffer (PLB), 500 μl per well, using the Dual-
Luciferase Reporter Assay System (Promega) according to the manufacturer’s in-
structions. Relative luciferase units were measured in a luminometer (model FB12; 
Zylux, Maryville, TN, USA.) with a delay time of 2 seconds and integration time of 
10 seconds. Firefly luciferase activity was measured by mixing 20 μl of cell lysate 
with luciferase assay reagent II (100 μl) followed by the Renilla reading using 
Stop&Glo Reagent (100 μl) according to the manufacturer’s instructions. The rela-
tive luciferase activity was calculated as the ratio of Firefly Luciferase to Renilla 
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Luciferase activity and normalized against average values given by transfection of 
the pGL3 basic empty vector. The results shown are means of standard deviations 
for at least three separate transfections performed in duplicate. Luciferase activity 
is expressed as relative lights units (RLU). Raw data and calculation methods are 
shown in Appendix 1 Table 7-2. 
2.9 Virus methods 
For recombineering experiments a BAC clone termed AdZ-5F35-CV5 adenovirus, a 
kind gift of Dr James Findlay, was used (Findlay, 2012). This adenovirus contains the 
backbone of the Ad5 vector, which contains a selection cassette in place of the E1 
region under the control of a CMV promoter (Figure 2-1). Furthermore, the Ad5 fi-
bre was replaced with the Ad35 fibre. Since the genome has the E1 and E3 regions 
deleted, the adenovirus is effectively replication deficient. These regions were re-
placed with the following genes of interest: ECFP (a kind gift of Gareth Howell) 
within the E3 region and HPV16 E6 or HPV16 E7 within the E1 region. 
 
Figure 2-1 Schematic representation of the AdZ-5 vector. 
The AdZ-5 vector vectors contain the Ad5 vector genome, deleted for E1 & E3 regions (rendering 
the vector non-replicative) in a single copy vector. It contains the CMV promoter and the PolyA 
signal sequence; the cassette encoding ampicillin resistance, lacZα & SacB is found within the MCS. 
SacB encodes for a gene giving sensitivity to sucrose, lacZα provides blue/white screening. em7-
galK recombineering.  
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2.9.1 Generation of recombinant adenovirus expressing GalK (positive 
selectoin) 
The em7-galK cassette (a kind gift of Dr James Findlay, University of Leeds, UK) was 
generated by PCR using the pUC19-em7-galK plasmid as a template and settings as 
described in Chapter 2.8.2. For positive selection, the em7-galK was inserted within 
the E3 region of the AdZ-5F35-CV5 and SW102 cells were employed as they have a 
defective phage which expresses the lambda red genes necessary to mediate ho-
mologous recombination between DNA fragments. These genes are under tempera-
ture sensitive control and therefore they are turned off at 32°C and they can be 
turned on by growing the bacteria at 42°C for 15 minutes. Therefore E. coli SW102 
cells containing the AdZ-5F35-CV5 BAC were grown at 32˚C overnight in 5 ml of half-
salt LB medium (supplemented with 12.5 μg/ml chloramphenicol and 50 μg/ml am-
picillin). The following day, 0.5 ml aliquot of the overnight culture was used to in-
oculate 25 ml half-salt LB (supplemented with 12.5 μg/ml chloramphenicol and 50 
μg/ml ampicillin) and grown in a 32˚C shaking incubator until OD600 of approx. 0.6 is 
reached. The culture was transferred into a 50 ml Falcon tube and incubated for 15 
minutes at 42˚C to induce the lambda red proteins. The falcon tube was inverted 
every 5 minutes and the culture was cooled on ice for 20 minutes and centrifuged 
at 4000 rpm for 5 minutes at 4˚C (Thermo Scientific IEC CL31R centrifuge). The su-
pernatant was discarded and 1 ml ice-cold sterile water was added to the pellet. 
This was gently re-suspended by rotation on ice-slurry. Water was added to make 
up the volume to 20 ml and cells were centrifuged at 4000 rpm for 5 minutes, 4˚C. 
The latter step was repeated at least 3 times. The re-suspended pellet was then 
transferred into ice cold 0.5 ml Eppendorf tubes and 3μl of the purified em7-galK 
selection cassette PCR product (250 ng) was added to 25 μl induced bacteria and 
incubated on ice for 5 minutes. The mixture was transferred into chilled 0.2 cm 
electroporation cuvettes and electroporated at 2.5 kV for 5 ms using the Biorad 
Gene Pulsar X cell electroporator. Cells were recovered in 1 ml half salt LB for 1 
hour in a 32˚C shaking incubator and then centrifuged at 17,000 x g for 30 seconds. 
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The pellets were washed twice with M9 salts and re-suspended in 1 ml M9 salts and 
three different dilutions (1:1, 1:10, 1:100) plated onto galK positive selection plates. 
Plates were incubated at 32˚C for 4-6 days. Colonies were selected and streaked 
into single colonies onto half salt agar plates supplemented with 12.5 μg/ml 
chloramphenicol and 50 μg/ml ampicillin and incubated at 32˚C for 2-3 days. Colo-
nies were subject to colony PCR (standard PCR reaction using Taq DNA Polymerase) 
where, as DNA template, a small aliquot of each colony was taken using a micropi-
pette tip. The PCR products were resolved by electrophoresis on a 1% agarose gel 
and colonies which resulted positive for the insert were grown in 5 ml half salt LB 
(supplemented with 12.5 μg/ml chloramphenicol and 50 μg/ml ampicillin) at 32˚C 
overnight. Following purification, BAC DNA was digested with Mlu I for 1.5 hours at 
37˚C to select positive colonies. If positive, these were grown in 500 ml half salt LB 
supplemented with 12.5 μg/ml chloramphenicol and 50 μg/ml ampicillin, purified 
and used for insertion of the ECFP cassette within the E3 region.  
2.9.2 Generation of recombinant adenovirus expressing ECFP (negative se-
lection) 
For insertion of ECFP into the AdZ-5F35-CV5 E3 region, E. coli SW102 cells contain-
ing the AdZ-5F35-CV5 BAC with the GalK selection cassette were grown in 5 ml of 
half-salt LB medium (supplemented with 12.5 μg/ml chloramphenicol and 50 μg/ml 
ampicillin) in a 32˚C shaking incubator overnight and recombineering performed as 
described above, using the ECFP PCR product generated previously to replace the 
GalK cassette. Recombineering products were plated onto GalK negative selection 
agar plates and incubated for 3-4 days at 32˚C until colonies were visible. A number 
of colonies were grown in half salt LB (supplemented with 12.5 μg/ml chloram-
phenicol and 50 μg/ml ampicillin) and a colony PCR performed to verify the pres-
ence of the insert. Positive colonies were grown in half salt LB at 32˚C overnight and 
following miniprep, the plasmid DNA was used as a template for a PCR. The PCR 
products were resolved by electrophoresis on a 1% agarose gel and the band of in-
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terest excised and gel purified using the Qiagen PCR purification kit according to the 
manufacturer’s instructions and sent for sequencing to verify correctness of the in-
sert. ECFP expression was also confirmed by transfection of 911 cells. 
2.9.3 Generation of recombinant adenovirus expressing HPV16 E6 or E7 
For insertion of the HPV16 E6 or E7 within the E1 region, E. coli SW102 cells contain-
ing the AdZ-5F35-CV5 BAC with ECFP in the E3 region were grown in 5 ml of half-salt 
LB medium (supplemented with 12.5 μg/ml chloramphenicol and 50 μg/ml ampicil-
lin) in a 32˚C shaking incubator overnight The following day, 0.5ml of the overnight 
culture was inoculated into 25ml half salt LB and incubated at 32 ˚C until the OD600 
reached approx. 0.6. The culture was transferred into a 50 ml Falcon tube and incu-
bated for 15 minutes at 42˚C with tube inversion every 5 minutes. The culture was 
cooled on ice for 20 minutes and centrifuged at 4000 rpm for 5 minutes at 4˚C 
(Thermo Scientific IEC CL31R centrifuge). The supernatant was discarded and 1 ml 
ice-cold sterile water was added to the pellet. This was gently re-suspended by rota-
tion on ice-slurry. Water was added to make up the volume to 20 ml and cells were 
centrifuged at 4000 rpm for 5 minutes, 4˚C. The latter step was repeated at least 3 
times. The pellet was re-suspended in the remaining water by gently swirling (20 ml 
final volume). The re-suspended pellet was then transferred into ice cold 0.5 ml Ep-
pendorf tubes and 3μl of the PCR product of the gene of interest to be inserted was 
added (HPV16 E7 C-terminus Myc or HPV16 E6 N-terminus HA). The mixture was 
transferred into chilled 0.2 cm electroporation cuvettes and electroporated at 2.5 
kV for 5 ms using the Biorad Gene Pulsar X cell electroporator. Cells were recovered 
in 1 ml half salt LB, transferred into 15 ml Falcon tubes and the volume increased to 
5ml by addition of low salt LB. Cells were incubated for at least 4 hours in a shaking 
incubator at 32˚C prior to plating on sucrose IPTG/Xgal plates. The suspensions 
were stored at 4˚C for up to 48 hours before plating to reduce the number of nega-
tive and false positive colonies. Plates were incubated for at least for 2 days, after 
which period several colonies were visible: for a gene giving sensitivity to sucrose, 
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lacZα provides blue/white screening, however these were discarded as they did not 
contain the insert, and thus only white colonies were tested for positivity for the 
insert. These were grown in half salt LB supplemented with 12.5 μg/ml chloram-
phenicol and following miniprep, a BamHI test digest was performed to confirm the 
presence of the insert. Positive colonies would lose two bands running at 1.7 kb and 
2.5 kb. Once a colony was found to be positive, the insert was amplified by PCR and 
the products sent for sequencing to verify correctness of the sequence (Chapter 0). 
This was expanded and the BAC DNA purified for transfection of 911 cells.  
2.9.4 Growth of recombinant adenoviruses in 911 cells 
911 cells provide the products of the E1 region necessary for virus replication in 
trans. The E1 region was replaced either with HPV16 E6 or E7 coding regions as de-
scribe above. Following transfection with Lipofectamine reagents according to the 
manifacturer’s instructions, the cells were incubated at 37 ˚C until they detached, 
approx. 4-5 days post-transfection. To verify the efficiency of the transfection cells 
were observed for expression of CFP using a fluorescent inverted microscope (Nikon 
Eclipse TS100) equipped with Nikon B-A fluorescent filter and Nikon digital Sight DS-
5M camera. Images were captured using the AxioVision 4.3 software. Cells were 
expanded in T175 flasks (Corning). After 3-4 days, cells were collected in 50 ml Fal-
cons and centrifuged at 1200 rpm for 3 minutes and the pellets were washed two 
times in ice cold PBS. The pellets were subjected to three cycles of snap-freeze in 
liquid nitrogen, thawed at 37˚C in a water bath and sonicated 45 seconds in a water 
bath sonicator (Kerry Ultrasonic bath sonicator). This lysate was used to infect a 
fresh T175 flask of 911 at 70-80% confluence. Ideally, lysate from one T175 flask 
would infect ten T175 flasks. This procedure was repeated until 30 T175 flasks of 
infected 911 cells had been generated. Once all the pellets were obtained, virus was 
purified as described below.  
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2.9.5 Virus purification 
Virus was purified from cell pellet derived from 30xT175 flasks using CsCl density 
centrifugation. In brief, the cell pellets were transferred into 50 ml falcon tubes and 
re-suspended in 10 ml sterile 0.1M Tris-HCl (pH 8.0) and 1 ml of 10% sodium deoxy-
cholate was added to a final concentration of 5% (w/v). The re-suspended pellet 
was left at room temperature for 30 minutes, until it appeared viscous. Then, 100 μl 
of 2 M MgCl2  and 50 μl DNase I (10mg/ml) were added and the solution incubated 
at 37˚C for 30 minutes with periodic inversion, until the viscosity was reduced. The 
lysate was centrifuged at 3000 rpm for 15 minutes at 4ºC and the supernatant 
transferred into a fresh tube and kept on ice until ready to be loaded on the CsCl 
gradient. one gradient was prepared for every 5ml of virus lysate. Therefore, two 
gradients were prepared inSW40 ultraclear Beckman tubes (14x95mm, Cat. 344060) 
each containing: a bottom layer with 1 ml 1.5d CsCl, a middle layer with 2.5ml of 
1.35d CsCl and a top layer with 2.5ml of 1.25d CsCl. The virus lysate was added on 
top of the gradients and tubes were balanced with 0.1M Tris-HCl (pH 8.0). To pre-
vent diffusion between the gradients the gradients were centrifuged as soon as 
possible. The tubes were centrifuged for 1 hour in a Beckman’s Optima L-80 ultra-
centrifuge using a SW40 rotor at 35000 rpm at 10ºC at the slowest acceleration and 
deceleration settings (deceleration was set to 1). After 1 hour, the virus band of in-
terest was located between the 1.35d and 1.25d interface (Figure 2-2). This band is 
carefully removed from the tubes and kept on ice until a further CsCl gradient was 
prepared. The purified virus was gently loaded on top of 2ml of 1.35d CsCl using a 
SW55ti ultracentrifuge tube (ultraclear 13x51mm, cat: 344057). Where required, to 
achieve layering, bands were diluted with 0.1 M Tris-HCl (pH 8.0). Following cen-
trifugation at 35000rpm, 4˚C for 12 hours using a SW50 rotor (with minimum accel-
eration, no brake), virus particles were detected in the upper of the two visible 
bands (Figure 2-2 C). both bands were collected and extensively dialysed against 3 
changes of 10mM Hepes-KOH buffer (pH 8.0) using Thermo Scientific Slide-A-lyzer 
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MINI Dialysis Devices, 3.5K MWCO (molecular weight cut off) 0.1ml (cat: 69550) 
over the course of a day at 4˚C. The purified virus is collected and sterile glycerol 
added to 10% (v/v) is. Aliquots were prepared and stored at -80˚C. 
 
Figure 2-2 CsCl gradient virus purification.  
Top panel, a schematic representation of the stages of virus purification (Adapted from (Jager et 
al, 2009)). B-C: purified bands following the first spin (B) and the overnight centrifuge (C), showing 
the bands containing complete virus particles. HC-AdV = High-capacity adenoviral vectors. 
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2.9.6 Virus quantification by the fluorescent focus unit (FFU) assay 
To determine the titre of the purified virus, 911 cells were seeded in a 24-well plate 
at a density of 1.2x105 cells/well. The following day, a series of 10-fold dilution of 
the virus were prepared for each well, in triplicate (Table 2-15). Cells were washed 
twice with cold PBS, virus particles diluted in serum-free medium (DMEM) and 
added to the cells. Following incubation for 1 hour at 37˚C, the medium was 
changed and complete DMEM was added and cells incubated at 37˚C for 24 hours. 
On the following day, the cells were washed twice with PBS and incubated with 
trypsin for 5 minutes. The cells were re-suspended in 500 μl complete DMEM and 
transferred into 1.5 ml Eppendorfs and centrifuged at 400g for 3 minutes at 4˚C. 
The pellet was re-suspended in 100 μl 2% PBS buffered paraformaldehyde and in-
cubated for 10 minutes at room temperature. Cells were centrifuged for 3 minutes 
at 2000g, 4˚C and pellets re-suspended in PBS and analysed by flow cytometry for 
CFP expression (FACS Fortessa Diva). To calculate FFU from the flow cytometric 
data, the dilution at which 50% of the cells were CFP positive (X) was multiplied by 
the number of cells plated at the beginning of the experiment (Y= 1.2x105). This was 
divided by the dilution factor (i.e. Z= 5x10-4) and multiplied by 2 to give the number 
of FFU/ml. To calculate the volume of purified virus to use in the experiments, the 
following calculation was performed: 
                              
which represents the amount of purified virus which infects 100% of the cells in 24 
hours (since cells were left in the presence of the purified virus for 24 hours prior to 
analysis by flow cytometry).  
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Table 2-15 Values for virus quantification by the fluorescent focus unit assay. 
Tube Serial 10-fold dilutions Virus Volume 
virus (μl) 
Volume 
media (μl) 
1 5x10-3 Stock solution  20 1980 
2 5x10-4 Tube 1 200 1800 
3 5x10-5 Tube 2 200 1800 
4 5x10-6 Tube 3 200 1800 
5 5x10-7 Tube 4 200 1800 
6 0 None  0 2000 
2.9.7 Transduction of HaCaT cells 
To analyse expression of HPV16 E6, E7 and Cx26, HaCaT cells were transduced with 
an appropriate concentration of virus particles. Cells were washed twice with cold 
PBS and virus diluted in serum-free DMEM and added directly to the cells in a final 
volume of 5 ml (T75 flasks) or 1 ml (6-well plates). Incubation was performed for up 
to 3 hours before the medium was removed and replaced with complete DMEM. 
For Western blots, cells were incubated at 37˚C for a further 48 hours, for im-
munofluorescence and dye transfer assays, cells were incubated for 24 hours at 
37˚C. 
2.9.8 Lyoplate assay 
The lyoplate assay was performed on normal human keratinocytes (NHK), CaSki and 
SiHa cells in collaboration with Dr Erica Wilson (Leeds Institute of Cancer and Pa-
thology, Leeds) according to the manufacturer’s instructions (BD Lyoplate™ Screen-
ing Panels, BD Bioscience). In brief, the three cell types were cultured until they 
reached 80-90% confluence and washed with 1x PBS, treated with trypsin and cen-
trifuged at 300g for 5 minutes; to remove any clumps, cells were passed through a 
BD Falcon™ 40 or 70 μm cell strainer and cells concentration determined. Pellets 
were re-suspended in 1x PBS with calcium and magnesium with the addition of 100 
units/ml DNase at 10 million cells per ml to mitigate cell clumping. Following incu-
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bation at room temperature for 15 minutes, cells were washed in two to four vol-
umes of 1X PBS and centrifuged at 300g for 5 minutes.  NHK, CaSki and SiHa cells 
were fluorescently labelled with 0.4μM cell trackerTM green- 5-
Chloromethylfluorescein Diacetate (CMFDA, C25H17ClO7), 2μM orange-CMRA 
(C30H25Cl2NO), 2μM violet-BMQC (C16H16BrNO2), respectively and incubated for 1 
hour at 37˚C. Cells were washed 3 times PBS/0.5%BSA and re-suspended in 5 ml BD 
Pharmingen Stain Buffer (275 ml of BD Pharmingen Stain Buffer (FBS) with the addi-
tion of 5 mM EDTA (final concentration)) and 100 μl of cell solution was aliquoted to 
three fresh, round-bottom 96-well plates at a density of 6x105/well. To reconstitute 
the antibody, the BD plates were centrifuged at 300 g for 5 minutes. Using a multi-
channel pipette, the lyophilized antibodies were reconstituted in 110 μl of 1X sterile 
PBS. This resulted in an antibody solution that contains five tests (20 μl/test). Re-
constituted antibodies were stored at 4˚C until further use. The reconstituted anti-
body was mixed using a multi-channel pipette, by pipetting carefully up and down 
2-3 times and 20 μl were added to corresponding wells of sample plate previously 
prepared. Cells were incubated on ice for 30 minutes and washed with 100 μl of BD 
Pharmingen Stain Buffer/ EDTA per well. Following the incubation, cells were centri-
fuged at 300 X g for 5 minutes and the supernatant carefully removed. Cells were 
washed with an additional 200 μl of BD Pharmingen Stain Buffer /EDTA and centri-
fuged at 300 X g for 5 minutes. The supernatant was discarded and 100 μl of the 
appropriate secondary antibody were added directly to cells in each well and incu-
bate for 30 minutes on ice in the dark. The secondary antibody was diluted in BD 
Pharmingen Stain Buffer+ EDTA to a final concentration of 1.25 μg/ml (1:200 dilu-
tion). Following incubation, cells were washed with 100 μl of BD Pharmingen Stain 
Buffer /EDTA and centrifuge at 300 X g for 5 minutes. The supernatant was dis-
carded and cells washed with an additional 200μl of BD Pharmingen Stain Buffer + 
EDTA. Cells were centrifuged at 300 x g for 5 minutes and the pellets re-suspended 
in 100 μl of live cell viability dye (Zombie NIR) and incubated at room temperature 
for 30 minutes. Cells were centrifuged at 300 X g for 5 minutes and re-suspended in 
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100 μl BD Pharmingen Stain Buffer/ EDTA. Cells were centrifuged at 300 X g for 5 
minutes and re-suspended in 150 μl BD Pharmingen Stain Buffer/ EDTA and ana-
lysed. Flow cytometry data analysis was done with FlowJo or FACSDiva. 
2.9.9 Lucifer yellow dye transfer assay 
The Lucifer yellow dye transfer assay was carried out in collaboration with Dr Paola 
Massimi (ICGEB, Trieste, Italy). This was done to assess the expression of gap junc-
tion proteins in HaCaT cells transduced with recombinant adenoviruses to investi-
gate the role of E6 in connexin expression. In brief, glass capillaries tubes were pre-
pared for microinjections using a heating apparatus set at a current of 17-18 mA at 
613-617 ˚C (BB.CH, Mekanex, Geneva). For the dye transfer, HaCaT cells were 
seeded in 3 cm dishes at a low density (approx. 25% confluent) a day before being 
transduced with the recombinant adenovirus as described above. The following 
day, the medium was replaced with PBS for microinjection which was performed 
using an Eppendorf Femtojet automated pressure microinjector, at an average 
pressure of 350 hPa, depending on the cell to be injected. To prepare the dye, 1 M 
lithium chloride was prepared in water and 400 μl were mixed with 16 μl Lucifer 
yellow dye (25 mg/ml) to obtain a final concentration of 4% dye. This was centri-
fuged for 1 minute at maximum speed and kept at 4˚C protected from light, until 
use. For visual guidance to identify cells for injection a white light and interference 
contrast optics connected to a screen (Sony Trinitron) was used; this was also con-
nected to the microinjectror. A confocal microscope was used to follow diffusion of 
the dye and take pictures at selected intervals (Zeiss LSM510). The percentage of 
cells that passed dye to at least one neighbouring cell was counted. For each sam-
ple, 10 to 15 injections were performed.   
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2.10 Next generation sequencing 
Samples used for high throughput RNA-Seq analysis of cell-surface transcripts had 
been previously prepared and sequenced by Dr Joanne Morgan at the sequencing 
facility in St James University Hospital, Leeds, UK (Watherston, 2010). In brief, fol-
lowing total RNA extraction and cDNA generation (Chapter 2.8.6 and 2.8.7), full-
length cDNA was sheared using a Covaris S-series instrument (USA) to generate 
fragments of approximately 200–400 bp. The paired-end sequence sample prepara-
tion kit (Illumina, USA) was used to perform end repair to create blunt ends in the 
cDNA as well as for addition of Adenine to the blunt-ended 3' ends of the 200-400 
bp cDNA fragments catalysed by Klenow-exo enzyme; 5' and 3' overhangs were re-
moved using a 3' exonuclease and a 5' DNA polymerase. These fragments were puri-
fied using the Qiagen PCR purification MinElute column kit (Qiagen, UK) according 
to the manufacturer’s instructions. Following purification, the Adenine-tagged DNA 
fragments were ligated to the flow cell using DNA ligase and PE adapter oligo-mix 
for 15 minutes at 20°C. The samples were purified using the Qiagen PCR purification 
MinElute column kit. Unligated adapter molecules were removed by agarose gel 
electrophoresis and the correct size templates for the high-throughput next genera-
tion sequencing were selected. RNA-Seq of cDNA was performed using the Illumina 
Genome Analyser II (Illumina Inc., USA). In brief, the nucleotide bases were modi-
fied by addition of a fluorophore and they were incorporated into oligo-primed DNA 
fragments (a sequence-by-synthesis approach). The fluorophore and 3'-OH group of 
the nucleotide bases, which has been chemically modified to prevent polymerisa-
tion, were removed to wash the flow cell before sequencing precedes the next ad-
dition of a nucleotide. The number of times the flow cells is washed depends on the 
read length. For this analysis, read were 75 bp long, thus, this step was repeated 75 
times. Reads were saved as fastq formats and ready to be analysed (Figure 2-3). 
These reads are defined as single-end reads or paired-end reads depending on 
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whether the sequencing was performed from one strand or both ends of the cDNA 
molecule, respectively. For this study reads were sequenced from one end only. 
 
Figure 2-3 Library preparation for Illumina RNA-Seq platform. Adapted from  (Kumar et al, 2012). 
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2.10.1 Analysis of next generation data: overview of the TopHat/Cufflinks 
pipeline 
Bioinformatics analysis was performed to interpret the sequencing results using the 
Galaxy platform. The Tophat-Cufflinks pipeline was used (Trapnell et al, 2012). In 
brief, the sequencing reads were first pre-processed to eliminate low quality bases 
which could interfere with the alignment (Figure 2-4). This was done using the 
FastQC kit analysis tool. The sequences were then aligned to a reference genome 
(hg19, 2009) using TopHat and transcript abundance was estimated using Cufflinks. 
Cuffdiff was used to evaluate differentially expressed transcripts between the sam-
ples.  
For this experiment, there were no replicates, either biological (i.e. replicates sam-
ples of the same tissue) or technical (replicates of the same RNA sample). There-
fore, to consolidate the results generated by Cuffdiff, the same samples were also 
run using a program designed to deal with non-replicated data: GFOLD (Feng et al, 
2012). GFOLD ranks the genes by expression level differences between the samples 
compared (Figure 2-4). Unless specified, TopHat, Cufflinks and Cuffdiff were ran us-
ing the default parameters as set on the Galaxy platform (Appendix 4: NGS/RNA-Seq 
analysis parameters). CummeRbund, an R based program, was used to visualize 
Cuffdiff outputs; the latter and GFOLD were both run using a UNIX operating system 
according to the instructions and commands provided in the respective manuals 
(Feng et al, 2012). 
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Figure 2-4 RNA-Seq pipeline adopted in this study. 
2.10.2 Quality reads analysis 
High throughput sequencing pipelines generate raw sequence data which contain 
low quality bases which must be trimmed off from the reads. In addition, contami-
nating adapter sequences must be removed, as well as reads that are too short to 
accurately align. The FastQC tool analyses all the sequences and gives a graphical 
view of the results. Results show basic statistics, per base sequence quality, per se-
quence quality scores, per base sequence content, per base GC content, per se-
quence GC content, per base N content, sequence length distribution, duplicate se-
quences, and over-expressed sequences. FastQC was run on all the samples, a qual-
ity score for each base was calculated and low quality bases trimmed off using 
FastQC Trimmer. Box and whisker plots of per-base sequence quality were used to 
assess the base quality. This output gives an overview of the quality values across all 
the bases in the sequence being analysed, at each position. Therefore, if the lower 
quartile for any base is <10 (or the median for any base <25), the output will be a 
“warning”; if the lower quartile for any base is <5 (or the median for any base is 
<20), the output will be a “fail”. In the latter case, by looking at the box and whisker 
Cuffcompare
Final transcriptome assembly
Tophat
Reads are mapped to a reference genome (hg19)
Cufflinks
Assembled reads
Cuffdiff
Differential Expression (on a per 
sample basis)
Pre-processed reads: quality control
Sample 1 Sample 2
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plot, low quality bases will be trimmed off. Similarly, all the other jobs run by 
FastQC gave a “pass”, “warning” or “fail” output, depending on which additional 
modification to the reads were done before aligning the sequences to the reference 
genome. 
2.10.3 How does TopHat work? 
TopHat is a program used to align RNA-Seq reads to a reference genome by finding 
exon-exon splice junctions (Trapnell et al, 2009).  TopHat is a wrapper for a program 
called Bowtie, which aligns sequenced reads one at the time (http://bowtie-
bio.sourceforge.net/bowtie2/manual.shtml). Bowtie is one of the earliest and most 
frequently used alignment tools. It is based on a computational program which “in-
dexes” the reference genome to speed up the process of mapping and use less 
space. Indexing is based on a technique for compressing large files known as the 
Burrows-Wheeler. Briefly, Bowtie will align the sequences one at the time to the 
Burrows-Wheeler compressed genome; as the alignment progresses, the mapping 
positions will be narrowed, since Bowtie will build up on pre-existing aligned se-
quences. If Bowtie cannot align the sequence will try again by considering one mis-
match; if this fails, then it will try with two mismatches. The number of mismatches 
allowed has to be set accordingly as it depends on the read length being analysed 
(Cullum et al, 2011). As a general rule, 2 mismatches are considered standard. To-
pHat additionally adds another feature: the ability to align exon-exon junctions. 
Aligning sequences which belong to the same exon requires fewer algorithms than 
those belonging to several exons; therefore Tophat will use Bowtie to align the se-
quences back to known exons in the genome, and the remaining sequences will be 
aligned to junctions between junctions. This is a very important feature since it can 
potentially predict new exons and thus new transcripts (Trapnell et al, 2009).   
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2.10.4 How does Cufflinks work? 
Following mapping, reads belonging to the same gene/transcripts have to be quan-
tified and normalised by taking into account gene length as well as the sequencing 
depth. Both are necessary to enable us to compare the samples analysed. By follow-
ing the pipeline, the next step is to use TopHat output (SAM/BAM format) to run 
Cufflinks; Cufflinks quantifies transcript levels in units of reads per kilobase per mil-
lion mapped reads, or RPKM (Mortazavi et al, 2008). In paired end reads it will cal-
culate fragments per kilobase per million reads (FPKM) (Trapnell et al, 2010). FPKM 
is defined as: 
FPKM = 109xC/NL 
Where: C represents the number of reads mapped on to the gene's exons, N the 
total number of reads in the experiment and L the sum of the exons in base pairs. 
This is a crucial step as the “RPKM/FPKM normalizes a transcript read count by both 
its length and the total number of mapped reads in the sample” (Mortazavi et al, 
2008). Default parameters from the Galaxy platform were used to analyse the data.  
Having calculated the variance of a transcript abundance in each condition (this is 
done also at the gene level), Cufflinks will use the Student t Test to find transcripts 
that are differentially expressed. Eventual changes in abundance are calculated by 
Cuffdiff using the square root of the Jensen-Shannon divergence. As output, Cuff-
links generates data which, together with TopHat outputs, is used to make a statis-
tical estimate of abundance of transcripts. The latter operation is performed using 
Cuffdiff which uses the square root of the divergence generated above to estimate 
the abundance between samples and assigning p and q values.  
2.10.5 Statistical analysis with Cuffdiff 
One of the biggest challenges of next generation sequencing is the analysis of the 
large amount of data. Although over the years costs and time of sequencing have 
considerably decreased, analysis has become more challenging. Different software 
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packages have been developed for the statistical analysis of next generation se-
quencing data. For the dataset used in this study, Cuffdiff was employed, which is 
part of the Cufflinks package. Cuffdiff is designed to search for significant changes in 
transcript expression, splicing, and promoter usage as well as levels of gene expres-
sion. It firstly determines for each transcript/gene the mean and variance of the  
fragment count within a certain condition and then it adopts the t test as a statisti-
cal method to detect differentially expressed (DE) transcripts and genes (Student’s 
T-test). It does so by assigning a log ratio between two conditions being compared. 
It assigns a cut off above which a transcript/gene can be called DE. It then converts 
the t test into p values: below a certain set value, that change in transcript/gene 
level will be considered significant. However, having had to deal with multiple com-
parisons (thousands of transcripts/genes) there is a high chance to incur type I er-
rors, which is when a transcript/gene is detected as a DE when it is actually not al-
tered. For this reason Cuffdiff, rather than using the p values as a tool to assign sig-
nificance, adopts the q value, which is the p value FDR-adjusted (FDR, false discov-
ery rate) (Benjamini et al, 2001). The FDR is defined as “the proportion of false posi-
tives among all of the genes identified as being DE, which is among the entire re-
jected null hypothesis” (with the null hypothesis being that there would not be a 
difference in expression between two conditions) (Noble, 2009). For the dataset 
used in this experiment, an FDR = 0.05 was adopted, which means approximately 
5% of the genes/transcripts considered by Cuffdiff as being statistically significant 
after the correction are actually found by chance and are false positives. 
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Chapter 3. Analysis of transcription factor binding to the promoters of 
sterile transcription 
3.1 INTRODUCTION 
Immunoglobulin gene rearrangement during V(D)J recombination depends on 
higher-order chromatin structure. Cis-regulatory elements such as enhancers and 
promoters contain binding sites for transcription factors whose interaction drives 
sterile transcription through the antigen recombining genes. Locus contraction via 
looping of these chromatin domains triggers long-range interaction and supports 
chromatin accessibility. 
Earlier studies already identified cell type specific transcription factors which bind to 
the enhancers of sterile transcription of both heavy and light (kappa) chains such as 
CTCF, Pax5, E2A, YY1, OBF-1, Ikaros and IRF4. Ikaros, YY1 and Pax5 are involved in 
IgH locus contraction and in their absence locus rearrangement is reduced (Fuxa et 
al, 2004; Meldrum, 1991; Reynaud et al, 2008), suggesting that cooperation be-
tween transcription factors facilitates long range interactions necessary for both 
VH-DH and Vκ-Jκ rearrangement (Jhunjhunwala et al, 2009). 
An important role is played by CTCF whose main function is to prevent inappropri-
ate interactions between regulatory elements. This was identified for example at 
the imprinted H19-Igf2 locus and the mouse β-globin locus (Phillips & Corces, 2009; 
Splinter et al, 2006). Indeed, CTCF binding sites were mapped across the immu-
noglobulin loci (Degner et al, 2011; Partin et al, 1990). Specifically, two CTCF binding 
sites at the Igh VH-DH locus were identified and implicated in the control of lineage 
specific V(D)J recombination and also in organizing the VH and DH regions into dis-
tinct chromatin domains. As found for the other transcription factors, knockdown of 
CTCF resulted in a decrease of Igh locus contraction (Degner et al, 2011). 
At the Igκ locus, V to J recombination occurs at the pre-B cell stage under the con-
trol of two enhancers, the intronic enhancer κEi and the 3' enhancer, κE3'. At this 
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locus, CTCF limits the interactions between the κ enhancers and the proximal Vκ 
genes and also prevents inappropriate contacts with elements outside the Igκ locus 
(Soler et al). Earlier studies also identified E2A to be crucial for the activation of this 
locus: in E2A-deficient mice, Igκ germline transcription is blocked and consequently 
accessibility to the locus by the recombinase machinery is severely reduced 
(Lazorchak et al, 2006). Since E2A interacts with IRF4, inhibition of IRF4 activity also 
leads to reduced germline transcription and accessibility and neither of the two 
transcription factors was able to support adequate levels of sterile transcription 
alone, pointing to the importance of this interaction during Igκ locus activation. 
Previous studies also identified transcription factors that bound to the two enhan-
cers at the Igλ locus, Eλ3-1 and Eλ2-4 (Eisenbeis et al, 1995).  The B cell specific 
transcription factors PU.1 and IRF4 were found to bind not only the lambda enhan-
cers but also the κE3' enhancer. The results also showed that IRF4 was present in 
the complex and could bind the DNA only in presence of DNA-bound PU.1 when this 
factor was phosphorylated at serine 148 (Eisenbeis et al, 1993; Eisenbeis et al, 1995; 
Pongubala et al, 1993). 
While the transcription factors binding to the enhancers have been elucidated for 
both heavy and light chains, the promoters of sterile transcription of the Igλ light 
chain loci have not been extensively studied. In particular, the transcription factors 
binding to the promoters of the J lambda genes are not known. The murine lambda 
locus is a good model since it only has four J gene segments whose transcription is 
under the control of the Eλ3-1 and Eλ2-4 enhancers. Of the four gene segments, 
60% of recombination involves the Jλ1 gene segment, followed by Jλ2 and Jλ3. Jλ1 
recombines mainly with Vλ1 (Reilly et al, 1984). Sterile transcription through these 
gene segments will open up the tight chromatin structure to allow binding of the 
RAG proteins. To this end, interaction between the promoter and the enhancer is 
crucial to allow delivery of RNA pol II to the promoters; however, what drives the 
specificity of this interaction is not known. A possible hypothesis is that binding of 
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transcription factors to the enhancers and the promoters specifically drives this in-
teraction to trigger sterile transcription through the gene segments. 
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3.2 RESULTS 
3.2.1 Bioinformatics analysis of the transcription factor binding sites at 
the promoters of sterile transcription  
A bioinformatics search analysis using the TESS program ( Transcription Element 
Search System, www.cbil.unpenn.edu) was carried out to identify the different 
transcription factors which potentially bind to the Jλ1, Jλ2 and Jλ3 promoters of 
sterile transcription. The sequences selected were submitted for analysis and only B 
cell-specific transcription factors were considered which were expressed and active 
at the pre-B cell stage (stage at which light chain recombination occurs) (Figure 3-2). 
To calculate the length of the sequence to be analysed for each promoter the previ-
ously mapped transcription start site (Engel et al, 2001) was used as a reference. 
The mouse transcription initiation sites for the J-C germ line transcripts had previ-
ously been characterized by rapid amplification of the 5′ cDNA ends (RACE) (Engel et 
al, 2001).  This showed transcripts initiating at 293, 116 and 73 bp upstream of the 
Jλ1, Jλ2 and Jλ3 gene segments, respectively. Taking into account these start sites, a 
region 260 bp upstream and 40 bp downstream of the start site of sterile transcrip-
tion of the Jλ1 gene segment, 230 bp upstream and 70 bp downstream of the Jλ2 
gene segment and 200 bp upstream and 40 downstream of the Jλ3 gene segment 
was the focus of the bioinformatics search and further analysis. 
The bioinformatics search identified several B cell transcription factors such as E47, 
E12/47, IRF1/2, LEF-1, PU.1, and general transcription factors such as TBP, TFIID, 
TFIIA, TFIII (Figure 3-2). However, for further analysis only a few were considered, 
mainly based on data from previous research. For example the transcription factor 
LEF-1 was excluded since it is degraded at the pre-B cell stage, thus it could not trig-
ger enhancer-promoter interactions at the lambda locus. Instead, particular atten-
tion was given to E47 that had previously been shown to interact with IRF4 at the 
kappa locus (Figure 3-1). While initial analysis focused on E47, none of the other 
transcription factors were excluded.  
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Figure 3-1 Position of E47 putative binding sites relative to the start site.  
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Figure 3-2 Distribution of transcription factor binding sites on the Jλ1 and Jλ3 promoters. 
The numbers in brackets indicate the region of the gene segments that were taken in consideration for TESS analysis: starting from the transcription start 
site, 500 bp upstream and 100 bp downstream were considered. These sequences were taken from NG004051.1, the number in brackets represent the 
range of sequence taken in consideration for analysis.  
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3.2.2 Analysis of the Jλ1 promoter by DNase I footprinting 
DNase I footprinting is an in vitro technique for locating the binding sites of proteins 
to specific regions of DNA. The technique is based on the property that the binding 
of a protein will protect the phosphodiester backbone of the DNA from enzymatic 
cleavage by the nuclease DNase I, generating a “footprint”. The fragmented DNA is 
subject to an electrophoresis in denaturing gel and the binding sites are detected by 
autoradiography. By analysing the position of the footprint it is then possible to de-
termine the DNA sequences to which the proteins potentially bind. 
A DNA fragment encompassing 300bp spanning the start site of sterile transcription 
of the Jλ1 promoter was incubated with a protein extract derived from 122-1 cells 
and DNase I footprinting was performed as described in Chapter 2.8.16. Five pro-
tected regions were identified on the Jλ1 promoter (Table 3-1). The footprinting re-
actions were carried out on both strands and the position of the protected regions 
were confirmed by comparison with the G+A ladder (Figure 3-3). The sequences 
were submitted to the TESS internet database search and different transcription 
factors were found to bind to the same protected region. These were located 
220bp, 190bp, 160bp, 60bp and 46bp, respectively upstream of the start site of 
sterile transcription of the Jλ1 promoter.  
Table 3-1 Protected regions on the Jλ1 promoter by DNase I footprinting. 
Protected region (TESS)  Protected sequence (5'-3') 
IRF1/IRF2/AP-1 AGTTTTCTTCAATAACTAGTGAAGATAAAG 
Lef-1 TTGCTGACTGTTTTATGAAG 
PouF1a TATTATACTAAACACTGAAGGATC 
E47/E12* GTGTTCTCCAACTGCTCTCTCCT 
E12* GCCTCAGATGTTTC 
* The putative E47/E12 binding site (CANNTG) is shown in bold. 
 
  
173 
 
 
Figure 3-3 DNase I footprinting on the Jλ1 promoter.  
(a) Position of the footprints in relation to the start site of sterile transcription. (b) DNase I foot-
printing of the lower strand of Jλ1 (500bp fragment spanning the promoter). (c) DNase I footprint-
ing of the upper strand of Jλ1 showing the position of the same transcription factors as in the 
lower strand. The open arrowheads indicate increasing amounts of DNase I; G+A: guanine-adenine 
ladder used to identify the sequences (prepared as described in Chapter 2.8.17).  
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3.2.3 Analysis of the Jλ2 promoter of sterile transcription by DNase I 
footprinting 
Although 60% of recombination at the immunoglobulin lambda light chain involves 
the JCλ1 gene segment, analysis of the other two J gene segments was also per-
formed in order to understand if the same transcription factors were implicated in 
enhancer/promoter interaction or if different proteins were involved. In the latter 
case, this could explain the lower rate of recombination of JCλ2 (30%) and JCλ3 
(10%) compared to JCλ1. 
DNase I footprinting was performed over a region of 300 bp on the Jλ2 promoter of 
sterile transcription. This region contained different transcription factor binding 
sites according to the TESS bioinformatics search, however, only a few were taken 
in consideration for further analysis. The reactions were performed on both strands 
and the protected regions were identified by comparison with the G+A ladder gen-
erated by the Maxam-Gilbert sequencing method. Four protected regions were 
found on one strand of Jλ2 promoter containing binding sites for more than one 
transcription factor (Table 3-2).  
Table 3-2 Protected regions on the Jλ2 promoter by DNase I footprinting. 
Protected region (TESS) Protected sequence (5'-3') 
IRF1/2, Nk x2-5, twi CTTCTCAAGTGAG 
AP-1 TGGTGTTGAATAA 
E12/E47* CAGCTGTCAGCA 
E12,Pou1F1a,Pou3F2d* CACCTGAATTAATAT 
* The putative E47/E12 binding site (CANNTG) is shown in bold. 
  
  
175 
 
 
Figure 3-4 DNase I footprinting on the Jλ2 promoter. 
(a) Position of the footprints relative to the start site of sterile transcription. (b) DNase I footprint-
ing of the upper strand of Jλ2 (300bp fragment spanning the promoter). (c) DNase I footprinting of 
the lower strand of Jλ2 showing the position of the same transcription factors found on the lower 
strand. The open arrowheads indicate increasing amounts of DNase I; G+A: guanine-adenine lad-
der was used to identify the sequences (prepared as described in Chapter 2.8.17).  
ApaI3’5’XbaI
AP-1
-110
SacI 3’ ClaI5’
a.
E12,Pou1F1a,Pou3F2d
+10
E47/E12
-70
IRF1/2
-140
Labelled end
Labelled end
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3.2.4 Analysis of the Jλ3 promoter by DNase I footprinting 
The Jλ3 promoter recombines with Vλ3 gene segment and it accounts for at least 
10% of the total recombination occurring at the Igλ locus. Sterile transcription at 
this locus is under the control of the same enhancer as at the Jλ1 (Eλ3-1), therefore 
it might be expected that the same transcription factors control enhancer/promoter 
interaction, but with a lower affinity. Initial DNase I footprinting analysis was carried 
out of a region of 500bp (Figure 3-2), but this was restricted to a 240 bp fragment to 
detect the observed footprints more clearly. 
Table 3-3 Protected regions on the Jλ3 promoter by DNase I footprinting. 
Protected region (TESS) Protected sequence (5'-3') 
AP-1, IRF1/2 CCCACTTCAAGTGAGGTCAC 
AP-1, E12/E47* ATTCAGTGCAGCTGTGAGA 
* The putative E47/E12 binding site (CANNTG) is shown in bold. 
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Figure 3-5 DNase I footprinting on the Jλ3 promoter.  
a) Position of the footprints relative to the start site of sterile transcription b) DNase I footprinting 
of the lower strand of Jλ3 (240 bp spanning the promoter). (c) DNase I footprinting of upper strand 
of Jλ3 showing the positions of the same transcription factors found on the lower strand. The G+A 
sequencing ladder is indicated as are incubations with (+) and without (-) extract. The open arrow-
heads indicate increasing amounts of DNase I; G+A: guanine-adenine ladder used to identify the 
sequences prepared as described in Chapter 2.8.17. 
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3.2.5 E47 binds to the Jλ1, Jλ2 and Jλ3 promoters of sterile transcription 
To identify and confirm which proteins bound to these regions, radiolabelled oli-
gonucleotides were prepared spanning the footprinted regions and used in gel re-
tardation assays (EMSA, electrophoretic shift assay). The DNase I footprinting ex-
periments showed that E47 is potentially able to bind to all three promoters ana-
lysed. Since E47 has been shown to interact with IRF4, it is a good candidate to me-
diate enhancer/promoter interactions. Therefore, of the different footprints found, 
oligonucleotides spanning the putative E47/E12 binding site were initially used in 
gel retardation assay. To test that the same factor binds to the Jλ1, Jλ2 and Jλ3 
promoters, a cross-competition experiment was performed. The Jλ1 probe was in-
cubated with a 500- to 4000-fold excess of unlabelled Jλ3 competitor and Jλ3 probe 
was incubated with the same concentration of Jλ1 unlabelled competitor.  As shown 
in Figure 3-6, each oligonucleotide competed for binding to the other, suggesting 
that a common factor may bind to both promoters. 
 
Figure 3-6 Cross competition between Jλ1 and Jλ3 promoters. 
A 500 to 4000 fold excess of Jλ3 unlabelled competitor was incubated together with the radio-
labeled Jλ1 probe and vice-versa. P= probe without extract added. Open arrowheads indicate in-
creasing amount of competitor.  indicates position of specific retarded DNA: probe complexes. 
Similarly, cross-competition was performed using the Jλ2 as a probe to determine 
whether E47 might also bind to this promoter, although it does not recombine as 
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extensively as the Jλ1 and Jλ3 gene segments. The data obtained showed that a 
similar factor did indeed bind to the Jλ2 gene segment (Figure 3-7). 
 
Figure 3-7 Cross-competition between the three promoters. 
Same conditions as for the previous cross competition were applied to show that the same factor, 
more likely E47, binds to the Jλ2 promoter.  P= probe without extract added. (A-B):  Jλ2 and Jλ1 
cross competition; C-D Jλ2 and Jλ3 cross competition. Open arrowheads indicate increasing 
amounts of competitor.  indicates position of specific retarded DNA: probe complexes. 
 
Jλ2 competitor Jλ1 competitor-P -
- Jλ2 competitor-
Jλ1 probe Jλ2 probe
A. B.
Jλ2 probe Jλ3 probe
Jλ3 competitor 
C. D.
P
P P
  
180 
3.2.5.1 Competition assay using the consensus site for E47 
To identify the bound factor more precisely, competition assays were performed 
using specific oligonucleotides added at 1000- to 4000-fold excess to both the Jλ1 
and Jλ3 promoter fragments (Figure 3-8). Unlabelled competitors containing a con-
sensus site for E47 and E2A were used as specific competitors, while oligonucleo-
tides containing consensus sites for EBF (early B cell factor) and AML (acute myeloid 
leukaemia) were used as non-specific competitors.  
 
Figure 3-8 Competition assay on the Jλ1 and Jλ3 promoters. 
A 1000-, 2000-, 4000-fold excess of unlabelled competitor was used to identify the factor binding 
to the Jλ1 and Jλ3 fragments. E47 and E2A unlabelled competitors both have a consensus binding 
site for E47 while EBF and AML do not. The middle band on Jλ1 (A) is competed by addition of E47 
and E2A unlabelled competitors, while addition of non-specific unlabelled competitor did not af-
fect the binding. The same was observed for the Jλ3 probe, where the only detectable band com-
peted in the presence of E47 and E2A (B). 1= E47, 2=E2A, 3=AML, 4=EBF. Open arrowheads indicate 
increasing amounts of competitor.  indicates position of specific retarded DNA: probe complexes. 
Figure 3-8 shows that addition of the specific competitor caused a reduction in the 
intensity of the middle (Jλ1) and bottom (Jλ3) complexes within the fragments ana-
lysed, suggesting that these complexes correspond to E47. In contrast, addition of 
the non-specific competitor did not change the intensity of the complexes, although 
the upper and lower complexes generated with the Jλ1 probe appeared to be 
bound by AML and EBF, respectively. Similarly, addition of the non-specific competi-
tors did not affect the binding of the putative E47. 
Jλ1 probe
P 1-
- - - -
- - - -
- - -
- - --
- - -- - -
- -- - - -
- - -- - -
- --- --
2
4
3
A.
Jλ3 probe
P 1-
- - - -
- - - -
- - -
- - --
- - -- - -
- -- - - -
- - -- - -
- --- --
2
4
3
B.
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Competition with specific and non-specific oligonucleotides was also performed us-
ing the Jλ2 promoter as a probe. As shown in Figure 3-9, the top and bottom com-
plexes were competed by the specific oligonucleotides, suggesting that two binding 
sites might be targeted by E2A or E47 alone.  
                               
Figure 3-9 Competition assay on Jλ2 promoter. 
The same conditions as for Jλ1 and Jλ3 were applied for Jλ2. 1= E47, 2=E2A, 3=AML, 4=EBF. Open 
arrowheads indicate increasing amounts of competitor.  indicates position of specific retarded 
DNA: probe complexes. 
3.2.5.2 Antibody competition confirms E47 binding to all three promoter regions 
To test if the complex competed by the unlabelled oligonucleotides was due to the 
binding of E47, an antibody competition was performed (Figure 3-10). Anti-E47-
Antibody was added in increasing concentration prior to addition of the extract and 
incubated for 10 minutes on ice. The middle complex on Jλ1 and the top complex 
on Jλ2 were lost in the presence of the antibody, suggesting that these complexes 
are indeed due to E47 binding to the Jλ1 and Jλ2 promoters. Similar results were 
obtained using the Jλ3 promoter where the putative E47 candidate also seemed to 
be competed for binding by the antibody, although at a higher antibody concentra-
tion compared to the other two promoters.  
Jλ2 probe
P 1-
- - - -
- - - -
- - -
- - --
- - -- - -
- -- - - -
- - -- - -
- --- --
2
4
3
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Figure 3-10 Antibody competition using the Jλ1, Jλ2 and Jλ3 promoters. 
The probes were incubated for 10 minutes on ice with 2.5, 5 or 10 μl of E47 antibody (αE47) prior 
addition of the protein extract.  The middle complex on Jλ1 (A), the top complex of Jλ2 (B) and the 
single complex observed on Jλ3 (C) are lost. P= probe without extract added. Open arrowheads 
indicate increasing concentration of anti-E47 antibody. 
3.2.5.3 E47 binds with higher affinity to Jλ1 
At the Igλ locus, 60% of rearrangements occur between Vλ1 and Jλ1, whereas only 
30% occur between Vλ2 and Jλ2, while only 10% between Vλ3 and Jλ3. To deter-
mine if this difference in recombination frequency is related to the activation of the 
Jλ1 and Jλ2 promoters, the relative affinity of E47 for the two promoter regions was 
measured. To this end, a competition assay was performed with E2A unlabelled 
competitor at 30- to 1000-fold excess. As shown in Figure 3-11 A and C, the complex 
corresponding to E47 was competed from the Jλ3 promoter by low concentrations 
of unlabelled E2A, while binding persisted at the Jλ1 promoter at the same concen-
trations. This suggests that E47 has a higher affinity for Jλ1 than Jλ3. 
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Figure 3-11 Relative affinity of E47 for the three promoters. 
E2A (E12/E47) unlabelled competitor was added at 30- to 1000-fold excess to determine the rela-
tive affinity of E47 for the three promoters analysed. The complex corresponding to E47 is com-
peted off at the Jλ2 and Jλ3 probes (B-C) at a lower concentration of E2A compared to the Jλ1 
probe (A). Open arrowheads indicate increasing concentration of E2A competitor. 
Similarly, a relative affinity assay was performed on the Jλ2 promoter, although this 
is less used during V(D)J recombination compared to Jλ1 and Jλ3. The results 
showed that the top complex (which in the antibody competition experiment was 
removed) disappeared at the lowest concentrations, as observed for Jλ3, suggesting 
that E47 has a higher affinity for the other two promoters analysed (Figure 3-11 B). 
3.2.6 E47 interacts with IRF4 and PU.1 as a complex 
The in vitro binding studies identified putative transcription factor binding sites near 
the start sites of sterile transcription and further identified E47 as a prime candidate 
to mediate enhancer/promoter interactions. A question of particular interest was 
whether this interaction is driven via IRF4. Previous studies have shown this interac-
tion for the kappa enhancer and analysis of transgenic mice over-expressing IRF4 
showed that this transcription factor alone can trigger premature V(D)J recombina-
tion of the light chain at the pro-B cell stage at the same level as in the pre-B cell 
stage, suggesting an important role played by IRF4 (Bevington, 2009). Therefore the 
next step was to test whether E47 interacts with IRF4 in vitro. Co-
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immunoprecipitation experiments (Co-Ip) with antibodies against E47 and IRF4 
were performed to identify interaction between the two transcription factors.  
Initially, Co-Ip was performed by using anti-E47 antibodies in the immunoprecipita-
tion reaction followed by immunoblotting with anti-IRF4 antibodies. As shown in 
Figure 3-12, an interaction between these factors was detected. Because E47 is de-
graded by the ubiquitin-proteasome pathway in response to phosphorylation by the 
MAP kinase signalling experiments were also performed to test if inhibition of E47 
degradation increased the interaction with IRF4 (Figure 3-13). In the presence of 
both a MEK inhibitor (U0126, 10µM final concentration) and a proteasome inhibitor 
(MG132, 10µM final concentration), both the amount of E47 protein in the input 
and the immunoprecipitate was increased. This suggests that inhibition of MAPK 
signalling and proteasome-mediated degradation increased either IRF4 or E47, or 
both (data not shown). 
 
Figure 3-12 Complex formation between E47 and IRF4. 
 (A) Co-Ip using anti-E47 antibody as a primary immunoprecipitating antibody and immunoblotting 
with anti-IRF4 antibody was performed as described in the text. Interaction of the two proteins is 
indicated by a protein migrating at 51 kDa corresponding to IRF4. (B) Co-Ip using anti-IRF4 anti-
body in the immunoprecipitation reaction and immunoblotting with anti-E47 antibody. A faint 
band of 67 kDa corresponding to E47 was detected. Normal mouse IgG antibody was used as a 
negative control.  In= input, IP= immunoprecipitate, IB= immunoblot. 
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Figure 3-13 Degradation of E47 is following phosphorylation by MAP kinases.  
122-1 cells were treated with the MEK inhibitor UO126, for two hours before harvesting in the 
presence of the proteasome inhibitor, MG132. Western blotting for E47 level and IRF4 were per-
formed. A loading control was performed by stripping the membrane and re-probing for β-tubulin. 
A reverse Co-Ip was also performed to validate the IRF4/E47 interaction. However, 
when probing with IRF4 and immunoblotting with E47, a very faint E47 band was 
detected (Figure 3-12 B). This may be due to the rapid degradation of E47 which is 
known to have a half-life of 55-60 minutes (Kho et al, 1997). To overcome the prob-
lem of degradation, cells were incubated with proteasome inhibitor for 8 hours and 
with MEK inhibitor for 3 hours before harvesting. Moreover, the same inhibitors 
were also added at increasing concentrations in buffers E and F used in the Co-Ip. In 
addition, shorter times of immunoprecipitation with the first antibody were tested 
(3 hours instead of overnight incubation) to overcome degradation of the protein. 
Unfortunately, in all cases, protein degradation was still present (data not shown).  
Finally, because IRF4 forms a complex with PU.1 (Eisenbeis et al, 1993) (Chapter 
1.2.5.1), a Co-IP was performed to test whether E47 also interacts with PU.1. This 
interaction was also confirmed (Figure 3-14), suggesting all three proteins form a 
protein-complex when the enhancer loops over to interact with the promoter.  
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Figure 3-14 Co-Immunoprecipitation between E47 and PU.1. 
(A) Co-Ip using anti-PU.1 antibody as a primary immunoprecipitating antibody and immunoblot-
ting with anti-E47 antibody was performed as described in the text. Interaction of the two proteins 
is indicated by a faint band migrating at 67 kDa corresponding to E47. (B) Co-Ip using anti-E47 an-
tibody in the immunoprecipitation reaction and immunoblotting with anti-PU.1 antibody. A strong 
band of 31-35 kDa corresponding to PU.1 was detected. Normal mouse IgG antibody was used as a 
negative control.  In= input, IP= immunoprecipitate, IB= immunoblot. 
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3.3 DISCUSSION  
The data presented in this Chapter show that E47 binds to the promoters of Jλ1, Jλ2 
and Jλ3 of sterile transcription in vitro and also that E47 can interact with IRF4 and 
PU.1 in vitro. These results suggest that the protein complex formed between E47 
and IRF4 could mediate interactions between the enhancer and the Jλ promoters of 
sterile transcription as previously shown for the immunoglobulin kappa locus. Simi-
lar experiments such as electrophoretic mobility shift assay where performed to 
identify factors binding to the region of interest (Haque, 2004; Haque et al, 2013). 
The Eλ3-1 enhancer and the Jλ promoters are separated by several kilobases, thus 
there is a major question of how this interaction is regulated. The IRF4-E47 interac-
tion has been previously investigated and found to be responsible for activation of 
the immunoglobulin κ germ line sterile transcripts (Lazorchak et al, 2006). Further-
more, IRF4 interaction with E47 enhanced E2A DNA binding and also resulted in 
strong E2A-IRF4 transcriptional synergy and the amino acids necessary for this in-
teraction were identified (Nagulapalli & Atchison, 1998). Using protein-DNA models 
to look at both transcription factors when bound to the DNA as well by mutagenesis 
experiments, it was found that critical amino acids involved in the interaction were 
Arg 567 or Asp 568 in the HLH domain of E47 and Leu 24 at the N-terminus of IRF4. 
A possible mechanism was proposed to explain this interaction, namely that IRF4 
induces conformational changes in E47 to enhance E47 DNA binding. Once E47 is 
bound, it triggers a conformational change in IRF4 (Nagulapalli et al, 2002). How-
ever, as shown in this study, the E2A and IRF4 binding sites lay immediately adja-
cent to each other. Therefore, a key question is how this interaction occurs when 
the proteins are bound to sites that are far apart: in the case of the Eλ3-1 enhancer 
and the Jλ promoters, the enhancer and the promoter must be brought together 
over distances of 35-40 kb.  A major finding reported in this Chapter is that these 
proteins interact with each other in vitro. Further studies should use transfection 
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experiments to determine whether these proteins trigger enhancer/promoter in-
teractions in vitro and whether the same regions, as identified above, are involved.  
The data presented in this Chapter support previous studies that showed E47 and 
E12 play a role in the regulation of sterile transcription of the Jλ promoters (Bain et 
al, 1997). Studies in pro-B cells from E12-/+ and E47-/+ mice showed that Vλ1-Jλ1 
rearrangements were severely affected by reduction in these proteins, suggesting 
that both transcription factors are essential to promote V-to-J rearrangement and 
sterile transcription at the Igλ locus (Beck et al, 2009; Quong et al, 2004). Further 
analysis revealed that E47 and E12 regulate Igλ locus rearrangement by modulating 
locus accessibility to the recombinase machinery. In particular, it was suggested 
that E2A proteins might modulate the level of methylation of lysine 4 of histone 3 
(H3K4me3) which is essential for the recruitment of RAG2 via its PHD domain (Beck 
et al, 2009). 
Regulation of the Igλ locus at the pre-B cell stage by E47-IRF4 interaction is also 
consistent with the levels of these two transcription factors during B cell develop-
ment: IRF4 levels start to increase during the pro-B to pre-B cell transition (Lu et al, 
2003). Conversely, at the pro-B cell stage, E47 levels are high, but the protein is ei-
ther sequestered by the Id proteins (Inhibitors of differentiation) to form inactive 
heterodimers (Quong et al, 1993) or is degraded via the ubiquitin-proteasome 
pathway (Nie et al, 2003). At the pre-B cell stage, Id proteins levels decrease and 
E47 levels increase (Beck et al, 2009). This suggests that at the pro-B cell stage there 
is no interaction because of the lower IRF4 levels and the high levels of Id proteins. 
However, at the pre-B cell stage, both transcription factors may be free to interact 
and promote Igλ locus rearrangement. Consistent with this hypothesis, knock-out of 
E47 at the pro-B cell stage leads to a decrease in Igλ locus rearrangement (Beck et 
al, 2009), while, as shown using transgenic mice, over-expression of IRF4 at the pro-
B cell stage stimulates premature lambda light chain recombination, even in the 
presence of high levels of Id proteins (Bevington, 2009). This suggests an interesting 
hypothesis in which IRF4 and E47 might be crucial to promote Igλ locus activation at 
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the correct stage of B cell development. This might be accomplished either by IRF4 
sequestering Id proteins or by increasing E47 proteins levels. 
3.3.1 Regulation of E2A protein stability 
E2A proteins are known to bind only as a homodimer in B cells, although they can 
form heterodimers with other E-box binding proteins, for example with MyoD to 
regulate muscle differentiation in other tissues (Lassar et al, 1991; Shen & Kadesch, 
1995). B cell restricted DNA binding of E47 proteins as homodimers depends on the 
phosphorylation state of the protein. Previous studies identified two serine residues 
at the N terminus of E47 as targets for phosphorylation: hypophosphorylation 
would allow E47 binding as a homodimer, while hyperphosphorylation would lead 
to heterodimer formation (Morcillo et al, 1996). Because they are ubiquitously ex-
pressed, E12 and E47 must be regulated mainly by post-translational mechanisms 
which include degradation of E2A proteins by the ubiquitin-proteasome pathway, 
sequestration of E2A proteins by the Id proteins to form non-DNA-binding dimers 
and phosphorylation of E47 upstream of its the basic region to inhibit DNA binding.  
Pulse-chase analysis revealed that E12/E47 proteins have a half-life of only 55-60 
minutes in vivo (Kho et al, 1997). Consistent with this, a previous study identified a 
ubiquitin-conjugating enzyme, UbcE2A, to be an interacting partner of E2A proteins. 
UbcE2A specifically interacts with a 54-amino acid region (residues 477-530) up-
stream of the bHLH region of E47 and E12. This interaction leads to protein degra-
dation via the ubiquitin proteasome pathway (Kho et al, 1997). Two highly con-
served regions are involved in the degradation: residues 479-494 and 505-513, 
where the latter contains a PEST sequence rich proline (P), glutamic acid (E), serine 
(S), and threonine (T) (Huggins et al, 1999). In fact, deletion of this region greatly 
increased E12/E47 stability. Consistent with these findings, treatment of cells with a 
proteasome inhibitor, MG132, reduced E12/E47 degradation.  
In this study however, reverse co-immunoprecipitation, also in presence of the pro-
teasome inhibitor, did not give similar results, suggesting that other mechanisms 
  
190 
may operate to regulate E47 protein turnover. Because the half-life of these pro-
teins is only 1 hour, further experiments could determine if incubation times 
shorter than 1 hour might prevent rapid degradation of the proteins or if there are 
other mechanisms that can be considered to prevent protein degradation. 
Notch signalling has been found to be important in targeting E47 protein for degra-
dation via the ubiquitin-proteasome pathway (Ordentlich et al, 1998). This pathway 
is dependent on phosphorylation of the E-box protein by the p42/p44 MAP kinase 
(Nie et al, 2003).  The target of this phosphorylation resides between the residues 
found in the EHD3 domain (E protein homeobox domain), upstream of the bHLH 
(residues 345-367). These residues have been mutated and will be tested in the fu-
ture to establish their role in E47 stability. 
3.3.2 Other factors bind to the promoter region of the Jλ gene segments 
DNase I footprinting also identified a protected region in the Jλ1 promoter that 
could be bound by other factors for example, LEF-1, Pou1F1a, IRF1/IRF2 and E12. 
LEF-1 was not investigated further since its levels fall dramatically during the pro-to-
pre-B cell transition (Schebesta et al, 2002). Hence it is unlikely to trigger enhan-
cer/promoter interactions to activate recombination of light chains that take place 
at the pre-B cell stage.  
Gel retardation experiments using unlabelled competitor DNAs showed that the 
Pou1F1a binding site may be bound by the octamer binding protein (Figure 7-1). 
Octamer binding proteins have been found in most Ig promoters suggesting a role 
of these proteins in determining B cell specificity or regulation of heavy or light 
chain transcription since their deletion led to promoter inactivity (Eaton & Calame, 
1987; Falkner & Zachau, 1984). Among these factors, Oct-2 is mainly expressed in B 
lymphocytes. Therefore, this is a strong candidate to activate sterile transcription at 
the Jλ promoters. To date, interactions between Oct-2 and IRF4 have not been de-
scribed; this could be tested in future work.  
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IRF1/2 sequences were also found to be protected in DNase I footprinting experi-
ments in all three promoters analysed. However, when these protected regions 
were tested in gel retardation experiments, competition assays failed to reveal the 
identity of the bound factor (data not shown). While cross-competition confirmed 
that the factor binding the three promoters might be indeed the same, antibody 
competition assays did not yield convincing results. This suggests that other, non-B 
cell specific transcription factors may bind to this footprinted region and it is possi-
ble that the factor that binds to this region is not IRF1/2 (Figure 7-3;Figure 7-2). 
3.3.3 E47 undergoes conformational changes following interaction with 
PU.1/IRF4 
Interestingly, co-immunoprecipitation experiments in which was immunoprecipi-
tated either IRF4 or PU.1 followed by Western blotting E47 showed a very faint 
band corresponding to E47 (67 kDa), suggesting instead some degree of degrada-
tion. In addition, two bands detected corresponding to approx. 28 and 48 kDa which 
could potentially correspond to the light and heavy chain of the immunoglobulins 
were detected; they might mask E7. To test whether E47 was degraded, the assay 
was performed on a non-denaturing gel, which would preserve the native confor-
mation of the E47 protein, ruling out the possibility of degradation. A Co-Ip was per-
formed between E47 and p300 (histone acetyltransferase) and the results showed 
that the E-box binding protein was not degraded, instead, E47 might undergo some 
conformational changes when interacting specifically with IRF4.  Preliminary data 
also showed that in non-denaturing conditions E47 interacts with IRF4 without any 
evidence of degradation (data not shown).  
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Chapter 4. Effect of mutations on enhancer/promoter interactions 
4.1 INTRODUCTION  
Coordinated recruitment of the basal transcription machinery is a key step during 
transcription of genes in eukaryotic cell, and the role played by promoters, enhan-
cers and locus control regions is now well established. However, when analysing the 
transcription of immunoglobulin genes, other factors have to be taken in considera-
tion.  As stated in Chapter 3, while enhancer/promoter interactions are crucial for 
sterile transcription of the loci, particular emphasis is given to the transcription fac-
tors driving this interaction and any play a key role in promoting enhancer looping 
towards the promoter (Lieberman-Aiden et al, 2009). 
The advent of the 3C technique has increased our knowledge of long-range interac-
tions and modification of the 3C, notably 4C and 5C, have confirmed the nature of 
several interactions occurring within the human genome (Dekker et al, 2002), in-
cluding the immunoglobulin loci (Ju et al, 2007). Within the immunoglobulin lambda 
light chain, long range interactions have been confirmed by 3C (Bevington, 2009) 
and earlier studies on the immunoglobulin kappa light chain locus have also ana-
lysed a series of mutations within the transcription factors involved in mediating 
these interactions (Brass et al, 1999).  
In this Chapter the importance of specific residues within the enhancer and the 
promoter of sterile transcription as well as residues within the transcription factors 
involved in the interaction between these two regulatory elements were investi-
gated to understand to what extent interaction between the specific transcription 
factors is required to trigger transcription.  
It has already been reported that specific residues involved in the interaction be-
tween E47, PU.1 and IRF4 transcription factors are crucial for different Ig loci: single 
amino acid mutations in IRF4 can affect the interaction with E47 (IRF4L24 and IRF4 
L368) or PU.1 (IRF4 K399 as well as IRF4 L368) (Brass et al, 1999; Meraro et al, 
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1999).  IRF4 L368 and IRF4 K399 are found at the C-terminal region of the protein, 
within the IRF4 association domain (IAD) (Figure 4-1). These residues were reported 
to be essential in mediating the interaction with PU.1 at the λB element and with 
other members of the IRF family. In addition, the IRF4 L368A mutant affected inter-
action with E47, driving lower levels of transcription compared to wild type IRF4. 
The L24 residue of IRF4 was described to be important at the kappa locus in mediat-
ing contacts with E47 (Nagulapalli et al, 2002).  
The major aim of the work described in this Chapter is to test these residues to in-
vestigate their importance in mediating long range interactions at the Igλ locus.  
 
Figure 4-1 Schematic representation of the structural domains of IRF1, IRF2 and IRF4. 
All interferon-regulatory factors (IRFs) are composed of a DNA-binding domain (DBD; blue) and a 
regulatory domain (green). For all IRFs, the DBD is defined by 5 tryptophan (W) residues that are 
each separated by 10–18 amino acids. Most IRFs also contain an IRF-association domain (IAD) of 
either type 1 (grey) or type 2 (pale yellow). Some IRFs contain a repression domain(s) (yellow) and 
a nuclear-localization signal(s) (orange). For IRF1 the activity depends on phosphorylation, as 
shown. The size of each IRF in number of amino acids is also indicated. C, carboxyl terminus; N, 
amino terminus. Adapted from (Lohoff & Mak, 2005).  
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4.2 RESULTS 
4.2.1 Transcription levels in presence of Jλ1 and Eλ3-1 
In Chapter 3 the protein complex driving the interaction between the Eλ3-1 enhan-
cer and the Jλ1 promoter was identified. It was then necessary to determine to 
what extent this interaction could affect sterile transcription levels through the Jλ1 
promoter. The other two promoters previously analysed, Jλ2 and Jλ3, were not 
tested in mutagenesis studies since they account only for 30% and 10% respectively 
of the recombination process. 
A plasmid DNA construct was made in which the Jλ1 promoter drives expression of 
the luciferase reporter gene (Clone I). A second construct had the Eλ3-1 enhancer 
cloned downstream of the luciferase reporter gene and the Jλ1 promoter upstream 
of the luciferase gene in order to test if, following interaction between these two 
regulatory elements, transcription levels increased, compared to the levels ob-
served in the presence of the promoter alone  (Clone II) (Figure 4-2). 
 
Figure 4-2 Luciferase reporter gene constructs. 
 A. The Jλ1 promoter containing the E47 binding site identified by DNase I footprinting reactions 
was cloned upstream of the luciferase reporter gene within the XhoI and Hind III restriction sites. 
This construct was employed to test promoter activity in the absence of the enhancer. B. The sec-
ond construct contains the Jλ1 promoter cloned as described in A  as well as the Eλ3-1 enhancer 
containing the PU.1/IRF4 binding sites cloned downstream of the luciferase reporter gene within 
the BamHI and SalI restriction sites. This construct was used to test enhancer activity in presence 
of E47, IRF4 and PU.1.  
Eλ3-1 EnhancerJλ1 promoter
Luc.
E47
pGL3-basic
Jλ1 promoter
Luc.
pGL3-basic
PU.1
IRF4
E47
A. B.
HindIII
XhoI
BamHI
SalI
Clone I Clone II
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The two constructs were transfected independently into Cos-7 cells together with 
plasmids designed to express E47, PU.1, and IRF4. Following transfection (three in-
dependent experiments per construct analysed, each performed in duplicates), the 
average relative luminescence units (RLU) were measured (Original values shown in 
Table 7-2). Initially, it was aimed to detect differences in transcription levels with 
and without the Eλ3-1 enhancer. 
 
Figure 4-3 Activity of the Jλ1 in presence of the E47 and IRF4 transcription factors.  
Cos-7 cells were transfected with Clone I (as described in Figure 4-2) and plasmid expressing either 
E47 or IRF4. Luciferase activity was measured as described in Chapter 2.8.19. The Eλ3-1 plasmid 
(Clone II) was always transfected in the presence of both E47 and IRF4/PU.1 protein complex. Val-
ues were divided by the co-transfected Renilla luciferase and normalised to the control group 
(pgl3). All experiments were repeated three times, each performed in duplicate. Expression data 
are shown as SEM (mean standard error) (Appendix Table 7-1) 
As expected, transcription driven by the Jλ1 promoter in the absence of the enhan-
cer did not yield high values with only a 4 fold increase compared to the promoter 
in the presence of both the transcription factors, E47 and IRF4 (Jλ1+ E47/IRF4) (Ta-
ble 7-1). Instead, when the promoter and the enhancer were transfected in the 
presence of the protein complex (E47 and PU.1/IRF4) transcription levels increased 
10 fold, suggesting that the enhancer element had a positive effect on the rate of 
transcription (Figure 4-3).  
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Since there are no binding sites for PU.1 on the promoter and these studies were 
mainly focused on the E47/IRF4 interaction, transfection of the promoter construct 
in the presence of PU.1 was not performed. 
4.2.2 Effect of mutations in the E47 binding site on Jλ1 
The data presented above show that E47 binds to the promoter and data from 
Chapter 3 also showed it interacts with both PU.1 and IRF4. But does it need to bind 
the promoter to drive this interaction? Therefore, to test if the increase in transcrip-
tion observed was a consequence of the interaction between the enhancer-bound 
PU.1/IRF4 and the promoter-bound E47, the E47 binding site in the promoter (Eλ3-
1/Jλ1 E47mt) was mutated in the construct that carried both promoter and enhan-
cer (Clone II). In this way it was possible to test if the lack of E47 binding to the 
promoter still allowed long-range interactions and therefore triggering of sterile 
transcription through the gene (Figure 4-4).  
 
Figure 4-4 Transcription in presence of mutations within the promoter. 
Cos-7 cells were transfected with Clone I as described in Figure 4-2 and a plasmid with a mutation 
in the E47 binding site within the promoter. Luciferase activity was measured as described in 
Chapter 2.8.19. The Eλ3-1 plasmid (Clone II) was always transfected in the presence of both E47 
and IRF4/PU.1 protein complex. Values were divided by the co-transfected Renilla luciferase and 
normalised to the control group (pgl3). All experiments were repeated three times, each per-
formed in duplicate. Expression data are shown as SEM (Appendix Table 7-1).  
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
R
LU
 
  
197 
While no significant differences between the wild type and mutated promoters in 
the presence of E47, a 4.6 fold decrease was observed when comparing the wild 
type promoter with the mutated promoter in the presence of the E47/IRF4 com-
plex. This suggests that, although not bound to the enhancer, IRF4 still interacts 
with the promoter, either through E47 or other transcription factors. As expected, 
transfection of the Eλ3-1 enhancer together with the mutated promoter triggered a 
two-fold reduction in transcription levels.  
Overall, this data suggests that the interaction between IRF4 and E47 is critical to 
maintain adequate levels of transcription and binding of E47 to its site on the pro-
moter is crucial to trigger first the interaction with IRF4 and secondly transcription 
through the Jλ1 promoter. However, since the reduction in transcription levels was 
not as high as expected, it may be proposed that other factors are equally impor-
tant in driving this interaction. 
4.2.3 The effect of mutations in the IRF4/PU.1 binding sites in the en-
hancer region  
Having defined the role played by E47, it was important to investigate the role of 
the enhancer-bound PU.1 and IRF4. Therefore, the binding site for IRF4 (Eλ3-
1/IRF4mt) and PU.1 (Eλ3-1/IRF4mt+PU.1mt) on the enhancer were also mutated 
and further investigated in luciferase assays (Figure 4-5).  
The data obtained showed that sterile transcription decreased considerably when 
comparing the wild type Eλ3-1 enhancer with one in which mutations had been in-
troduced. A 2.1- and 2.4-fold decrease for the Eλ3-1/IRF4mt and Eλ3-
1/IRF4mt+PU.1mt were found, respectively. These results suggest that IRF4 needs to 
bind to its binding site on the Eλ3-1 enhancer to trigger adequate levels of tran-
scription. Since it known that IRF4 is the PU.1 interacting partner, it is expected that 
mutations in the PU.1 binding site would affect the rate of transcription.  
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Figure 4-5 The effect of mutations in the IRF4 and PU.1 binding sites in the enhancer region. 
Cos-7 cells were transfected with Clone II as described in Figure 4-2 with mutations in the IRF4 or 
PU.1 binding site in the Eλ3-1 enhancer. Luciferase activity was measured as described in Chapter 
2.8.19. The Eλ3-1 plasmid (Clone II) was always transfected in the presence of both E47 and 
IRF4/PU.1 protein complex. Values were divided by the co-transfected Renilla luciferase and nor-
malised to the control group (pgl3). All experiments were repeated three times, each performed in 
duplicate. Expression data are shown as SEM (Appendix Table 7-1). 
However, no significant decrease in transcription following mutation of the PU.1 
binding site within the same construct carrying the Eλ3-1/IRF4mt mutation was de-
tected, as it might have been expected. Previous studies have shown that IRF4 can 
bind to the DNA only in the presence of bound PU.1 (Brass et al, 1999). Therefore, 
when PU.1 is unable to bind DNA, it should not recruit IRF4, and thus transcription 
should decrease to lower levels than those observed when IRF4 is not bound. The 
data obtained, however suggested that IRF4 binding is independent of PU.1, but is 
essential to mediate interaction with E47 to trigger transcription of the Jλ1 gene 
segment. As outlined above, other transcription factors are believed to be essential 
for this interaction. 
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4.2.4 The IRF4 L24A, IRF4 L368A and IRF4 K399A mutants do not affect 
protein-protein interaction but affect sterile transcription levels 
Specific residues within the transcription factor IRF4 are known to be essential for 
productive interaction with both E47 and PU.1. To test if this was the case within 
the Jλ1 promoter, mutations were prepared and tested in a luciferase assay as well 
as in a co-immunoprecipitation assay. 
Initial results showed that none of these mutations decreased protein-protein in-
teraction when transfected in Cos-7 cells followed by co-immunoprecipitation 
(Figure 4-6), instead it seemed as one of these mutation (L368) stabilised the inter-
action; only IRF4 L24A and IRF4 L368A were tested in co-immunoprecipitation as-
says since IRF4 K399 is known to be important in mediating interactions with PU.1 
rather than E47. The immunoprecipiation was performed by transfecting either E47 
or IRF4 alone as well as the respective IRF4 mutants (IRF4 L24A and L368A). 
On the other hand, when analysing transcription levels, they had a considerable ef-
fect compared to wild type IRF4 (Figure 4-7). Transfection of IRF4 L24A or IRF4 
L368A mutants in the presence of the enhancer-binding site led to a 2.4 fold de-
crease in transcription levels for both mutants, suggesting that these two residues 
in IRF4 are important in making contacts with PU.1 and /or E47 to trigger transcrip-
tion (Table 7-1). 
 IRF4 K399 is one of the residues that make electrostatic contacts with PU. 1. This 
mutation led to only a 1.4-fold decrease compared to the wild type IRF4, suggesting 
that the other residues may be important in mediating interaction with PU.1. 
 
 
  
200 
 
Figure 4-6 Complex formation between E47 and IRF4 mutants. 
Co-immunoprecipitation was performed in Cos-7 cells transfected with E47, IRF4 or both, with or 
without the mutants. As loading control and to monitor transfection efficiency, β-gal was trans-
fected together with the construct. 24 and 368 are the residues in IRF4 that were mutated into 
alanine. The first four lanes show the transcription factors transfected singularly. The last four 
lanes show IRF4 and E47 co-transfected together (IRF4 wild type and mutant forms). 
 
 
Figure 4-7 Mutations on IRF4 at residues 24, 399 and 368. 
Cos-7 cells were transfected with Clone II as described in Figure 4-2. Transfections were performed 
using three different mutants for IRF4, namely IRF4 L24, IRF4 K399 or IRF4 L368. Luciferase activity 
was measured as described in Chapter 2.8.19. The Eλ3-1 plasmid (Clone II) was always transfected 
in the presence of both E47 and IRF4/PU.1 protein complex. The promoter-less cloning vector 
pGL3-Basic was used as a negative control. . Values were divided by the co-transfected Renilla 
luciferase and normalised to the control group (pgl3). All experiments were repeated three times, 
each performed in duplicate. Expression data are shown as SEM (Appendix Table 7-1)  
4.2.5 Effects of mutating residues in IRF4 on promoter activity 
Having tested the IRF4 mutations within the enhancer, the effect of these muta-
tions was tested on the promoter activity in the absence of the enhancer, since ini-
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tial data showed that IRF4 had some effect on the promoter, although in the ab-
sence of the enhancer as shown in Figure 4-4.  
When comparing the levels of transcription in the presence of E47/IRF4 wild type 
versus E47/IRF4 L368A or E47/IRF4 L24A, initial data suggested a 2- and 2.6-fold de-
crease respectively, suggesting that IRF4 is still contacting E47 to trigger higher lev-
els of transcription, presumably by binding within another site on the promoter and 
then, interacting with the enhancer-bound PU.1 (Figure 4-8, Table 7-1). 
This supports the hypothesis that enhancer-promoter interactions are mediating 
the interaction of E47 with IRF4/PU.1. However, since Co-IP results show that the 
interaction in presence of the mutants is still occurring, it can be proposed that 
other residues may be crucial for the interaction and nevertheless, these mutants 
still allow the interaction to occur. 
 
Figure 4-8 Effects of IRF4 mutations on the promoter activity. 
Cos-7 cells were transfected with Clone I or Clone II as described in Figure 4-2. Transfections were 
performed using two different mutants for IRF4, namely IRF4 L24 or IRF4 L368. Luciferase activity 
was measured as described in Chapter 2.8.19. The Eλ3-1 plasmid (Clone II) was always transfected 
in the presence of both E47 and IRF4/PU.1 protein complex. The promoter-less cloning vector 
pGL3-Basic was used as a negative control. Values were divided by the co-transfected Renilla 
luciferase and normalised to the control group (pgl3). All experiments were repeated three times, 
each performed in duplicate. Expression data are shown as SEM (Appendix Table 7-1).  
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4.3 DISCUSSION  
The data presented in this Chapter show that E47-PU.1/IRF4 interaction is neces-
sary, but not sufficient to trigger full promoter activation and that both mutations 
of the E47 binding site on the Jλ1 promoter and the PU.1/IRF4 binding site on the 
Eλ3-1 enhancer decrease transcription levels by approx. 2- and 2.4-fold respectively. 
However, promoter activity is still detectable at significant levels in the presence of 
these mutants, suggesting that other factors might be involved in stabilizing this in-
teraction or simply interacting with E47 at the promoter to stabilize the protein it-
self. Indeed, footprinting analyses of the Jλ1 promoter showed binding of other fac-
tors, among which AP-1 (in particular c-Jun and c-Fos as found in the bioinformatic 
search). AP-1 has already been described to be essential for transcription at the 
immunoglobulin kappa locus, confirming the notion, consistent with the current 
data, that it is unlikely that only one factor mediates these long range interactions. 
The binding sites for AP-1 were verified by EMSA, but antibody supershift assays 
using a c-Jun antibody failed to reveal the identity of the factor analysed, suggesting 
that other transcription factors or c-Fos might bind this region (data not shown).  
In addition, mutation of the residue IRF4 K399 led only to a 1.4 fold decrease in 
promoter activity compared to that in the presence of wild type IRF4 (Figure 4-7). 
This suggests that the other residues which are known to be important in making 
contacts with PU.1 might be required. Previous studies, using deletion analysis and 
secondary structure predictions, suggested that different amino acids within the 
putative -helical region of IRF4 (amino acids 399–413) at the C-terminus are im-
portant for ternary complex formation with PU.1 (Brass et al, 1999). These other 
residues should be studied in the future to test this hypothesis. 
Interestingly, preliminary co-immunoprecipitation assay using protein extracts pre-
pared from both a pro- and pre-B cell line (122-1 and 103 Bcl) showed that E47 is 
cleaved when interacting with PU.1 and IRF4 (data not shown). This suggests a 
novel mechanism which might regulate enhancer-promoter interactions at the 
  
203 
lambda locus. This cleavage reaction could either be required to activate E47 or it 
could be a specific “signal” to activate the promoter itself. E47 cleavage upon inter-
action with other proteins has not been previously described before. The E2A pro-
teins are ubiquitously expressed and several interacting partners have been identi-
fied, such as MyoD and NeuroD1 (Lluis et al, 2005; Longo et al, 2008), however, a 
possible clipping reaction involving E47 has not been described, suggesting that this 
mechanism might be restricted only to B cells or to this specific interaction. 
Nevertheless, the mechanism of this cleavage reaction is not yet clear. Initial analy-
ses to predict the site of cleavage in E47 based on co-immunprecipitation analyses 
in Cos-7 cells where a N-terminally Myc-tagged E47 was used, suggested a possible 
Caspase 1 cleavage site at position 219 (in mouse E47), which would generate the 
two products observed in the Western blots. These results are consistent with the 
hypothesis formulated by Nagulapalli et al. (1998), who proposed that “part of the 
synergy mechanism between E47 and IRF4 at Ig(k) 3’ enhancer involves the ability 
of IRF4 to enhance DNA binding by E47, possibly by inducing a conformational 
change in the E47 protein”, which they also suggested is more favourable for DNA 
binding (Nagulapalli & Atchison, 1998). Future work should be directed towards 
elucidating the mechanism of this cleavage reaction to improve understanding of 
the role of E47 in the activation of of the J lambda gene promoters, in particular Jλ1. 
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Chapter 5. High throughput RNA sequencing (RNA-Seq) analysis of HPV-
positive cervical cancer cell lines and tissues: search for cervical cancer 
biomarkers 
5.1 INTRODUCTION  
Viruses are associated with approx. 20% of human cancers. Cervical cancer is the 
second most common cancer in women, causing over 250000 deaths each year 
world-wide (Arbyn et al, 2011; WHO, 2008).  
More than 100 different HPV types have been identified and infection with high risk 
HPVs (HR- HPVs) such as HPV16 and 18 is directly linked to the development of cer-
vical cancer (Walboomers et al, 1999). Over 80% of cervical cancer cases are known 
to be HPV16 or HPV18 positive. Since cancer develops decades after the initial in-
fection, it has been suggested that the virus had evolved unique mechanisms to 
evade the immune system, probably by altering expression of a number of cellular 
genes involved in immune regulation or recognition. While it is widely accepted that 
the two viral oncogenes, E6 and E7, alter the levels of the cellular p53 and pRb tu-
mor suppressor proteins, respectively, de-regulation of cellular transcripts (and pos-
sible downstream effects of this) is poorly understood.  
Cancer is a complex multi-step  disease, which involves deregulation of multiple cel-
lular pathways and transcripts and understanding what is directly linked to the virus 
infection and what is a consequence of infection is challenging (Floor et al, 2012). In 
addition, tumours have historically been classified and studied based on morpho-
logical appearance, as well as epidemiology. However, similar histological appear-
ance does not necessarily mean similarity at the molecular level.  Analyses of gene 
expression profiles, as well as identification of genetic markers can undoubtedly 
improve the accuracy of a diagnosis and thus treatment of the cancer. 
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In the past two decades, the development of microarrays and next generation se-
quencing (NGS) has improved our knowledge of how the expression of cellular tran-
script change in malignant, compared to normal cells. DNA microarrays permit the 
genome-wide assessment of the expression of many thousands of genes at any 
given time point in normal and malignant cells at any stage of development or un-
der timed experimental conditions in cultured cells. Microarrays may be more lim-
ited than NGS technologies, but have been recognized as potential diagnostic tools 
in cancer. 
In this study, using high throughput RNA sequencing (RNA-Seq) of HPV-positive cer-
vical cancer tissues and cell lines (Table 5-1), differential expression of several cellu-
lar transcripts that encode putative cell-surface proteins, was detected between 
normal and HPV-positive cancer cells and/or tissues. Transcripts encoding cell-
surface proteins were selected for detailed study because they may be involved in 
immune regulation or recognition. 
Table 5-1 Source of the patients’ data used in this study. 
Patient Age Grade LVSI Stage Nodal status Histology 
1 43 3 Y 2B negative SCC 
2 42 2 Y 3B positive SCC 
3 29 3 Y 2B positive SCC 
4 59 2 N 2B positive SCC 
5 55 2 N 2B positive AdenoSCC 
6 57 2 Y 2B negative SCC 
7 32 3 ? 1B2 negative SCC 
CaSki 40 - - - N/A SCC 
SiHa 55 2 - - N/A SCC 
HeLa 31 - - 1 N/A AdenoSCC 
SCC: squamous cell carcinoma; LVSI:  lymphovascular space involvement. 
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Up-regulated transcripts included Bst2, NKD2, GBP2, ENO2, CA9, CDH2, CDH24, 
while the down-regulated transcripts included FGFBP1, AMIGO2, FEZ1, GJB2, GJA1, 
GJB4 and GJB5.  Among these, attention was focussed on connexin 26 known as 
GJB2 (Cx26), a gap junction (GJ) protein that mediates intercellular communication. 
GJs are intercellular channels that allow the free passage of ions and small mole-
cules (<1 kDa) between cells and they are important in maintaining cell homeostasis 
(Goodenough & Paul, 2009; Pointis et al, 2007). GJ proteins such as Cx43, Cx26 and 
Cx30 are down-regulated in HR-HPV cervical samples compared to normal cervix 
and loss of GJs correlates with cell transformation (Aasen et al, 2005; McNutt & 
Weinstein, 1969; Mesnil et al, 2005). However, the mechanism behind its relation-
ship to HPV oncoproteins expression remains largely unknown. Low levels of con-
nexin expression on the cell surface permits the tumour cell to grow without receiv-
ing inhibitory, localisation or differentiation signals: in HPV-positive cells, this could 
help the virus evade the immune response. Furthermore, GJs allow antigenic pep-
tides to move between polarised cells in the epithelium. Loss of GJs may confer a 
survival advantage to cancer cells by restricting immune recognition by cytolytic kil-
ler cells of the immune system (Ernesto Oviedo-Orta, 2013). 
Down-regulation of Cx26 transcripts was further investigated in HPV-transformed 
cells and in human keratinocytes (HaCaT cells) at both the structural level (i.e. by 
analysing levels of the Cx26 protein by Western blotting and immunofluorescence) 
and at the functional level, by analysing the function of gap junctions in normal and 
HPV-positive epithelial cells using dye microinjection into living cells. These studies 
were further expanded by attempting to define the possible role of either (or both) 
the viral E6 and E7 oncoproteins in regulating Cx26 protein expression and gap junc-
tion function using HaCaT cells transduced by recombinant human adenoviruses 
designed to express the E6 or E7 proteins. 
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5.2 RESULTS 
5.2.1 Analysis of transcript expression  
Bioinformatic analysis was performed using the Galaxy platform and the TopHat-
Cufflinks pipeline on samples that had been previously prepared (Watherston, 
2010). To analyse differentially-expressed transcripts, the Cuffdiff program was em-
ployed. Cuffdiff estimates differentially-expressed genes and transcripts based on 
transcript quantification performed by Cufflinks. Cuffdiff calculates gene and tran-
script expression levels in different conditions and it tests them for significant dif-
ferences. A number of output files containing results for changes in expression at 
the level of transcripts and genes are generated. In addition, it estimates changes in 
the relative abundance of transcripts which share a common transcription start site 
(TSS) (to study changes in splicing events) as well as in the relative abundances of 
the primary transcripts of each gene (relative promoter usage within a gene). It 
generates several results data that can be divided in 3 groups:  
1. FPKM tracking files: the FPKM (expression metric) value of each tran-
script, primary transcript and gene in each sample. 
 gene FPKM tracking 
 CDS (coding sequence) FPKM tracking 
 transcript FPKM tracking 
 TSS (transcription start site) groups FPKM tracking 
2. Count tracking files: the raw data i.e. non-normalised number of frag-
ments that originated from each transcript, primary transcript, and gene 
in each sample. 
 CDS overloading differential expression testing 
 CDS FPKM differential expression testing 
 TSS groups differential expression testing 
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3. Differential expression tests: the results of differential expression testing 
between samples for spliced transcripts, primary transcripts, genes, and 
coding sequences 
 gene differential expression testing 
 splicing differential expression testing 
 transcript differential expression testing  
 promoters differential expression testing 
 In this study only the “transcript differential expression testing” output for each of 
the samples analysed has been considered. Results were sorted so that only statisti-
cally significant data were considered. Thus, of a total of over 40000 transcripts, 
those whose changes in transcript abundance were not statistically significant were 
discarded (unless they were considered for comparison with samples which had the 
same transcripts significantly deregulated). Heatmaps were generated to show the 
overall expression of all the cellular transcripts between the samples analysed 
(Figure 5-1, Figure 5-2).  
Since attention was focussed on transcripts encoding cell-surface proteins, the re-
sults were narrowed down by filtering for encoded cell-surface proteins only (gene 
ontology, GO: 005886,). This gave a total of about 100 transcripts per sample ana-
lysed. These were sorted by expression level (log2[fold change]) and the top 20 and 
bottom 20 were chosen as representatives of up-regulated and down-regulated 
transcripts, respectively (Appendix 6: Significantly deregulated cell surface tran-
scripts). Only transcripts that were consistently deregulated between all samples 
were considered for further analysis (Figure 5-3, Figure 5-4 and Figure 5-5).   
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Figure 5-1 Transcript expression levels between the cell lines and NHK. 
Values obtained from Cuffdiff output “transcript differential expression testing” were used to 
compare expression levels between the samples. The transcripts expression levels are represented 
by the log10 FPKM+1 that corresponds to a certain intensity of the colours indicated in the Heat-
map. For the Heatmap, all the transcripts generated by Cuffdiff were used, whether the difference 
was significant or not. NHK=normal human keratinocytes. 
 
Figure 5-2 Transcript expression levels between the patient cervical cancer tissue samples and 
NHK. 
The heatmaps were generated as described in Figure 5-1.   
NHK NHK NHKCaSki SiHa HeLa
Patient 1
NHK
Patient 2 Patient 3
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Since the cell lines were used as standard examples where expression of all tran-
scripts should not be affected by the history of the specific patient, common tran-
scripts were first analysed between CaSki, SiHa and HeLa cells. These were then 
analysed in the patient samples to determine whether similar expression could be 
observed. 
Among the up-regulated transcripts encoding cell-surface proteins, Bst2, NKD2, 
GBP, ENO2 and CA9 were found to be commonly deregulated in all samples ana-
lysed (Figure 5-3). Literature surveys did not report a connection between these 
transcripts and HPV infection or cervical cancer, making them an interesting target 
to follow up for further studies. Bst2, also known as tetherin (CD317) has been re-
cently investigated for its role in the immune response and anti-viral activity against 
enveloped viruses (Hotter et al, 2013), in particular retroviruses (HIV) (Kuhl et al, 
2010; Tokarev et al, 2009). HPVs are not enveloped viruses and they are DNA vi-
ruses, nevertheless, Bst2 was a good candidate for further investigation. 
Down-regulated transcripts included FGFBP1 (fibroblast growth factor binding fac-
tor 1), AMIGO2 (adhesion molecule with Ig-like domain 2), FEZ1 (fasciculation and 
elongation protein Z-1) and 4 members of the connexin family: GJB (gap junction 
protein) 2, GJB4, GJB5 and GJA1 (Figure 5-4, Figure 5-5). Of the latter, only one con-
nexin, GJB2 was commonly down-regulated in all samples analysed, while the other 
connexins could be not analysed in Cuffdiff due to low values assigned during the 
analysis. This occurred for many transcripts whose expression values were too low 
to be considered for statistical analysis by Cuffdiff. 
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Figure 5-3 Up-regulated cell surface transcripts within the samples analysed.  
Unless otherwise stated only statistically significant values were considered for the comparison.  
(ns= non-significant, Pat_= patient).  
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Figure 5-4 Down-regulated transcripts between the samples analysed. 
Unless otherwise stated, only statistically significant values were considered for the comparison.  (ns= non-significant, Pat_= patient).  
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Figure 5-5 Down-regulated connexin transcripts between the samples analysed. 
GJA1, GJB4 and GJB5 did not yield values which Cuffdiff could use for the statistical analysis in the patient samples (infinite number). For comparison pur-
poses GFOLD values have been used which, despite being without statistical analysis, are consistent with the fold changes observed in Cuffdiff. Unless 
otherwise stated, only statistically significant values were considered for the comparison.  (ns= non-significant, Pat_= patient).  
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5.2.2 Data comparison with a lyoplate assay 
The lyoplate assay was performed in collaboration with Dr Erica Wilson (Leeds Insti-
tute of Cancer and Pathology, Leeds), according to the manufacturer’s instructions 
(BD Bioscience). The experiment was performed to analyse the expression of pro-
teins belonging to the CD family (cluster of differentiation) and then compare the 
results with the RNA-Seq data (Table 5-2). While the assay only covers a small frac-
tion of the repertoire of cell-surface molecules, it can give an estimate of how 
mRNA levels calculated by the RNA-Seq reflect the protein levels, as well as giving 
an indication of which molecules might have a role in the immune system during 
HPV infection and transformation.  
Following flow cytometry, CD antigens/proteins were filtered based on the Mean 
Fluorescence Intensity (MFI) and the highest and lowest values were considered for 
further analysis and comparison with the sequencing data (Figure 5-6).  
 
 
Figure 5-6 Identification of differentially-regulated cell-surface molecules using the lyoplate assay. 
Top, cell surface antigens with the lowest MFI in NHK compare to HPV-transformed cells, bottom, 
cell-surface antigens with the highest MFI. MFI = mean fluorescence intensity. 
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Deregulated proteins were compared with the RNA-Seq respective mRNA levels. 
The results showed that some transcripts were similar deregulated at the protein 
and mRNA level: CD13 (Anpep, an aminopeptidase N), CD73 (NT5E, a 5'-
nucleotidase) and CD49d (α subunit of α4β1) were significantly down-regulated in 
CaSki and SiHa cells compared to normal primary human keratinocytes, while in the 
patients’ samples they were down-regulated but not significantly, except for pa-
tients 4 and 7 (data not shown). The up-regulated CD antigens/proteins were also 
consistent with the mRNA levels and this was also observed in the patients’ data, 
despite not being statistically significant. In addition, some patient data showed 
down-regulation of these transcripts, such as CD70, which is down-regulated in pa-
tient 3, 4, and 8, although not significantly (Table 5-2). 
Table 5-2 Cuffdiff values for the transcripts compared with the lyoplate assay. 
Bold = up-regulated transcripts, Italic = down-regulated transcripts 
 
5.2.3 Expression of HPV16 E6 and E7 by recombinant adenoviruses  
The HPV16 E6 and E7 open reading frames (ORFs) were generated by PCR using the 
pEF-399 HPV16 plasmid as template (NCBI reference AF125673.1). The PCR samples 
were ligated into PCR Blunt and this was used as a template to generate the PCR 
products used for the recombineering reactions, where the primers included the 
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homology regions for the E1 region of the adenovirus (for insertion of E6 and E7) or 
the E3 region (for insertion of CFP). To test for positive colonies, a colony PCR was 
performed (Figure 5-7A and Figure 5-8A) and where found, colonies were subjected 
to BamHI digest. If the insert was effectively within the E1 region, then two bands of 
1.7 kb and 2.5 kb were lost. This can be compared with the adenovirus expressing 
only CFP, where the two bands are still visible (Figure 5-7B and Figure 5-8B). Pro-
vided the colony was positive, it was sent for sequencing and 911 cells transfected 
to expand the virus. Following virus purification, HaCaT were transduced with the 
recombinant adenovirus. To eventually confirm that the construct was working, 
RNA was extracted and cDNA generated, to be used as a template for PCR reac-
tions. Purified virus was also quantitated for number of infective particles as de-
scribed in Chapter 2.9.6.  
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Figure 5-7 Generation of a recombinant adenovirus expressing HPV16 E6. 
A. A colony PCR was performed to identify which colony had incorporated the E6 ORF following 
recombineering. B. BamHI restriction digest of the three putative positive colonies was performed 
to confirm the presence of the insert within the E1 region. Colony N.1 (red) contained the insert 
and thus expanded for transfection in 911 cells C. cDNA from transduced HaCaT cells was used as 
an RT-PCR template to generate an RT-PCR product (PCR gradient 54 to 65°C) to confirm that 
mRNA is made within the cells.  
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Figure 5-8 Generation of recombinant adenovirus expressing HPV16 E7 
A. A. A colony PCR was performed to identify which colony had incorporated the E7 ORF following 
recombineering. B. BamHI restriction digest of the eight putative positive colonies was performed 
to confirm the presence of the insert within the E1 region. Colony N.3 (red) contained the insert 
and thus expanded for transfection in 911 cells C. cDNA from transduced HaCaT cells was used as a 
RT-PCR template to generate an RT-PCR product. CaSki and SiHa cells were used as a positive con-
trol, GAPDH as a loading control.  
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5.2.4 Studies on the expression of Cx26  
Analysis of the RNA-Seq data showed that among the down-regulated transcripts, 
GJB2 (Cx26) showed a particular expression pattern compared to the other connex-
ins, which were down regulated only in the cervical cancer cell lines. To investigate 
the expression of Cx26 further, RT-PCR was performed to validate the expression 
levels detected by RNA-Seq as well as to test the hypothesis that E6 or E7 might 
down-regulate Cx26 mRNA levels. The results showed that Cx26 mRNA levels were 
decreased in the presence of E6 (6 -fold decrease) and E7 (2.7-fold decrease) while 
it was recorded a larger decrease in the presence of E6/E7 (65.4-fold decrease). The 
figure also shows that the control CFP construct did affect the levels of Cx26 tran-
scripts with 1.4-fold decrease (although in other repeats of the RT-PCR levels were 
equal to non-transduced HaCat cells; data not shown). Finally, the data shown in 
Figure 5-9 confirmed that Cx26 mRNA levels were greatly reduced in CaSki, SiHa and 
HeLa cells compared to HaCaT cells. This also suggests that different factors other 
than E6 and E7 are involved in regulating Cx26 mRNA levels. 
Immunofluorescent antibody labelling was performed to test whether mRNA levels 
observed in the cell lines reflected protein levels. The data showed that HaCaT cells 
had a different pattern of Cx26 protein expression to that in CaSki and SiHa cells, 
suggesting that the low mRNA levels observed reflected lower levels of protein ex-
pression on the surface of the cells. Previous literature reports that HeLa cells do 
not express connexins were confirmed in these experiments (Figure 5-10). 
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Figure 5-9 Expression of Cx26, HPV16 E6 and E7 mRNAs in cervical cancer (CaSki, SiHa and HeLa) 
and normal human keratinocytes (HaCaT). 
A. Top panel shows a graph with the quantified mRNA values calculated with the Aida Soft Imager 
which calculates the intensity of the bands. Values normalised against GAPDH and the negative 
control (HaCaT). Bottom panel (B) shows mRNA for E6 and its variant, E7, Cx26 and GAPDH in Ha-
CaT cells transduced with the recombinant adenoviruses and in the HPV positive cell lines CaSki, 
SiHa and HeLa. GAPDH was used as a loading control. Red stars indicate the two E6 products.  
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Figure 5-10 Immunofluorescent antibody staining for Cx26 in HaCaT, CaSki, SiHa and HeLa cells. 
The picture shows pattern of expression for Cx26 in HaCat, CaSki, SiHa and HeLa cells.  Left panel: 
labelling for nuclei only (DAPI), middle panel: labelling for Cx26; right panel: merged. Scale bar: 10 
μm. Pattern of expression confirmed as observed in published literature (Bakirtzis et al, 2003; 
Gemel et al, 2006; Gilleron et al, 2008). 
5.2.4.1 The effect of HPV16 E6 and E7 expression on Cx26 localization  
Two adenoviruses that expressed either HPV16 E6 or E7 where prepared as de-
scribed in Chapter 5.2.3 to test the hypothesis that deregulated mRNA levels ob-
served in the RNA-Seq analysis might be a consequence of the expression of either 
or both viral oncogenes, E6 and E7. In particular, attention was directed at the pat-
tern of Cx26expression. HaCaT cells were transduced with each construct (or the 
control Ad vector) and immunofluorescence microscopy performed as previously 
described (Chapter 2.7.7). CFP-positive cells were selected to identify virally-
transduced cells and in those cells the expression of E6 or E7 was confirmed fol-
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lowed by analysis of Cx26 expression. While in non-transduced HaCaT cells a distinc-
tive pattern of Cx26 expression was observed, in cells expressing either E6 or E7, 
Cx26 seemed to be more diffuse and the regular pattern previously observed was 
lost, suggesting that Cx26 might be accumulating in the cytoplasm and failing to be 
transported to the cell surface (Figure 5-11). 
 
Figure 5-11 Immunofluorescent antibody staining for Cx26 in transduced HaCaT cells. 
The picture shows pattern of expression for Cx26 in normal HaCat cells and in transduced HaCaT 
cells. From the left panel: labelling for nuclei only (DAPI), labelling for Cx26; labelling for E7 Myc 
tagged or E6 HA tagged; labelling for CFP and far right panel: merged. The first row indicates nor-
mal HaCaT cells, the second HaCaT transduced with the control adenovirus, the third HaCaT in 
presence of E7-Myc-tagged and the last row HaCaT in presence of E6-HA-tagged. Scale bar: 10 μm. 
It is worth mentioning that not all CFP-positive cells appeared to co-express either 
E6 or E7, and it was also observed that some cells that expressed E6 or E7 were at 
times, not CFP-positive. In addition, CFP-positive cells (in the presence or absence of 
E6 or E7) seemed to have a bigger nucleus than non-transduced cells, suggesting 
that the virus might be involved somehow in altering nuclear morphology (data not 
shown). 
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5.2.4.2 Cx26 protein levels in transduced HaCaT cells 
To provide a more quantitative analysis of the above, HaCaT cells were transduced 
with the recombinant adenoviruses, whole cell extract was prepared and Western 
blotting was performed to compare protein levels for Cx26 as well as to confirm the 
expression of the viral oncoproteins. The results showed that Cx26 protein levels 
were not affected by expression of either the E6 or the E7 oncogenes, however, 
when both viral oncoproteins were present, Cx26 protein levels fell dramatically 
(Figure 5-12). 
                                  
Figure 5-12 Cx26 protein expression in presence of E6 and E7. 
Western Blot for Cx26 in HaCaT cells transduced with the recombinant adenovirus expressing E6 
and E7.  
Moreover, since immunofluorescent antibody staining results showed a re-
localization of Cx26 to the cytoplasm from the membrane, cell fractionation was 
performed to further investigate these findings. Initial results showed that Cx26 re-
located to the cytosol in the presence of E6 and E7, while in non-transduced HaCaT 
or the positive control AdZ, Cx26 does not seem to be expressed in the cytosol 
(Figure 5-13). As shown in Figure 5-13, analysis of the membrane fractions showed 
expression of Cx26 protein in both the AdZ negative control and transduced HaCaT 
cells suggesting that relocation to the cytosol is partial. Knock-down of Cx26 was 
performed to show that the band was effectively Cx26 since the antibody used rec-
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ognized a single band running at 50 kDa, whereas the predicted molecular mass of 
Cx26 is 25-26 kDa (Figure 5-14 ). 
 
Figure 5-13 Cell fractionation assay on transduced HaCaT cells.  
HaCaT cells were transduced with the recombinant adenovirus and assessed for Cx26 expression in 
the cytosol and membrane fractions. 
                                                              
Figure 5-14 Reduction of Cx26 by RNA interference to detect Cx26 protein. 
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5.2.5 Lucifer yellow dye transfer assay  
Lucifer yellow dye transfer assay was performed to monitor functional gap junction 
expression in HaCaT cells transduced with the recombinant adenovirus expressing 
E6. Following microinjection of the dye, images were captured between 0 and 5 
minutes to follow the dispersion of the dye to the neighbouring cells. This was in-
dicative of the structural identity of the junctions between the cells following trans-
duction by the recombinant adenovirus. An average of 4 injections where per-
formed per cell sample in 3 replicates and spreading of the dye was assessed as the 
number of cells which became green following dispersion of the dye (Figure 5-15, 
Figure 5-16).  
 
Figure 5-15 Lucifer yellow dye transfer assay in transduced HaCaT cells.  
A series of microinjection were performed in HaCaT cells transducer with the recombinant adeno-
virus and the number of cells in which the Lucifer yellow dye has diffused was counted. The num-
ber of cells is reduced in HPV16 E6 transduced cells suggesting that E6 is effectively altering cell-
cell communication in HaCaT cells. 
The series of injections showed that gap junctions are interrupted in HaCaT cells 
that were transduced with the recombinant adenovirus expressing E6, while com-
munication is well established in non-transduced HaCaT or the control adenovirus, 
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suggesting that E6 is somehow involved in altering cell-cell communication in HaCaT 
cells (Figure 5-15 and Figure 5-16). This is consistent with the immunofluorescence 
results where HPV16-positive, E6-expressing cells appeared to be deficient in gap 
junction expression. The construct expressing E7 was not tested for loss of GJs since 
previous reports have ascribed a role key for the high-risk E6 oncoproteins (Grm & 
Banks, 2004).  
 
Figure 5-16 Lucifer yellow dye transfer assay in transduced HaCaT cells. 
As shown in the picture, while in HaCaT and CFP-transduced cells the dye can diffuse, in E6 positive 
cells the dye does not diffuse due to the lack of gap junctions. Arrows indicate the injected cell. 
Cells appearing green other than those indicated by the arrow are CFP-positive cells.  
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5.3 DISCUSSION 
Bioinformatic analysis of RNA-Seq data was performed on three HPV-positive cell 
lines (CaSki, HeLa, SiHa), seven cervical tumour biopsies and normal human kerati-
nocytes (NHKs). Nine cellular transcripts encoding cell-surface proteins were found 
to be differentially expressed in all samples analysed. Among these, attention was 
focused on Cx26, a protein belonging to the gap junction protein family. These re-
sults alone cannot provide a direct link between E6 and/or E7 expression and Cx26 
deregulation, although both CaSki and SiHa cells showed a reduction in connexin 
mRNA expression compared to normal keratinocytes, as shown by the RNA-Seq 
data as well as by RT-PCR analysis. The immunofluorescent antibody staining ex-
periments supported these findings since they showed that Cx26 was expressed, 
but localized in the cytoplasm, suggesting that additional mechanisms are adopted 
by the two viral oncoproteins to impair the proteins’ localization in the membrane. 
Understanding how and why Cx26 is down-regulated in cervical cancer and whether 
this is a direct or indirect consequence of HPV oncoprotein expression might eluci-
date a significant aspect of the mechanism of HPV oncogenesis. Previous reports 
have suggested a correlation between loss of GJ proteins and HPV-related tumour 
progression; however, specific mechanisms are not well understood. In particular, it 
is not known whether several or all members of the Cx family are deregulated in 
cervical cancer or whether deregulation is tissue-specific and restricted to certain 
connexin family members. Elucidating correlations between transcript and protein 
levels of Cx26 and the underlining mechanisms may form the basis for future stud-
ies on GJ proteins and their role during HPV infection. 
It can be proposed that there may be a connection between loss of connexin ex-
pression and cervical cancer development as suggested for other types of cancer 
and as shown by the data presented in this chapter, however at this stage specific 
mechanisms still need to be elucidated. It can be suggested that, given that kerati-
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nocytes are antigen-presenting cells (APC) important in directing the T cell response 
(Banerjee et al, 2004), GJs can work as immunological junctions to transfer antigenic 
peptides between infected cells and professional APCs, such as dendritic cells (DCs); 
DC, in turn present the antigen on their surface and, following activation, migrate to 
the lymph nodes. HPVs might take advantage of the role played by GJs by down-
regulating their expression. HPV16 E5 is known to inhibit gap junction contacts, di-
rectly or indirectly by inﬂuencing the phosphorylation status of connexin 43 (Oelze 
et al, 1995), thus increasing the chances of promoting abnormal growth of those 
cells that have not been specifically recognized by the immune system. In addition it 
is known that HPV can down-regulate MHC class I molecules (Bottley et al, 2008). 
These processes might explain how, over a period of 10-20 years, the virus escapes 
immune surveillance and promotes tumour generation.  
Other mechanisms have to be considered to account for loss of GJs. Indeed, elegant 
studies in Dr Banks’ laboratory have shown that a PDZ-domain protein, MAGI-1 
(membrane associated guanylate kinase 1), a member of the MAGUK family, is one 
of the major targets of HPV16 E6 and its degradation leads to disruption of tight 
junction (TJ), another major component of cell junctions, along with GJs, desmo-
somes and adherens junctions. It has been also shown that Cx43 establishes a func-
tional interaction with the hDlg protein triggering Cx43 relocation to the cytoplasm, 
reducing the membrane-bound form and thus reducing GJ intercellular communica-
tion.  This is consistent with the results presented in this chapter where relocation 
of Cx26 to the cytoplasm was also observed in presence of HPV16 E6. (Macdonald 
et al, 2012)  
Finally, it has been reported for other tumours that low level of GJs may be a con-
sequence of reduced levels of mRNA due to promoter hypermethylation (Chen et al, 
2005; Tan et al, 2002). HPV16 E7 is known to interact with DNA methyltransferases 
(DNMTs) while HPV16 E6 is known to up-regulate DNMT1 levels following p53 re-
pression , suggesting other possible mechanisms by which HPV controls the levels of 
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GJ protein expression, namely through regulation of promoter activity and tran-
script levels (Au Yeung et al, 2010; Burgers et al, 2007). Sequence analysis of the 
Cx26 gene has indeed revealed a putative CpG island adjacent the promoter (Figure 
5-17) and it overlaps the promoter region (within the exon 2 of Cx26) as confirmed 
by the sequence alignment of the CpG island DNA sequence (UCSC) with the Cx26 
gene (NCBI GenBank: JQ595559.1) (Kiang et al, 1997). This suggests that promoter 
methylation may account for low levels of mRNA observed in the RNA-Seq data. Fu-
ture experiments, for example, using inhibitors of cytosine methylation such as 5-
Aza-2′-Deoxycytidine, might address this hypothesis to test if this is the case. 
 
Figure 5-17 Genomic features on the GJB2 gene segment. 
The picture was generated using the UCSC genome browser. It shows the presence of the regula-
tory elements on the GJB2 gene such as promoters and enhancers as well as the CpG island over-
lapping the promoter (in HeLa cells). CpG islands were predicted by searching the sequence one 
base at a time, scoring each dinucleotide (+17 for CG and -1 for others) and identifying maximally 
scoring segments. Each segment was then evaluated for the following criteria: GC content of 50% 
or greater, length greater than 200 bp, ration greater than 0.6 of observed number of CG dinucleo-
tides to the expected number on the basis of the number of GCs and Cs in the segment. The CpG 
count (145) is the number of CG dinucleotides in the island. This suggests a possible methylation of 
the GJB2 promoter which may trigger low mRNA levels as observed in the NGS/RNA-Seq data. 
PromF: promoter flanking, PromP: inactive promoter, Low: low activity proximal to active sites, 
EnhW: candidate weak enhancer, CTCF: distant CTCF/candidate insulator, Repr/D/W:  Polycomb 
repressed (http://genome.ucsc.edu; the picture has been adapted from the original). 
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Chapter 6. General discussion and future considerations 
In this study the mechanism by which a remote enhancer communicates with the 
cognate promoter over long distances was addressed. Using the murine immu-
noglobulin lambda light chain locus (Igλ), it was shown that E47 forms a protein link 
between the promoter and the enhancer of sterile transcription of the Jλ1 gene 
segment by interacting with the enhancer-bound protein complex PU.1/IRF4. The 
results obtained confirm that the protein link is necessary but not sufficient to me-
diate productive enhancer-promoter communication in order to trigger sterile tran-
scription of the murine Jλ1 gene segment.  
This is in agreement with recent studies that have investigated the presence of ad-
ditional enhancers at the immunoglobulin heavy and light chains, known as “super-
enhancers”, in addition to those addressed in this study, suggesting that these other 
regulatory elements may be targeted for binding by B-cell specific transcription fac-
tors such as E47 and IRF4 or that other factors might be involved in this interaction, 
as shown by the additional factors found in the initial DNase footprinting reactions 
in Chapter 3 (Predeus et al, 2014). Of these, of particular interest is the transcription 
factor AP-1 which has been previously shown to be essential at the kappa locus 
(Schanke et al, 1994) and which should be further studied to determine whether it 
plays a role during transcription of the antigen receptor light chain loci. 
Several human diseases are a consequence of altered action of enhancers’ mecha-
nism. To establish how enhancer/promoter interaction occurs during B and T cells 
development (in the context of the antigen receptor loci transcription) and to inves-
tigate the factors involved will be vital considering that mistakes in V(D)J recombi-
nation account for 40% of all leukaemia cases (Table 6-1). Illegitimate recombina-
tion between Ig or TCRs and non-antigen receptor loci triggers chromosomal trans-
locations that can lead to different forms of leukaemia in both B and T cells 
(Marculescu et al, 2006). This occurs because the RAG proteins recognize a site that 
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is similar to the RSSs, namely “cryptic RSSs” (cRSSs), which are found within every 1-
2 kb on average (Lewis et al, 1997). Upon cleavage, chromosome translocation is 
promoted; these translocations are characterised by the ectopic activation of a si-
lent proto-oncogene when it is re-located in the vicinity of an active regulatory ele-
ment.  However, several factors have to be taken in account to explain why such 
mistakes occur. For example, chromatin accessibility as well as recruitment of co-
activators by enhancer-bound transcription factors might play a key role in this 
process. Taking in consideration the mistakes occurring during V(D)J recombination, 
the non-antigen receptor loci involved in the recombination reaction must be ac-
cessible for RAG cutting, suggesting that, for reasons to be clarified, at that specific 
moment of B or T cell development, those loci can be accessed by the recombinase 
machinery.  
The advent of 3C and its variants circularized chromosome conformation capture 
(4C) and genome-wide chromosome conformation captures (Hi-C) have been widely 
used to determine direct physical contact between separated DNA sequences. 
These techniques, complemented by studies on histone modification and HAT-
binding patterns have helped to predict enhancers within several cell types, sug-
gesting that a similar approach could potentially be applied in B and T cells to study 
which enhancers are simultaneously active during V(D)J recombination and how 
distant genes are selected for activation following RAG cutting. In addition, further 
studies have also shown the presence of stalled RNA polymerases at certain genes 
suggesting that the main role of enhancers is to promote the transition between 
transcription initiation and elongation phases (Nechaev & Adelman, 2011). This 
suggests that a combination of chromatin accessibility factors, enhancer-promoter 
interaction and transcription factors required to promote this interaction, are nec-
essary at the non-antigen receptor loci to be equally recognized by the recombinase 
machinery and trigger chromosome translocations. To complement current knowl-
edge of these interactions a combination of 3C with the new high-throughput se-
quencing methodologies could help discover novel long-range interactions of a spe-
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cific locus, such as those involving non-antigen receptor loci. This could be poten-
tially studied in a temporal and spatial manner to investigate loci activation at spe-
cific times during development and further understand how certain loci are acti-
vated and why, in some cases, they are brought into close proximity of non-antigen 
loci, promoting chromosomal translocations.  
Another prospect is to study these interactions by FISH (fluorescent in situ hybridi-
zation). FISH as been already applied to study V(D)J recombination events (Daly et 
al, 2007; Holwerda et al, 2013), and a similar approach could improve the robust-
ness of the data presented in this thesis. For example, using two different probes 
for enhancer and promoter, long-range interaction could be studied under different 
conditions. For example, additional mutagenesis studies, such as mutation of the 
E47 phosphorylation sites as mentioned in Chapter 4, could be performed and this 
will expand our current knowledge of the importance of these interactions and why 
the RAG protein complex equally recognizes these cRSSs. 
Table 6-1 Representative translocations associated with lymphoid malignancies.  
Type Transloca-
tion 
Fusion 
genes 
References 
TCR RSS to cryptic RSS t (7;9) TCRβ/tal2 Tycko et al. 1989 
IgH RSS to locus without 
RSS 
t (14;18) IgH/bcl2 Tsujimoto et al. 1985 
Coding joint t (1;19) 
t (9;11) 
E2A/pbx1 
AF-9/ALL-1 
Wiemels et al. 2002 
Negrini et al. 1993 
Interstitial RSS Exon 2/3 
deletion 
Hprt Finette et al. 2002 
Deletion d(1) sil/tal1 Aplan et al. 1990 
Indeed, single amino acids mutants have been prepared to test in the hypothesis 
that phosphorylation might regulate E47 stability, triggering its degradation and 
that interaction with IRF4 could possibly protect E47, by masking the phosphoryla-
tion sites.  As discussed in Chapter 1, different molecular mechanisms control the 
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transcriptional activity of E47, from regulation by the Id proteins to post transla-
tional mechanism, such as phosphorylation events. For example, phosphorylation of 
serine 140 by the p38 MAPK is known to regulate muscle-specific gene transcrip-
tion, thus MyoD/E47 heterodimerization (Lluis et al, 2005). It is conceivable to sug-
gest that other phosphorylation events might dictate association of E47-interacting 
partners, such as IRF4 and PU.1 as described in Chapter 3 and as suggested for the 
Myo/E47 interaction, p38 MAPK could also exert a negative effect by phosphorylat-
ing other residues within E47. In light of the various residues that have been pre-
pared, it will not be surprising if analysis of the phosphorylation status by a MAP 
kinase would result in different outcomes. Moreover, as it was shown in another 
study, E47 phosphorylation at serine residues found within the N-terminal domain 
by AKT (in particular S528) were absent in E12, although the two proteins are two 
splice variant of the E2A gene (Teachenor et al, 2012b). In addition to this, because 
of two distinct acceptor splice sites flanking the E47 exon, two distinct E47 isoforms 
where generated, of which only one was phosphorylated by AKT site. This suggests 
another level of regulation of E47 activity by post-transcriptional modification that 
should be further investigated also in the context of E47 interaction with IRF4 or 
PU.1. 
In the second part of the thesis next generation sequencing was used to analyse 
HPV-positive cell lines and tumour biopsies. High-throughput sequencing method-
ologies have been widely used to investigate differences in gene expression be-
tween two different conditions, e.g. normal vs. cancerous. As discussed in Chapter 
1, the immune system is a very complex system in which interactions between dif-
ferent regulatory elements allows the generation of a diverse array of antibodies 
and T cell receptors, specific for certain antigens. However, in the case of an HPV 
infection, it is known that the immune system somehow oversees the infection, for 
decades, inevitably triggering cervical cancer. Cancer is itself a multifaceted disease 
  
234 
involving more than one pathway and deregulation of several proteins and mole-
cules.  
In this study, high-throughput sequencing methodologies were adopted to analyse 
differences in transcript expression levels between normal human keratinocytes 
and HPV-positive tumour samples and three cell lines, representative of both 
HPV16 and 18. Several transcripts were found to be deregulated, among which a 
member of the gap junction protein family, Cx26.  Although the results suggest that 
the two viral oncogenes E6 and E7 are affecting both Cx26 mRNA and protein levels, 
this cellular protein is unlikely to solely account for cancer development; therefore, 
understanding the pathways that trigger its down-regulation and which other mole-
cules might be involved may help in elucidating the mechanism behind the evasion 
of immunosurveillance by HPVs.  
In 2000, a well-known paper from Hanahan and Weinberg stated “…One day, we 
imagine that cancer biology and treatment—at present, a patchwork quilt of cell 
biology, genetics, histopathology, biochemistry, immunology, and pharmacology—
will become a science with a conceptual structure and logical coherence that rivals 
that of chemistry or physics.”(Hanahan & Weinberg, 2000). At that time, high 
throughput technologies were less advanced than today; at present researchers are 
eager to find differences in transcripts/gene expression between tumour samples 
versus normal tissues that could be used as biomarkers for cancer detection or pre-
vention. Biomarkers may not only help prevent the disease, but at the same time 
can help elucidate connections between the various altered molecules within a cer-
tain condition, to better formulate a diagnosis and a more direct treatment.  
Indeed, in addition to Cx26, other transcripts were of particular interest and should 
be considered for future studies. For example, CD13 (APN, NCBI Ref.NM_001150) is 
an amino peptidase N that degrades proteins with an N-terminal neutral amino 
acid. It is described as a “moonlighting ectoenzyme” given the multitude of proc-
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esses it is involved in, such as antigen presentation, receptor for some human vi-
ruses (coronaviruses), regulation of cell motility and angiogenesis in colon cancer, 
non-small cell lung cancer and human pancreatic cancer (Ghosh et al, 2012; Hashida 
et al, 2002; Ikeda et al, 2003; Tokuhara et al, 2006; Yeager et al, 1992). In this study, 
APN was found to be down regulated, however it was not further analysed as prior-
ity was given those transcripts whose expression was significantly deregulated in all 
samples analysed. However, the fact that APN is involved in antigen presentation in 
dendritic cells raises an interesting hypothesis that it might be crucial in keratino-
cytes as well, which are known to be APCs. In this context, HR-HPVs might down-
regulate APN as a means to limit cell-cell communication between the cells during 
viral infection, and thus bypass the immune response. This is a hypothesis that 
should be considered in future work to complement our understanding of viral in-
fection and immune escape by HR-HPVs. To this end, a plasmid expressing APN has 
been prepared to better understand the role played by this protein. 
Future work should also be addressed to understand whether the virus targets the 
same cellular protein in different cells. HPV is known to be the causative agent of 
head and neck cancers as well. To this end, head and neck cell carcinoma have been 
sent for sequencing to analyse their transcriptome. A comparison between the data 
will allow a better understanding of the transcripts targeted by the virus. 
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Chapter 7. APPENDICES 
7.1 Appendix 1: Supplemental figures 
 
Figure 7-1 Competition assay on the Jλ1 probe. 
The competition assay shows that the band to which the extract is binding does correspond to an 
octamer factor since the band is competed off only in present of the specific oligonucleotide carry-
ing a binding site for an octamer factor. 
 
 
Figure 7-2 Antibody competition to identify IRF1/2 transcription factor. 
αIRF4-P -P 
Jλ1 probe
-P 
IRF1/2?
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IRF1/2? IRF1/2?
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Figure 7-3 Cross competition for IRF1/2. 
Although the same factor seems to bind the three promoters, subsequent testing failed to reveal 
the identity of such factor. Open arrows indicate increasing amount of competitor.  
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Table 7-1 RLU and standard deviation (SD) values obtained in luciferase assays. 
                     
                                  
Table 7-2 Luciferase assay raw data. 
Sample Luciferase Renilla Luciferase/ Renilla ratio Normalized pGL3/Renilla 
pgl3 2472 297307 0.008314638 0.618107888 
pgl3 4873 262146 0.018588878 1.381892088 
pgl3 average   0.013451758  
2 29273 151179 0.193631391 14.39450447 
2 23268 127406 0.182628762 13.57657204 
3 44263 162632 0.272166609 20.23279108 
3 46294 157287 0.294328203 21.88027785 
4 89340 166214 0.53749985 39.95759139 
4 81692 142834 0.571936654 42.51761396 
5 74580 285580 0.261152742 19.41402319 
5 57586 361109 0.159469855 11.85494531 
 
PLASMID  RLU +/- SD 
pgl3 0.99 8.1733E-08 
Jλ1+E47 8.5 3.93906815 
Jλ1+E47/IRF4 34.37 1.5985352 
Eλ3-1 89.92 4.05284523 
Jλ1/E47mt 7.46 2.80063692 
Jλ1/E47m/IRF4 6.96 2.83318882 
Eλ3-1/Jλ1 E47mt 47.02 1.26710013 
Eλ3-1/Jλ1 /IRF4mt 40.1696408 5.79311503 
Eλ3-1/Jλ1 /IRF4mt /PU.1mt 46.2760251 10.6707235 
Eλ3-1/Jλ1/IRF4 L24A 32.7761891 9.544866715 
Eλ3-1/Jλ1/IRF4 K399A 55.84231 16.07477412 
Eλ3-1/Jλ1/IRF4 L368A 36.9322176 4.967296607 
Jλ1/IRF4 L24A 16.1391114 7.68555232 
Jλ1/IRF4 L368A 25.6052831 18.251045 
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The table shows an example of raw data obtained in the luciferase assays.  To obtain the values as 
shown in the graphs in Chapter 4, Renilla values where divided by Luciferase values 
(Luciferase/Renilla ratio).  These, where further normalised by the average Luciferase/Renilla ratio 
value calculated as mean of the two repeats for pgl3 (highlighted in yellow). Using this latter value, 
normalized values were calculated for each sample by dividing Luciferase/Renilla ratio values by 
the average pgl3 values (yellow). Average of the normalized values, standard deviation (SD) and 
standard error of the mean (SEM) were calculated. The latter was used to draw error bars. Sam-
ples chosen are just an example of early experiments, which were performed only in duplicates for 
titration purposes. 2: Promoter; 3: Enhancer+ IRF4; 4: Enhancer+IRF4+PU.1; 5: Enhancer+PU.1. 
 
 
Figure 7-4 911 cells expressing CFP. 
911 cells were transfected with the recombinant adenoviruses and 2-3 days later pictures were 
taken to confirm expression of CFP. 
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Figure 7-5 Viral infective particles concentration for AdZ/CFP. 
The graphs were used to extrapolate the dilution of the virus stock that killed 50% of the infected 
cells. These values were used to calculate the actual volume of purified virus to be used.  
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Figure 7-6 Gap junctions fold change values using GFOLD. 
 
 
Figure 7-7 Volcano plots for transcripts comparison between HPV-positive cells lines and NHK.  
Transcripts expression is shown as log2(fold change) vs log10 (p values) to output the ratio be-
tween the significant vs non-significant transcripts The plot was generated to complement the 
heatmaps used in Chapter 5 (Figure 5-1).  
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Figure 7-8 Volcano plots for transcripts comparison between patients samples and NHK.  
Transcripts expression is shown as Log2(fold change) vs Log10 (p values) to output the ratio be-
tween the significant vs non-significant transcripts. The plot was generated to complement the 
heatmaps used in Chapter 5 (Figure 5-2). 
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7.2 Appendix 2: Selected analysis tools for NGS 
Table 7-3 Selected analysis tools for NGS/RNA-Seq data. 
Galaxy https://usegalaxy.org/ 
FastQC http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 
TopHat http://tophat.cbcb.umd.edu/ 
Bowtie http://bowtie-bio.sourceforge.net/bowtie2/manual.shtml 
Cufflinks http://cufflinks.cbcb.umd.edu/ 
Cuffdiff http://cufflinks.cbcb.umd.edu/howitworks.html/ 
CummeRbund http://compbio.mit.edu/cummeRbund/ 
IGV http://www.broadinstitute.org/software/igv/  
GFOLD http://web.tongji.edu.cn/~zhanglab/GFOLD/ 
UCSC https://genome.ucsc.edu/index.html 
R http://www.bioconductor.org/ 
Bioinformatics forums http://seqanswers.com/  
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7.3 Appendix 3: Sequencing analysis of the recombinant adenovi-
ruses 
Green, Kozak sequence; Red, Stop codon; Yellow, Tag sequence. Reverse/Forward = 
primers used for sequencing. 
AdZ/CFP/E6_N_terminus HA sequence 
(Reverse) -----------------------------------------ganngCCTG 
Reference gagatctccctatcagtgatagagagtttagtgaaccgtcagatcgcctg 
(Forward) -------------------------------------------------- 
(Reverse) GAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGAT 
Reference gagacgccatccacgctgttttgacctccatagaagacaccgggaccgat 
(Forward) -------------------------------------------------- 
(Reverse) CCAGCCTGGATCCCCTACCATGTACCCATACGACGTCCCAGACTACGCTA 
Reference ccagcctggatcccctACCatgTACCCATACGACGTCCCAGACTACGCTa 
(Forward) -------------------------------------------------- 
(Reverse) TGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACAGGAGCGACCCAGA 
Reference tgcaccaaaagagaactgcaatgtttcaggacccacaggagcgacccaga 
(Forward) ------------------------------------------------GA 
(Reverse) AAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAAT 
Reference aagttaccacagttatgcacagagctgcaaacaactatacatgatataat 
(Forward) nngTTACCaCAGTTATGCACAGAGCTGCAAACAACTATACATGATATAAT 
(Reverse) ATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGTGAGGTATATG 
Reference attagaatgtgtgtactgcaagcaacagttactgcgacgtgaggtatatg 
(Forward) ATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGTGAGGTATATG 
(Reverse) ACTTTGCTTTTCGGGATTTATGTATAGTATATAGAGATGGGAATCCATAT 
Reference actttgcttttcgggatttatgtatagtatatagagatgggaatccatat 
(Forward) ACTTTGCTTTTCGGGATTTATGTATAGTATATAGAGATGGGAATCCATAT 
(Reverse) GCTGTATGTGATAAATGTTTAAAGTTTTATTCTAAAATTAGTGAGTATAG 
Reference gctgtatgtgataaatgtttaaagttttattctaaaattagtgagtatag 
(Forward) GCTGTATGTGATAAATGTTTAAAGTTTTATTCTAAAATTAGTGAGTATAG 
(Reverse) ACATTATTGTTATAGTGTGTATGGAACAACATTAGAACAGCAATACAACA 
Reference acattattgttatagtgtgtatggaacaacattagaacagcaatacaaca 
(Forward) ACATTATTGTTATAGTGTGTATGGAACAACATTAGAACAGCAATACAACA 
(Reverse) AACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTG 
Reference aaccgttgtgtgatttgttaattaggtgtattaactgtcaaaagccactg 
(Forward) AACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTG 
(Reverse) TGTCCTGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCATAA 
Reference tgtcctgaagaaaagcaaagacatctggacaaaaagcaaagattccataa 
(Forward) TGTCCTGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCATAA 
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(Reverse) TATAAGGGGTCGGngGACCGGTCGAngt---------------------- 
Reference tataaggggtcggtggaccggtcgatgtatgtcttgttgcagatcatcaa 
(Forward) TATAAGGGGTCGGTGGACCGGTCGATGTATGTCTTGTTGCAGATCATCAA 
(Reverse) -------------------------------------------------- 
Reference gaacacgtagagaaacccagctgTAAggatcccacgtcactattgtatac  
(Forward) GAACACGTAGAGAAACCCAGCTGTAAGGATCCCACGTCACTATTGTATAC 
(Reverse) -------------------------------------------------- 
Reference tctatattatactctatgttatactctgtaatcctactcaataaacgtgt 
(Forward) TCTATATTATACTCTATGTTATACTCTGTAATCCTACTcAaTAAACGTgt 
(Reverse) -------------------------------------------------- 
Reference cacgcctgtgaaaccgtactaagtctcccgtgtcttcttatcaccatcag 
(Forward) caA----------------------------------------------- 
AdZ/CFP/E7_C_terminus_Myc sequence 
Reference --------------ttgacgcaaatgggcggtaggcgtgtacggtgggag 
(Forward) anaACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAG 
Reference gtctatataagcagagctctccctatcagtgatagagatctccctatcag 
(Forward) GTCTATATAAGCAGAGCTCTCCCTATCAGTGATAGAGATCTCCCTATCAG 
Reference tgatagagagtttagtgaaccgtcagatcgcctggagacgccatccacgc 
(Forward) TGATAGAGAGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGC 
Reference tgttttgacctccatagaagacaccgggaccgatccagcctggatccAcc 
(Forward) TGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTGGATCCACC 
Reference ATGcatggagatacacctacattgcatgaatatatgttagatttgcaacc 
(Forward) ATGCATGGAGATACACCTACATTGCATGAATATATGTTAGATTTGCAACC 
Reference agagacaactgatctctactgttatgagcaattaaatgacagctcagagg 
(Forward) AGAGACAACTGATCTCTACTGTTATGAGCAATTAAATGACAGCTCAGAGG 
Reference aggaggatgaaatagatggtccagctggacaagcagaaccggacagagcc 
(Forward) AGGAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCC 
Reference cattacaatattgtaaccttttgttgcaagtgtgactctacgcttcggtt 
(Forward) CATTACAATATTGTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGGTT 
Reference gtgcgtacaaagcacacacgtagacattcgtactttggaagacctgttaa 
(Forward) GTGCGTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAA 
Reference tgggcacactaggaattgtgtgccccatctgttctcagaaaccaGAACAA 
(Forward) TGGGCACACTAGGAATTGTGTGCCCCATCTGTTCTCAGAAACCAGAACaA 
Reference AAACTTATTTCTGAAGAAGATCTGTAAggatcccacgtcactattgtata 
(Forward) AAACTTATTTCTGAAGAAGATCTGTAAGGATCCCacgtCacTAttGTATA 
Reference ctctatattatactctatgttatactctgtaatcctactcaataaacgtg 
(Forward) CTCTATATTATACTctATGTTATACTCTGTaatCctACtcAATaaAcnt- 
Reference tcacgcctgtgaaaccgtactaagtctcccgtgtcttcttatcaccatca 
(Forward) -------------------------------------------------- 
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7.4 Appendix 4: NGS/RNA-Seq analysis parameters 
The parameters were extrapolated from the keratinocytes dataset but they apply to 
all the samples analysed.  
TOOL: TOPHAT FOR ILLUMINA 
Name: Tophat for Illumina on data 1: accepted_hits 
Created: Oct 17, 2012 
Filesize: 596.1 MB 
Dbkey: hg19 
Format: bam 
Galaxy Tool Version: 1.5.0 
Tool Version: 
 
Tool Standard Output: stdout  
Tool Standard Error: stderr  
Tool Exit Code: None 
API ID: 6651297061e28527 
Input Parameter Value Note for rerun 
RNA-Seq FASTQ file 
1:  
kerat_raw.fq  
Use a built in reference genome or own from your history indexed 
 
Select a reference genome /galaxy/data/hg19/bowtie_index/hg19 
 
Is this library mate-paired? single 
 
TopHat settings to use full 
 
Library Type FR Unstranded 
 
Anchor length (at least 3) 8 
 
Maximum number of mismatches that can appear in 
the anchor region of spliced alignment 
0 
 
The minimum intron length 70 
 
The maximum intron length 500000 
 
Allow indel search Yes 
 
Max insertion length. 3 
 
Max deletion length. 3 
 
Maximum number of alignments to be allowed 20 
 
Minimum intron length that may be found during 
split-segment (default) search 
50 
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TOOL: TOPHAT FOR ILLUMINA 
Maximum intron length that may be found during 
split-segment (default) search 
500000 
 
Number of mismatches allowed in the initial read 
mapping 
2 
 
Number of mismatches allowed in each segment 
alignment for reads mapped independently 
2 
 
Minimum length of read segments 25 
 
Use Own Junctions No 
 
Use Closure Search No 
 
Use Coverage Search Yes 
 
Minimum intron length that may be found during 
coverage search 
50 
 
Maximum intron length that may be found during 
coverage search 
20000 
 
Use Microexon Search No 
 
TOOL: CUFFLINKS 
Name: Cufflinks on data 8 and data 25K: assembled transcripts 
Created: Jul 16, 2012 
Filesize: 93.7 MB 
Dbkey: hg19 
Format: gtf 
Galaxy Tool Version: 0.0.5 
Tool Version: 
 
Tool Standard Output: stdout  
Tool Standard Error: stderr  
Tool Exit Code: None 
API ID: 7dd06fde8fb56fe3 
Input Parameter Value Note for rerun 
SAM or BAM file of aligned RNA-Seq 
reads 
8: Tophat for Illumina on data 1: accepted_hits 
 
Max Intron Length 300000 
 
Min Isoform Fraction 0.1 
 
Pre MRNA Fraction 0.15 
 
Perform quartile normalization Yes 
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TOOL: TOPHAT FOR ILLUMINA 
Use Reference Annotation Use reference annotation 
 
Reference Annotation 25: UCSC Main on Human: refGene (genome) 
 
Perform Bias Correction Yes 
 
Reference sequence data cached 
 
Use multi-read correct not used (parameter was added after this job was run) 
 
Use effective length correction not used (parameter was added after this job was run) 
 
Global model (for use in Trackster) No dataset 
 
TOOL: CUFFCOMPARE 
Name: Cuffcompare on data 1, data 4, and others: combined transcripts 
Created: Jul 22, 2012 
Filesize: 92.8 MB 
Dbkey: hg19 
Format: gtf 
Galaxy Tool Version: 0.0.5 
Tool Version: 
 
Tool Standard Output: stdout  
Tool Standard Error: stderr  
Tool Exit Code: None 
API ID: 09b8046b0fe0fca0 
Input Parameter Value Note for rerun 
GTF file produced by Cufflinks 
1: Cufflinks on data 68 and data 79 
caski: assembled transcripts  
GTF file produced by Cufflinks 
2: Cufflinks on data 8 and data 25 
kerat: assembled transcripts  
GTF file produced by Cufflinks 
3: Cufflinks on data 70 and data 75 
siha: assembled transcripts  
Use Reference Annotation Yes 
 
Reference Annotation 
4: UCSC Main on Human: refGene 
(genome)  
Ignore reference transcripts that are not over-
lapped by any transcript in input files 
False 
 
Use Sequence Data Yes 
 
Choose the source for the reference list cached 
 
TOOL: CUFFDIFF 
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TOOL: TOPHAT FOR ILLUMINA 
Name: 
Cuffdiff on data 12, data 14, and others: transcript dif-
ferential expression testing 
Created: Jul 29, 2012 
Filesize: 5.2 MB 
Dbkey: hg19 
Format: tabular 
Galaxy Tool Version: 0.0.5 
Tool Version: 
 
Tool Standard Output: stdout  
Tool Standard Error: stderr  
Tool Exit Code: None 
API ID: 6318041400ee9c4c 
Input Parameter Value Note for rerun 
Transcripts 
153: Cuffcompare on data 1, data 4, and oth-
ers: combined transcripts  
Repeat (Condition) 
not used (parameter was added after this job 
was run)  
Library normalization method 
not used (parameter was added after this job 
was run)  
Dispersion estimation method 
not used (parameter was added after this job 
was run)  
False Discovery Rate 0.05 
 
Min Alignment Count 10 
 
Use multi-read correct 
not used (parameter was added after this job 
was run)  
Perform Bias Correction Yes 
 
Reference sequence data cached 
 
Include Read Group Datasets 
not used (parameter was added after this job 
was run)  
Set Additional Parameters? (not recom-
mended for paired-end reads) 
not used (parameter was added after this job 
was run)  
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7.5 Appendix 5: FASTQC results  
Keratinocytes 
https://usegalaxy.org/datasets/b24ed2066d2f400b/display?to_ext=html/ 
CaSki 
https://usegalaxy.org/datasets/3de7e21bd8faa424/display?to_ext=html/ 
SiHa 
https://usegalaxy.org/datasets/daa5b3d8b71c898f/display?to_ext=html/ 
Patient 1 
https://usegalaxy.org/datasets/5bf80111e06db349/display?to_ext=html/ 
Patient 2: 
https://usegalaxy.org/datasets/8fbe4d77d9eb3275/display?to_ext=html/ 
Patient 3: 
https://usegalaxy.org/datasets/c81eb53a531c4316/display?to_ext=html/ 
Patient 4: 
https://usegalaxy.org/datasets/9ee21b6aa04e50a2/display?to_ext=html/ 
Patient 5: 
https://usegalaxy.org/datasets/debc1daa5ca2d906/display?to_ext=html/ 
Patient 6: 
https://usegalaxy.org/datasets/f9d179e51850f7c2/display?to_ext=html/ 
Patient 7: 
https://usegalaxy.org/datasets/204da6c38255d7ff/display?to_ext=html/ 
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7.6 Appendix 6: Significantly deregulated cell surface transcripts 
Figure 7-9 Top 20 and bottom 20 significantly deregulated transcripts in  CaSki cell lines. 
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Figure 7-10 Top 20 and bottom 20 significantly deregulated transcripts in SiHa cell lines. 
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Figure 7-11 Top 20 and bottom 20 significantly deregulated transcripts in  HeLa cell lines. 
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Figure 7-12 Top 20 and bottom 20 significantly deregulated transcripts in patient 1. 
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Figure 7-13 Top 20 and bottom 20 significantly deregulated transcripts in patient 2. 
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Figure 7-14 Top 20 and bottom 20 significantly deregulated transcripts in patient 3. 
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Figure 7-15 Top 20 and bottom 20 significantly deregulated transcripts in patient 4. 
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Figure 7-16 Top 20 and bottom 20 significantly deregulated transcripts in patient 5. 
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Figure 7-17 Top 20 and bottom 20 significantly deregulated transcripts in patient 6. 
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Figure 7-18 Top 20 and bottom 20 significantly deregulated transcripts in patient 7. 
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7.7 Appendix 7: Mass spectrometry results 
Control (Un-transduced HaCaT) 
1 -84.96.749.0/16711 108.6ENSP00000346634  gpmDB | psyt | snap [1039/9290]  homo (1/1) 
  protein THRAP3:p 
2 -30.06.715.0/835 68.1ENSP00000254719  gpmDB | psyt | snap [2590/7319]  protein  RPA1:p, 
3 -29.26.5019/2223 12.3ENSP00000451080  gpmDB | psyt | snap [1063/5488]  homo (0/1)   protein 
no protein information available 
4 -23.46.5118/2535 16.1ENSP00000221975  gpmDB | psyt | snap [2045/8029]  protein RPS19:p,  
5 -22.15.832.0/411 76.1ENSP00000349748  gpmDB | psyt | snap   protein  
SFPQ:p, splicing factor proline/glutamine-rich [Source: HGNC 10774] 
  IPR012975 NOPS  IPR000504 (×6) RRM dom   
6 -18.46.289.4/1433 29.5ENSP00000326219  gpmDB | psyt | snap   homo (2/17)   protein 
DHRS4:p,  
7 -15.75.757.3/1123 38.7ENSP00000341826  gpmDB | psyt | snap   homo (0/7)   protein 
HNRNPA1:p,  
8 -15.75.952.4/72½3½ 78.3ENSP00000340329  gpmDB | psyt | snap   homo (4/6)   protein CA-
PRIN1:p,  
9 -10.86.065.9/1822 53.4ENSP00000254108  gpmDB | psyt | snap   homo (4/7)   protein FUS:p, 
fused in sarcoma [Source: HGNC 4010] 
  IPR000504 (×3) RRM dom    IPR001876 (×3) Znf RanBP2   
10 -9.46.966.9/922 24.4sp|TRYP_PIG|  gpmDB | psyt | snap   protein  
Trypsin; EC 3.4.21.4; Flags: Precursor;  
11 -9.25.932.6/423 112.3ENSP00000322542  gpmDB | psyt | snap   homo (3/11)   protein GTF2I:p,  
12 -3.05.822.4/312 42.0ENSP00000355645  gpmDB | psyt | snap   homo (32/32)  protein 
ACTA1:p,  
13 -2.85.314.0/611 37.4ENSP00000346694  gpmDB | psyt | snap   homo (2/2)   protein 
HNRNPA2B1:p, heterogeneous nuclear ribonucleoprotein A2/B1 [Source: HGNC 5033] IPR021662 
HnRNPA  IPR000504 (×6) RRM dom   
14 -2.55.601.7/311 54.1ENSP00000254436  gpmDB | psyt | snap   homo (1/1)   protein TRIM21:p,  
15 -2.46.087.4/1013 13.6ENSP00000223129  gpmDB | psyt | snap   homo (3/3)   protein RPA3:p,  
16 -2.46.171.1/213 88.9ENSP00000393151  gpmDB | psyt | snap   homo (3/3)   protein 
HNRNPU:p,  
17 -2.46.071.2/312 68.4ENSP00000381031  gpmDB | psyt | snap [6110/6343]  homo (6/6)   protein 
EWSR1:p,  
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18 -2.25.371.7/311 54.8ENSP00000372804  gpmDB | psyt | snap [2662/2787]  homo (2/2)   protein 
RNMT:p,  
19 -2.25.636.4/711 25.2ENSP00000355354  gpmDB | psyt | snap [161/193]  homo (1/1)   protein 
SOX15:p,  
20 -2.05.874.7/611 17.2ENSP00000265304  gpmDB | psyt | snap [7381/7450]  homo (6/6)   protein 
SSBP1:p,  
21 -1.85.846.4/811 14.9ENSP00000420311  gpmDB | psyt | snap [8927/8973]  homo (1/1)   protein 
RPL23:p,  
22 -1.86.201.0/111 119.4ENSP00000264107  gpmDB | psyt | snap [5714/5815]  homo (6/6)   protein 
ITGA6:p,  
23 -1.65.991.7/311 54.2ENSP00000276079  gpmDB | psyt | snap [12742/12896]  homo (6/6) 
  protein NONO:p, 
24 -1.25.170.4/111 358.5ENSP00000357643:reversed  homo (1/1)   protein no protein information 
available 
25 -1.15.782.8/411 33.3ENSP00000336579:reversed  homo (4/4)  protein no protein information 
availableμ½ = #8#8 
 
CFP (AdZ/CFP empty vector) 
1 -167.68.0930/481426 68.1ENSP00000254719  gpmDB | psyt | snap [315/7319]  protein RPA1:p,  
2 -117.57.8915/271022 90.5ENSP00000283179  gpmDB | psyt | snap [3034/20016]  homo (1/3) 
  protein HNRNPU:p, heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor 
A)[Source: HGNC 5048]IPR001870 B30.2/SPRY IPR008985 ConA-like lec gl sf  IPR027417 P-loop 
NTPase IPR003034 (×3) SAP dom IPR003877 SPRY rcpt IPR018355 SPla/RYanodine receptor subgr 
IPR010488 Zeta toxin domain   
3 -105.97.569.8/17812 108.6ENSP00000346634  gpmDB | psyt | snap [759/9290]  homo (1/1) 
  protein THRAP3:p,  
4 -62.77.8739/53711 16.1ENSP00000221975  gpmDB | psyt | snap [451/8029]  protein RPS19:p 
5 -61.97.559.6/2648 68.4ENSP00000381031  gpmDB | psyt | snap [289/6343]  homo (4/8)   protein 
EWSR1:p, 
6 -55.37.8734/50611 17.7ENSP00000393241  gpmDB | psyt | snap [1258/10742]  homo (4/11) 
  protein RPS18:p, 
7 -43.37.205.7/1034 76.1ENSP00000349748  gpmDB | psyt | snap [4971/14647]  protein SFPQ:p, 
splicing factor proline/glutamine-rich [Source: HGNC 10774] IPR012975 NOPS  IPR000504 (×6) RRM 
dom   
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8 -40.17.6311/3347 53.4ENSP00000254108  gpmDB | psyt | snap [2366/10275]  homo (4/7)   protein 
FUS:p, fused in sarcoma [Source: HGNC 4010]   IPR000504 (×3) RRM dom  IPR001876 (×3) Znf 
RanBP2   
9 -30.95.929.8/1322 27.5ENSP00000421592  gpmDB | psyt | snap [1781/6514]  homo (0/1)   protein 
THOC4:p,  
10 -30.86.4913/1922 18.6ENSP00000322887  gpmDB | psyt | snap [685/4385]  homo (0/1)   protein 
CIRBP:p,  
11 -29.56.6312/1834½ 34.2ENSP00000448617  gpmDB | psyt | snap [7003/12937]  homo (7/15) 
  protein heterogeneous nuclear ribonucleoprotein A1 [Source: HGNC 5031]IPR021662 
HnRNPA1 IPR000504 (×6) RRM dom   
12 -25.97.2519/2224 12.3ENSP00000451080  gpmDB | psyt | snap [1303/5488]  homo (0/1)   protein 
no protein information available 
13 -24.66.998.3/1226 22.9ENSP00000196551  gpmDB | psyt | snap [4252/12186]  protein RPS5:p,  
14 -24.66.745.1/83360.0ENSP00000252252  gpmDB | psyt | snap [15362/39375]  homo (4/14) 
  protein KRT6B:p,  
15 -23.47.5415/193½5 24.4sp|TRYP_PIG|  gpmDB | psyt | snap [58294/104275]  protein Trypsin; EC 
3.4.21.4; Flags: Precursor;  
16 -22.86.691.4/211 62.3(H) ENSP00000252242  gpmDB | psyt | snap [12850/31245]  homo (4/14) 
  protein KRT5:p,  
17 -22.76.933.4/534 112.3ENSP00000322542  gpmDB | psyt | snap [3594/8761]  homo (4/5) 
  protein GTF2I:p,  
18 -20.87.2626/3634 13.6ENSP00000223129  gpmDB | psyt | snap [992/3996]  homo (1/3)   protein 
RPA3:p,  
19 -17.96.8012/1824 29.2ENSP00000363021  gpmDB | psyt | snap [1285/3821]  homo (3/3)   protein 
RPA2:p, 
20 -15.26.2315/3123 35.9ENSP00000361626  gpmDB | psyt | snap [7536/13276]  homo (2/2) 
  protein YBX1:p,  
21 -14.86.967.2/2023 78.3ENSP00000340329  gpmDB | psyt | snap [3981/7872]  homo (5/6) 
  protein CAPRIN1:p,  
22 -14.06.642.5/311 51.5ENSP00000167586  gpmDB | psyt | snap [15777/30111]  homo (4/4) 
  protein KRT14:p,  
23 -12.66.541.7/323 140.9ENSP00000356520  gpmDB | psyt | snap [11263/15186]  homo (0/1) 
  protein DHX9:p,  
24 -10.57.673.5/622 100.2ENSP00000376159  gpmDB | psyt | snap [4186/7031]  homo (1/11) 
  protein BCLAF1:p,  
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25 -10.37.025.3/724 29.6ENSP00000362744  gpmDB | psyt | snap   homo (0/1)   protein RPS4X:p,  
26 -9.97.307.2/1124 29.5ENSP00000326219  gpmDB | psyt | snap   homo (2/10)   protein 
DHRS4:p,  
27 -9.86.863.7/912 38.4ENSP00000313199  gpmDB | psyt | snap   homo (9/9) protein HNRNPD:p,  
28 -7.15.605.6/911 24.6ENSP00000358832  gpmDB | psyt | snap   homo (4/4)   protein RPL10:p,  
29 -4.96.2016/3413 7.8ENSP00000397872  gpmDB | psyt | snap   protein RPS28:p,  
30 -4.96.976.4/712 25.2ENSP00000355354  gpmDB | psyt | snap   homo (1/1)   protein SOX15:p,  
31 -4.86.170.7/111 157.8ENSP00000260665  gpmDB | psyt | snap   homo (1/1)   protein 
LRPPRC:p,  
32 -4.45.244.4/711 42.4ENSP00000360033  gpmDB | psyt | snap   homo (3/3)   protein SERBP1:p, 
SERPINE1 mRNA binding protein 1 [Source: HGNC 17860]IPR006861 HABP4 PAIRBP1-bd   
33 -4.36.152.2/312 59.6ENSP00000349428  gpmDB | psyt | snap   homo (3/3)   protein PTBP1:p, 
polypyrimidine tract binding protein 1 [Source: HGNC 9583] 
  IPR006536 HnRNP-L PTB   IPR000504 (×11) RRM dom   
34 -3.36.692.5/411 37.4ENSP00000346694  gpmDB | psyt | snap   homo (3/3)   protein 
HNRNPA2B1:p, heterogeneous nuclear ribonucleoprotein A2/B1 [Source: HGNC 5033]IPR021662 
HnRNPA1  IPR000504 (×6) RRM dom 
35 -2.75.811.0/211 51.3ENSP00000357980:reversed  protein no protein information available 
36 -2.76.524.9/612 26.7ENSP00000434643  gpmDB | psyt | snap   homo (7/7)   protein RPS3:p,  
37 -2.66.231.2/21193.6ENSP00000295770:reversed  protein  
no protein information available 
38 -2.56.264.9/811 21.4ENSP00000397798  gpmDB | psyt | snap   homo (1/1)   protein RPL17:p,  
39 -2.56.595.4/611 16.8ENSP00000406181  gpmDB | psyt | snap   protein  
SEPT2:p,  
40 -2.55.881.1/211 87.0ENSP00000331678  gpmDB | psyt | snap   protein  
PKP3:p,  
41 -2.36.116.2/812 16.4ENSP00000251453  gpmDB | psyt | snap   homo (1/1)   protein RPS16:p,  
42 -2.27.3023/100+11 9.2ENSP00000421635  gpmDB | psyt | snap   protein C5orf60:p,  
43 -2.26.654.7/612 17.2ENSP00000265304  gpmDB | psyt | snap   homo (6/6)   protein SSBP1:p,  
44 -2.15.8617/3811 10.7ENSP00000370284  gpmDB | psyt | snap   protein  
ZNF561:p, 
45 -2.16.991.1/211 157.7ENSP00000362776  gpmDB | psyt | snap   homo (3/3)   protein 
COL16A1:p, collagen, type XVI, alpha 1 [Source: HGNC 2193] 
  IPR008160(×12)Collagen IPR008985 ConA-like lec gl sf   IPR001791 Laminin G 46 -1.86.307.0/1211 
13.0ENSP00000348849  gpmDB | psyt | snap   homo (2/2)   protein RPS26:p, 
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47 -1.86.135.3/811 27.7ENSP00000238081  gpmDB | psyt | snap   homo (2/2)   protein YWHAQ:p, 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta [Source: HGNC 
12854]IPR000308 (×7) 14-3-3  IPR023410 (×3) 14-3-3 domain   
48 -1.76.702.2/311 61.8ENSP00000374461  gpmDB | psyt | snap   homo (1/1)   protein ACOXL:p,  
49 -1.76.651.5/311 50.5ENSP00000446271  gpmDB | psyt | snap   homo (2/2) protein no protein 
information available 
50 -1.65.431.3/211 70.6ENSP00000313007  gpmDB | psyt | snap   homo (9/9)   protein  
PABPC1:p,  
51 -1.55.521.8/311 157.9ENSP00000351875  gpmDB | psyt | snap   homo (2/2)   protein 
ANKRD30B:p,  
52 -1.56.516.0/1011 26.5ENSP00000418634:reversed  homo (4/4)   protein  
no protein information available 
53 -1.45.393.6/611 22.6ENSP00000302896  gpmDB | psyt | snap   homo (6/6)   protein RPS9:p,  
54 -1.46.320.7/111 301.6ENSP00000369365:reversed  homo (2/2)   protein no protein information 
available 
55 -1.45.802.0/311 83.2ENSP00000262843  gpmDB | psyt | snap   homo (1/1)   protein MID2:p,  
56 -1.46.302.5/411 35.9ENSP00000374987  gpmDB|psyt| snap   protein  
IGHG2:p, 
57 -1.46.482.9/511 54.7ENSP00000355437:reversed  protein no protein information available 
58 -1.35.354.8/611 18.9ENSP00000347271  gpmDB | psyt | snap   homo (1/1)   protein RPS10:p,  
59 -1.36.231.8/211 50.1ENSP00000264193  gpmDB | psyt | snap   protein CPOX:p,  
60 -1.36.431.7/311 54.2ENSP00000276079  gpmDB | psyt | snap   homo (6/6)   protein NONO:p,  
61 -1.34.809.1/1011 32.0ENSP00000392152:reversed  homo (1/1)   protein no protein information 
available 
62 -1.36.450.7/111 118.0ENSP00000386727  gpmDB| psyt | snap   homo (1/1)   protein RBM44:p,  
63 -1.36.831.3/211 138.0ENSP00000364798  gpmDB| psyt | snap   homo (3/3)   protein ZBTB40:p,  
64 -1.36.951.3/211 92.0ENSP00000345498:reversed  homo (6/6)   protein  
no protein information available 
65 -1.26.083.6/911 51.8ENSP00000453793  gpmDB| psyt | snap   homo (3/3)   protein no protein 
information available 
66 -1.27.551.4/211 73.0ENSP00000344233:reversed  homo (2/2)   protein no protein information 
available 
67 -1.16.571.2/211 47.1ENSP00000393074  gpmDB | psyt | snap   homo (2/2)   protein ZNF561:p,  
68 -1.16.394.9/611 27.8ENSP00000389345  gpmDB | psyt |snap   homo (17/17)   protein BDNF:p,  
69 -1.15.992.6/611 58.2ENSP00000445929:reversed  protein no protein information available 
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70 1.14.881.5/211 236.5ENSP00000376306  gpmDB | psyt | snap   homo (1/1) protein CIT:p,  
71 -1.17.672.3/411 79.2ENSP00000364867  gpmDB | psyt | snap   homo (1/1)   protein ROR2:p,  
72 -1.16.297.3/1111 15.7ENSP00000342787  gpmDB | psyt | snap   homo (9/9)   protein RPL28:p, 
μ½ = #15#11 
 
E6 (AdZ/CFP/E6) 
1 -126.67.4115/261218 108.6ENSP00000346634  gpmDB | psyt | snap[574/9290]  homo (1/1) 
  protein THRAP3:p,  
2 -104.27.6218/3092068.1ENSP00000254719  gpmDB | psyt | snap [641/7319]  protein RPA1:p,  
3 -83.87.0713/24713 90.5ENSP00000283179  gpmDB | psyt | snap[4485/20016]  homo (0/3) 
  protein HNRNPU:p, heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) 
[Source: HGNC 5048]IPR001870 B30.2/SPRY  IPR008985 ConA-like lec gl sf  IPR027417 P-loop NTPase 
 IPR003034 (×3) SAP dom  IPR003877 SPRY rcpt  IPR018355 SPla/RYanodine receptor subgr 
 IPR010488 Zeta toxin domain   
4 -50.97.139.6/2647 68.4ENSP00000381031  gpmDB | psyt | snap [460/6343]  homo (4/6)   protein 
EWSR1:p,  
5 -48.66.466.2/1144 76.1ENSP00000349748  gpmDB |psyt | snap [4514/14647]  homo (0/1)   protein 
SFPQ:p, splicing factor prline/glutaminerich [Source: HGNC 10774] IPR012975 NOPS  IPR000504 (×6) 
RRM dom   
6 -40.16.765.5/858 112.3ENSP00000322542  gpmDB | psyt | snap [2454/8761]  homo (4/4)   protein 
GTF2I:p,  
7 -36.87.2510/31412 53.4ENSP00000254108  gpmDB | psyt | snap [2604/10275]  homo (4/7) 
  protein FUS:p, fused in sarcoma [Source: HGNC 4010] IPR000504 (×3) RRM dom  IPR001876 (×3) Znf 
RanBP2   
8 -31.07.0718/2536 16.1ENSP00000221975  gpmDB | psyt | snap [1455/8029]  protein RPS19:p,  
9 -27.96.264.0/522 51.5ENSP00000167586  gpmDB | psyt | snap [11151/30111]  homo (1/14) 
  protein KRT14:p,  
10 -27.47.2919/2223½ 12.3ENSP00000451080  gpmDB | psyt | snap [1177/5488]  homo (0/1) 
  protein no protein information available 
11 -26.26.9614/2337 29.2ENSP00000363021  gpmDB |psyt | snap [905/3821]  homo (3/3)   protein 
RPA2:p,  
12 -26.16.273.3/423 65.4ENSP00000310861  gpmDB | psyt | snap [21457/42389]  homo (1/11) 
  protein KRT2:p,  
  
267 
13 -25.96.504.7/133½4 78.3ENSP00000340329  gpmDB | psyt | snap [2546/7872]  homo (4/6) 
  protein CAPRIN1:p,  
14 -20.66.598.7/1235 29.6ENSP00000362744  gpmDB | psyt | snap[6435/13307]  homo (0/3) 
  protein RPS4X:p,  
15 -20.06.595.3/833 54.1ENSP00000254436  gpmDB | psyt | snap [663/2205]  homo (1/1)   protein 
TRIM21:p,  
16 -19.16.7015/2334 17.7ENSP00000393241  gpmDB | psyt | snap [4535/10742]  homo (4/11) 
  protein RPS18:p,  
17 -17.86.889.4/1435 29.5ENSP00000326219  gpmDB | psyt | snap [346/1642]  homo (2/16) 
  protein DHRS4:p,  
18 -17.86.221.7/233 157.8ENSP00000260665  gpmDB | psyt | snap [8929/13493]  homo (1/4) 
  protein LRPPRC:p,  
19 -16.75.961.8/211 48.7(H) sp|K1C15_SHEEP|  gpmDB | psyt | snap [17216/43948]  homo (3/14) 
  protein Keratin, type I cytoskeletal 15; Cytokeratin-15; CK-15; Keratin-15; K15;  
20 15.96.443.9/623 59.6ENSP00000349428  gpmDB | psyt | snap [9083/14463]  homo (3/3)   protein 
PTBP1:p, polypyrimidine tract binding protein 1 [Source: HGNC 9583]IPR006536 HnRNP-L PTB 
 IPR000504 (×11) RRM dom  
21 -15.05.9221/4522 35.9ENSP00000361626  gpmDB | psyt | snap [7573/13276]  homo (0/2) 
  protein YBX1:p,  
22 -13.65.797.8/1111 22.9ENSP00000196551  gpmDB | psyt | snap [6315/12186]  protein RPS5:p,  
23 -13.36.416.5/924 37.4ENSP00000346694  gpmDB | psyt | snap [14284/20298]  homo (2/3) 
  protein HNRNPA2B1:p, heterogeneous nuclear ribonucleoprotein A2/B1 [Source: HGNC 
5033]IPR021662 HnRNPA1  IPR000504 (×6) RRM dom   
24 -13.06.5919/2124 25.2ENSP00000355354  gpmDB | psyt | snap [41/193]  homo (1/1)   protein 
SOX15:p,  
25 -11.66.032.4/422 121.4ENSP00000386786  gpmDB | psyt | snap [27250/32039]  homo (8/34) 
  protein POTEF:p,  
26 -10.56.5313/1823 13.6ENSP00000223129  gpmDB | psyt | snap [1993/3996]  homo (1/3)   protein 
RPA3:p,  
27 -10.06.254.0/722 54.2ENSP00000276079  gpmDB | psyt | snap [8684/12896]  homo (4/7) 
  protein NONO:p,  
28 -9.27.126.9/922 24.4sp|TRYP_PIG|  gpmDB | psyt | snap [80976/104275]  protein Trypsin; EC 
3.4.21.4; Flags: Precursor;  
29 -7.66.235.8/812 18.6ENSP00000322887  gpmDB | psyt | snap [2662/4385]  protein CIRBP:p,  
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30 -4.86.303.7/612 29.1ENSP00000420588  gpmDB | psyt | snap [2113/3143]  homo (1/1)   protein 
TFAM:p,  
31 -2.96.543.9/611 28.0ENSP00000378378  gpmDB | psyt | snap [8108/9045]  homo (6/6)   protein 
RPL8:p,  
32 -2.76.406.4/812 14.9ENSP00000420311  gpmDB | psyt | snap [8513/8973]  homo (1/1)   protein 
RPL23:p,  
33 -2.55.744.5/911 20.2ENSP00000363676  gpmDB | psyt | snap [9714/10188]  protein RPL11:p, 
34 2.46.1810/111212.3ENSP00000450909  gpmDB | psyt | snap [3461/3593]  homo (1/1)   protein 
no protein information available 
35 -2.05.957.0/121113.0ENSP00000348849  gpmDB | psyt | snap [7092/7298]  homo (2/2)   protein 
RPS26:p,  
36 -2.05.934.7/611 17.2ENSP00000265304  gpmDB | psyt | snap [7381/7450]  homo (6/6)   protein 
SSBP1:p,  
37 -1.96.850.4/112 245.3ENSP00000407602:reversed  protein no protein information available 
38 -1.86.312.4/411 96.7ENSP00000017003  gpmDB | psyt |snap [312/350]  homo (2/2)   protein 
XYLT2:p,  
39 -1.65.801.4/211 62.3ENSP00000252242  gpmDB | psyt | snap[30399/31245]  homo (1/1)   protein 
KRT5:p,  
40 -1.66.410.7/112227.4ENSP00000267622:reversed homo 2/2 protein; no protein information 
available 
41 -1.55.870.7/111274.2ENSP00000349437:reversed  protein no protein information available 
42 -1.56.561.4/212 73.7ENSP00000360541: reversed  protein no protein information available 
43 -1.45.820.4/111,148.3ENSP00000364526:reversed  protein  
no protein information available 
44 -1.46.193.4/511 31.3ENSP00000341885  gpmDB| psyt | snap [12694/12868]  homo (4/4)   protein 
RPS2:p, 
45 -1.44.792.6/411 65.7ENSP00000382349:reversed  protein no protein information available 
46 -1.46.800.3/111509.8ENSP00000349892  gpmDB | psyt | snap [3310/3514]  homo (2/2)   protein 
MYCBP2:p,  
47 -1.25.871.3/211 138.0ENSP00000364798  gpmDB | psyt | snap [434/449]  homo (3/3)   protein 
ZBTB40:p,  
48 -1.26.621.1/111 116.1ENSP00000182096:reversed  homo (2/2) protein no protein information 
available 
49 -1.26.9833/4411 2.2ENSP00000451870  gpmDB | psyt | snap [660/715]  protein T cell receptor 
alpha joining 56 [Source: HGNC 12088] 
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50 -1.25.951.2/21187.3ENSP00000272313:reversed  protein no protein information available 
51 -1.15.613.3/411 26.7ENSP00000434643  gpmDB | psyt | snap[11910/11917]  homo (15/15) 
  protein RPS3:p, μ½ =  
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